

10/712,456-ALW

Connecting via Winsock to STN

Welcome to STN International! - Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

| | | | |
|--------------|----|--------|--|
| NEWS | 1 | | Web Page for STN Seminar Schedule - N. America |
| NEWS | 2 | JAN 08 | CHEMLIST enhanced with New Zealand Inventory of Chemicals |
| NEWS | 3 | JAN 16 | CA/CAPLUS Company Name Thesaurus enhanced and reloaded |
| NEWS | 4 | JAN 16 | IPC version 2007.01 thesaurus available on STN |
| NEWS | 5 | JAN 16 | WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data |
| NEWS | 6 | JAN 22 | CA/CAPLUS updated with revised CAS roles |
| NEWS | 7 | JAN 22 | CA/CAPLUS enhanced with patent applications from India |
| NEWS | 8 | JAN 29 | PHAR reloaded with new search and display fields |
| NEWS | 9 | JAN 29 | CAS Registry Number crossover limit increased to 300,000 in multiple databases |
| NEWS | 10 | FEB 15 | PATDPASPC enhanced with Drug Approval numbers |
| NEWS | 11 | FEB 15 | RUSSIAPAT enhanced with pre-1994 records |
| NEWS | 12 | FEB 23 | KOREAPAT enhanced with IPC 8 features and functionality |
| NEWS | 13 | FEB 26 | MEDLINE reloaded with enhancements |
| NEWS | 14 | FEB 26 | EMBASE enhanced with Clinical Trial Number field |
| NEWS | 15 | FEB 26 | TOXCENTER enhanced with reloaded MEDLINE |
| NEWS | 16 | FEB 26 | IFICDB/IFIPAT/IFIUDB reloaded with enhancements |
| NEWS | 17 | FEB 26 | CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases |
| NEWS | 18 | MAR 15 | WPIDS/WPIX enhanced with new FRAGHITSTR display format |
| NEWS | 19 | MAR 16 | CASREACT coverage extended |
| NEWS | 20 | MAR 20 | MARPAT now updated daily |
| NEWS | 21 | MAR 22 | LWPI reloaded |
| NEWS | 22 | MAR 30 | RDISCLOSURE reloaded with enhancements |
| NEWS | 23 | APR 02 | JICST-EPLUS removed from database clusters and STN |
| NEWS | 24 | APR 30 | GENBANK reloaded and enhanced with Genome Project ID field |
| NEWS | 25 | APR 30 | CHEMCATS enhanced with 1.2 million new records |
| NEWS | 26 | APR 30 | CA/CAPLUS enhanced with 1870-1889 U.S. patent records |
| NEWS | 27 | APR 30 | INPADOC replaced by INPADOCDB on STN |
| NEWS | 28 | MAY 01 | New CAS web site launched |
| NEWS | 29 | MAY 08 | CA/CAPLUS Indian patent publication number format defined |
| NEWS | 30 | MAY 14 | RDISCLOSURE on STN Easy enhanced with new search and display fields |
| NEWS | 31 | MAY 21 | BIOSIS reloaded and enhanced with archival data |
| NEWS | 32 | MAY 21 | TOXCENTER enhanced with BIOSIS reload |
| NEWS | 33 | MAY 21 | CA/CAPLUS enhanced with additional kind codes for German patents |
| NEWS | 34 | MAY 22 | CA/CAPLUS enhanced with IPC reclassification in Japanese patents |
| NEWS EXPRESS | | | NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006. |
| NEWS HOURS | | | STN Operating Hours Plus Help Desk Availability |

10/712,456-ALW

NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:20:35 ON 29 MAY 2007

=> file reg

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 09:20:53 ON 29 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 MAY 2007 HIGHEST RN 935999-19-2
DICTIONARY FILE UPDATES: 28 MAY 2007 HIGHEST RN 935999-19-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10712456ALW.str



chain nodes :

6 7 9 11 12 13 14 17 65 66 68 69

ring nodes :

1 2 3 4 5 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
37 38 39 40 41 42 43 44 45 49 50 51 52 53 54 55 56 57

chain bonds :

1-6 2-12 6-7 6-9 9-11 12-13 12-14 14-17 23-65 33-66 43-69 52-68

ring bonds :

1-2 1-5 2-3 3-4 4-5 20-21 20-25 21-22 22-23 23-24 24-25 24-26 25-29
26-27 27-28 28-29 30-31 30-35 31-32 32-33 33-34 34-35 34-36 35-39 36-37
37-38 38-39 40-41 40-45 41-42 42-43 43-44 44-45 49-50 49-54 50-51 51-52
52-53 53-54 53-55 54-57 55-56 56-57

exact/norm bonds :

1-2 1-5 1-6 2-3 2-12 3-4 4-5 6-7 6-9 9-11 12-13 12-14 14-17 23-65
24-25 24-26 25-29 26-27 27-28 28-29 30-31 30-35 31-32 32-33 33-34 33-66
34-35 34-36 35-39 36-37 37-38 38-39 40-41 40-45 41-42 42-43 43-44 43-69
44-45 52-68 53-55 54-57 55-56 56-57

normalized bonds :

20-21 20-25 21-22 22-23 23-24 49-50 49-54 50-51 51-52 52-53 53-54

isolated ring systems :

containing 1 :

10/712,456-ALW

G1:O,N

G2:Cb,Ak,H

G3:C,O,S,N

G4:C,N

G5:C,N

G6:C,O,N

G7:[*1],[*2],[*3],[*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 9:CLASS 11:CLASS
12:CLASS 13:CLASS 14:CLASS 17:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom
25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom
34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:Atom 40:Atom 41:Atom 42:Atom
43:Atom 44:Atom 45:Atom 49:Atom 50:Atom 51:Atom 52:Atom 53:Atom 54:Atom
55:Atom 56:Atom 57:Atom 65:CLASS 66:CLASS 68:CLASS 69:CLASS

Element Count :

Node 17: Limited

N,N0-6

O,O0

S,S0

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 09:21:23 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 25149 TO ITERATE

8.0% PROCESSED 2000 ITERATIONS

3 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.04

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 493492 TO 512468

PROJECTED ANSWERS: 386 TO 1122

L2 3 SEA SSS SAM L1

=> d scan


10/712,456-ALW

L2 3 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN L-Isoleucine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-
L-prolyl-L- α -aspartyl-, 3-methyl ester (9CI)

MF C32 H41 N5 O8

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2


10/712,456-ALW

L2 3 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 2-Pyrrolidinecarboxamide, 1-[(acetyloxy)(4-methoxyphenyl)acetyl]-N-[(1-amino-6-isoquinolinyl)methyl]-, (2S)- (9CI)

MF C26 H28 N4 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


10/712,456-ALW

L2 3 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN L-Proline, 1-[[(3-chloro-4-cyano-2-methylphenyl) amino] carbonyl]-3-hydroxy-
, methyl ester, (3R)-

MF C15 H16 Cl N3 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

10/712,456-ALW

=> s l1 sss ful

FULL SEARCH INITIATED 09:21:51 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 504112 TO ITERATE

97.8% PROCESSED 492961 ITERATIONS

668 ANSWERS

100.0% PROCESSED 504112 ITERATIONS

670 ANSWERS

SEARCH TIME: 00.00.20

L3 670 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.55

172.76

FILE 'CAPLUS' ENTERED AT 09:22:16 ON 29 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 May 2007 VOL 146 ISS 23

FILE LAST UPDATED: 28 May 2007 (20070528/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 174 L3

=> d l4 1-174 bib hitstr

10/712,456-ALW

L4 ANSWER 1 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2007:438817 CAPLUS

DN 146:433450

TI Preparation of gallium complexes of N-(carboxylmethyl)azamacrocycles linked to biovectors as PET imaging agents

IN Port, Marc; Corot, Claire; Gautheret, Thierry

PA Guerbet, Fr.

SO PCT Int. Appl., 91pp.



CODEN: PIXXD2

DT Patent


LA French.


FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2007042504 | A2 | 20070419 | WO 2006-EP67211 | 20061009 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | FR 2891830 | A1 | 20070413 | FR 2005-10289 | 20051007 |
| PRAI | FR 2005-10289 | A | 20051007 | | |
| | FR 2006-2975 | A | 20060405 | | |
| IT | 934164-64-4P 934164-74-6P | | | | |
| | RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (preparation of gallium complexes of N-(carboxylmethyl)azamacrocycles linked to biovectors as PET imaging agents) | | | | |
| RN | 934164-64-4 CAPLUS | | | | |
| CN | INDEX NAME NOT YET ASSIGNED | | | | |

● 3 H⁺

RN 934164-74-6 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED






● 2 H^+

L4 ANSWER 2 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:34978 CAPLUS
DN 146:351552
TI Pharmacological and X-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats
AU Ostrowski, Jacek; Kuhns, Joyce E.; Lupisella, John A.; Manfredi, Mark C.; Beehler, Blake C.; Krystek, Stanley R., Jr.; Bi, Yingzhi; Sun, Chongqing; Seethala, Ramakrishna; Golla, Rajasree; Sleph, Paul G.; Fura, Aberra; An, Yongmi; Kish, Kevin F.; Sack, John S.; Mookhtiar, Kasim A.; Grover, Gary J.; Hamann, Lawrence G.
CS Department of Metabolic Diseases, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543, USA
SO Endocrinology (2007), 148(1), 4-12
CODEN: ENDOAO; ISSN: 0013-7227
PB Endocrine Society
DT Journal
LA English
IT 627531-49-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(characterization of a novel selective androgen receptor modulator and its potent stimulation of skeletal muscle with hypostimulation of prostate in rats)
RN 627531-49-1 CAPLUS
CN L-Proline, 1-[[[(3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-3-hydroxy-, methyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW


L4 ANSWER 3 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1331239 CAPLUS
DN 146:155316
TI Design and study of some novel ibuprofen derivatives with potential
nootropic and neuroprotective properties
AU Siskou, Ioanna C.; Rekka, Eleni A.; Kourounakis, Angeliki P.; Chrysseis,
Michael C.; Tsiakitzis, Kariofyllis; Kourounakis, Panos N.
CS Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotelian
University of Thessaloniki, Thessaloniki, 54124, Greece
SO Bioorganic & Medicinal Chemistry (2007), 15(2), 951-961
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier Ltd.
DT Journal
LA English
IT 919803-09-1P 919803-10-4P 919803-11-5P
919803-12-6P 919803-17-1P 919803-18-2P
919803-19-3P 919803-20-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(ibuprofen derivs. with potential nootropic and neuroprotective
properties)
RN 919803-09-1 CAPLUS
CN L-Proline, 1-[2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]-,
2-methoxy-4-methylphenyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 919803-10-4 CAPLUS
CN L-Proline, 1-[(2S)-2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]-,
3-(3-pyridinyl)propyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 919803-11-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-(2-mercaptoethyl)-1-[(2S)-2-[4-(2-
methylpropyl)phenyl]-1-oxopropyl]-, (2S)- (CA INDEX NAME)

10/712,456-ALW


Absolute stereochemistry.



RN 919803-12-6 CAPLUS

CN L-Cysteine, 1-[2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]-L-prolyl-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 919803-17-1 CAPLUS

CN L-Proline, 1-[(2R)-2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]-, 2-methoxy-4-methylphenyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 919803-18-2 CAPLUS

CN L-Proline, 1-[(2S)-2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]-, 2-methoxy-4-methylphenyl ester (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 919803-19-3 CAPLUS

CN L-Cysteine, 1-[(2R)-2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]-L-prolyl-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 919803-20-6 CAPLUS

CN L-Cysteine, 1-[(2S)-2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]-L-prolyl-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 662165-78-8P 919803-16-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(ibuprofen derivs. with potential nootropic and neuroprotective properties)

RN 662165-78-8 CAPLUS

CN L-Proline, 1-[(2S)-2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]- (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 919803-16-0 CAPLUS

CN L-Proline, 1-[2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:1252166 CAPLUS
 DN 146:114246
 TI Discovery of Potent, Orally-Active, and Muscle-Selective Androgen Receptor Modulators Based on an N-Aryl-hydroxybicyclohydantoin Scaffold
 AU Sun, Chongqing; Robl, Jeffrey A.; Wang, Tammy C.; Huang, Yanting; Kuhns, Joyce E.; Lupisella, John A.; Beehler, Blake C.; Golla, Rajasree; Sleph, Paul G.; Seethala, Ramakrishna; Fura, Aberra; Krystek, Stanley R., Jr.; An, Yongmi; Malley, Mary F.; Sack, John S.; Salvati, Mark E.; Grover, Gary J.; Ostrowski, Jacek; Hamann, Lawrence G.
 CS Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-5400, USA
 SO Journal of Medicinal Chemistry (2006), 49(26), 7596-7599
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 146:114246
 IT 496840-99-4P 918344-29-3P 918344-30-6P
 918344-31-7P 918344-32-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (aryl bicyclohydantoin as selective androgen receptor modulators)
 RN 496840-99-4 CAPLUS
 CN L-Proline, 1-[[[4-nitro-1-naphthalenyl)amino]carbonyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 918344-29-3 CAPLUS
 CN L-Proline, 4-hydroxy-1-[[[4-nitro-1-naphthalenyl)amino]carbonyl]-, methyl ester, (4R)- (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 918344-30-6 CAPLUS

CN L-Proline, 4-hydroxy-1-[[4-nitro-1-naphthalenyl]amino]carbonyl]-, methyl ester, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 918344-31-7 CAPLUS

CN L-Proline, 3-hydroxy-1-[[4-nitro-1-naphthalenyl]amino]carbonyl]-, methyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 918344-32-8 CAPLUS

CN L-Proline, 1-[[4-cyano-1-naphthalenyl]amino]carbonyl]-3-hydroxy-, methyl ester, (3S)- (CA INDEX NAME)

10/712,456-ALW

Absolute stereochemistry.




RE.CNT 20

THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 5 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:920477 CAPLUS
 DN 145:450754
 TI Identification of early intermediates of caspase activation using selective inhibitors and activity-based probes
 AU Berger, Alicia B.; Witte, Martin D.; Denault, Jean-Bernard; Sadaghiani, Amir Masoud; Sexton, Kelly M. B.; Salvesen, Guy S.; Bogyo, Matthew
 CS Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA
 SO Molecular Cell (2006), 23(4), 509-521
 CODEN: MOCEFL; ISSN: 1097-2765
 PB Cell Press
 DT Journal
 LA English
 IT 913253-20-0P
 RL: BSU (Biological study, unclassified); CPN (Combinatorial preparation); PRP (Properties); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation)
 (identification of early intermediates of caspase activation using selective inhibitors and activity-based probes)
 RN 913253-20-0 CAPLUS
 CN L-Alaninamide, 1-[(4-hydroxy-3-nitrophenyl)acetyl]-L-prolyl-L-leucyl-N-[(1S)-1-(carboxymethyl)-3-[(2,6-dimethylbenzoyl)oxy]-2-oxopropyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:884878 CAPLUS
 DN 145:292874
 TI Preparation of pyridineacetic acid derivatives as peptidase inhibitors for the treatment of diabetes
 IN Maezaki, Hironobu; Suzuki, Nobuhiro
 PA Takeda Pharmaceutical Company Limited, Japan
 SO PCT Int. Appl., 98pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 2006090915 | A1 | 20060831 | WO 2006-JP304177 | 20060224 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | JP 2006265238 | A | 20061005 | JP 2006-47921 | 20060224 |
| PRAI | JP 2005-52018 | A | 20050225 | | |
| OS | MARPAT 145:292874 | | | | |
| IT | 907609-35-2P 907610-10-0P 907610-93-9P | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyridineacetic acid derivs. as peptidase inhibitors for treatment of diabetes) | | | | |
| RN | 907609-35-2 CAPLUS | | | | |
| CN | 2-Pyrrolidinecarboxamide, 1-[[5-(aminomethyl)-6-(2,2-dimethylpropyl)-2-ethyl-4-(4-methylphenyl)-3-pyridinyl]acetyl]-, (2S)- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.



RN 907610-10-0 CAPLUS

10/712,456-ALW


CN 2-Pyrrolidinecarboxamide, 1-[[5-(aminomethyl)-4-(4-methylphenyl)-2,6-bis(2-methylpropyl)-3-pyridinyl]acetyl]-, (2S)-, bis(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1

CRN 907610-09-7

CMF C28 H40 N4 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 907610-93-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[5-(aminomethyl)-6-(2,2-dimethylpropyl)-2-ethyl-4-(4-methylphenyl)-3-pyridinyl]acetyl]-, (2S)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 907609-35-2

CMF C27 H38 N4 O2

Absolute stereochemistry.


10/712,456-ALW



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 907611-13-6P 907611-18-1P 907611-36-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyridineacetic acid derivs. as peptidase inhibitors for treatment of diabetes)

RN 907611-13-6 CAPLUS

CN Carbamic acid, [[5-[2-[(2S)-2-(aminocarbonyl)-1-pyrrolidinyl]-2-oxoethyl]-2-(2,2-dimethylpropyl)-6-ethyl-4-(4-methylphenyl)-3-pyridinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

RN 907611-18-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[5-(aminomethyl)-2-methyl-4-(4-methylphenyl)-6-(2-methylpropyl)-3-pyridinyl]acetyl]-, dihydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 907611-36-3 CAPLUS

CN Carbamic acid, [[5-[2-[(2S)-2-(aminocarbonyl)-1-pyrrolidinyl]-2-oxoethyl]-6-methyl-4-(4-methylphenyl)-2-(2-methylpropyl)-3-pyridinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 7 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:847174 CAPLUS
DN 145:347820
TI Antitumor agents 251: Synthesis, cytotoxic evaluation, and
structure-activity relationship studies of phenanthrene-based tylophorine
derivatives (PBTs) as a new class of antitumor agents
AU Wei, Linyi; Brossi, Arnold; Kendall, Ross; Bastow, Kenneth F.;
Morris-Natschke, Susan L.; Shi, Qian; Lee, Kuo-Hsiung
CS Natural Products Research Laboratories, School of Pharmacy, University of
North Carolina, Chapel Hill, NC, 27599, USA
SO Bioorganic & Medicinal Chemistry (2006), 14(19), 6560-6569
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier Ltd.
DT Journal
LA English
OS CASREACT 145:347820
IT 910488-27-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(antitumor phenanthrene-based tylophorine derivs.)
RN 910488-27-6 CAPLUS
CN L-Proline, 1-[3-(4,5-dimethoxy-2-nitrophenyl)-2-(4-methoxyphenyl)-1-oxo-2-
propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 8 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:195904 CAPLUS

DN 144:267310

TI T type calcium channel blockers and the treatment of diseases

IN Gray, Lloyd S.; Haverstick, Doris M.

PA University of Virginia Patent Foundation, USA

SO PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 2006023881 | A2 | 20060302 | WO 2005-US29851 | 20050822 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | AU 2005277154 | A1 | 20060302 | AU 2005-277154 | 20050822 |
| | CA 2576186 | A1 | 20060302 | CA 2005-2576186 | 20050822 |
| | EP 1778245 | A2 | 20070502 | EP 2005-803731 | 20050822 |
| | R: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU | | | |

PRAI US 2004-603159P P 20040820

WO 2005-US29851 W 20050822

OS MARPAT 144:267310

IT 106789-32-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(T type calcium channel blockers and treatment of diseases including proliferative disorders)

RN 106789-32-6 CAPLUS

CN L-Proline, 1-[(4-methoxyphenyl)acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 9 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:1262237 CAPLUS

DN 144:35272

TI Augmenting B cell depletion by promoting intravascular access

IN Chan, Andrew C.; Gong, Qian; Martin, Flavius

PA Genentech, Inc., USA

SO PCT Int. Appl., 165 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|--|----------|-----------------|----------|
| PI | WO 2005113003 | A2 | 20051201 | WO 2005-US12984 | 20050415 |
| | WO 2005113003 | A3 | 20060316 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | AU 2005244751 | A1 | 20051201 | AU 2005-244751 | 20050415 |
| | CA 2563432 | A1 | 20051201 | CA 2005-2563432 | 20050415 |
| | US 2005276803 | A1 | 20051215 | US 2005-107028 | 20050415 |
| | EP 1735000 | A2 | 20061227 | EP 2005-778447 | 20050415 |
| | R: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | |
| PRAI | US 2004-563263P | P | 20040416 | | |
| | WO 2005-US12984 | W | 20050415 | | |
| OS | MARPAT 144:35272 | | | | |
| IT | 331471-51-3 331471-52-4 331471-57-9 331471-73-9 331471-89-7 870484-67-6 870484-68-7 | | | | |
| | RL: | THU (Therapeutic use); BIOL (Biological study); USES (Uses) (integrin $\alpha 4$ antagonist; augmenting B cell depletion by promoting intravascular access) | | | |
| RN | 331471-51-3 CAPLUS | | | | |
| CN | L-Tyrosine, 1-[(4-aminophenyl)acetyl]-L-prolyl-, 4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.




10/712,456-ALW

RN 331471-52-4 CAPLUS

CN L-Tyrosine, 1-[[4-(acetamino)phenyl]acetyl]-L-prolyl-,
4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331471-57-9 CAPLUS


CN L-Tyrosine, 1-[[4-[2-[(2-carboxyethyl)amino]-2-oxoethyl]phenyl]acetyl]-L-prolyl-, 4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B




RN 331471-73-9 CAPLUS

CN L-Tyrosine, 1-[[4-[2-[(carboxymethyl)amino]-2-oxoethyl]phenyl]acetyl]-L-prolyl-, 4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CO₂H

RN 331471-89-7 CAPLUS

CN L-Tyrosine, 1-[[4-(carboxymethyl)phenyl]acetyl]-L-prolyl-,
4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870484-67-6 CAPLUS


CN L-Tyrosine, L-tyrosyl-4-aminobenzeneacetyl-L-prolyl-, 4-(4-morpholinecarboxylate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 870484-68-7 CAPLUS


CN L-Tyrosine, N-acetyl-L-tyrosyl-4-aminobenzeneacetyl-L-prolyl-,
4-(4-morpholinecarboxylate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




10/712,456-ALW

L4 ANSWER 10 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1242804 CAPLUS
DN 144:6806
TI Preparation of pyrimidine hydantoin analogs which inhibit leukocyte adhesion mediated by VLA-4
IN Konradi, Andrei W.; Stappenbeck, Frank; Pleiss, Michael A.; Semko, Christopher; Smith, Jenifer L.
PA Elan Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|--|----------|-----------------|----------|
| PI | WO 2005111020 | A2 | 20051124 | WO 2005-US14885 | 20050429 |
| | WO 2005111020 | A3 | 20060126 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | US 2005261324 | A1 | 20051124 | US 2005-118862 | 20050429 |
| | US 7205310 | B2 | 20070417 | | |
| PRAI | US 2004-566784P | P | 20040430 | | |
| OS | MARPAT 144:6806 | | | | |
| IT | 869882-74-6P | | | | |
| | RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) | | | | |
| | (preparation of pyrimidine hydantoin analogs which inhibit leukocyte adhesion mediated by VLA-4) | | | | |
| RN | 869882-74-6 CAPLUS | | | | |
| CN | L-Proline, 1-[[[4-[(2S)-3-(1,1-dimethylethoxy)-3-oxo-2-[[[(phenylmethoxy)carbonyl]amino]propyl]phenyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 11 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:1216425 CAPLUS

DN 143:477970

TI Preparation of benzene derivatives containing amide moiety as ACC inhibitors

IN Suzuki, Nobuyasu; Nihei, Yukio; Ichinose, Hidehiro; Tanaka, Hideyuki; Yasa, Noriko; Hatanaka, Toshihiro; Masuzawa, Youko; Nakanishi, Eiji; Kondo, Nobuo

PA Ajinomoto Co., Inc., Japan

SO PCT Int. Appl., 227 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2005108370 | A1 | 20051117 | WO 2005-JP7392 | 20050418 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 2007105899 | A1 | 20070510 | US 2006-549450 | 20061013 |
| PRAI | JP 2004-122199 | A | 20040416 | | |
| | JP 2004-122200 | A | 20040416 | | |
| | JP 2004-122201 | A | 20040416 | | |
| | JP 2005-21616 | A | 20050128 | | |
| | WO 2005-JP7392 | A1 | 20050418 | | |

OS MARPAT 143:477970

IT 869574-93-6P 869574-94-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzene derivs. containing amide moiety as ACC inhibitors


for

treatment of hyperlipidemia, diabetes, etc.)

RN 869574-93-6 CAPLUS

CN D-Proline, 1-[[[4-[[3-(trifluoromethyl)phenyl]ethynyl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869574-94-7 CAPLUS

10/712,456-ALW

CN L-Proline, 1-[[[4-[[3-(trifluoromethyl)phenyl]ethynyl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 12 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:1125507 CAPLUS

DN 143:387379

TI Synthesis of thiocarbamoylproline derivatives for use as coagulation factor inhibitors in the prevention or treatment of thromboembolic diseases or tumors

IN Mederski, Werner; Tsaklakidis, Christos; Dorsch, Dieter; Cezanne, Bertram; Gleitz, Johannes

PA Merck Patent GmbH, Germany

SO Ger. Offen., 19 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|-----------------|------|----------|----------------------|----------|
| PI | DE 102004016605 | A1 | 20051020 | DE 2004-102004016605 | 20040403 |
| | WO 2005097783 | A1 | 20051020 | WO 2005-EP2745 | 20050315 |
| | WO 2005097783 | A8 | 20070419 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA

PRAI DE 2004-102004016605 A 20040403

OS MARPAT 143:387379

IT 866832-65-7P 866832-66-8P 866832-67-9P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiocarbamoylproline derivs. as coagulation factor VIIa or Xa inhibitors for prevention or treatment of thromboembolic diseases or tumors)

RN 866832-65-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[(4-ethynylphenyl)amino]thioxomethyl]-4-methoxy-N-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 866832-66-8 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[(4-ethynylphenyl)amino]thioxomethyl]-N-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-methoxy-, (2R,4R)- (9CI) (CA

10/712,456-ALW

INDEX NAME)


Absolute stereochemistry.



RN 866832-67-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[[4-ethynylphenyl]amino]thioxomethyl]-4-methoxy-N-[2-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 13 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:1075769 CAPLUS
 DN 143:347450
 TI Synthesis of prolanyl derivatives for use in the treatment of
 thromboembolic diseases or tumors
 IN Mederski, Werner; Tsaklakidis, Christos; Dorsch, Dieter; Cezanne, Bertram;
 Gleitz, Johannes
 PA Merck Patent G.m.b.H., Germany
 SO PCT Int. Appl., 51 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|----------------------|----------|
| PI | WO 2005092849 | A1 | 20051006 | WO 2005-EP2306 | 20050304 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | DE 102004014945 | A1 | 20051013 | DE 2004-102004014945 | 20040326 |
| | AU 2005225489 | A1 | 20051006 | AU 2005-225489 | 20050304 |
| | CA 2561057 | A1 | 20051006 | CA 2005-2561057 | 20050304 |
| | EP 1735279 | A1 | 20061227 | EP 2005-715737 | 20050304 |
| | R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LV | | | | |
| | CN 1938269 | A | 20070328 | CN 2005-80009735 | 20050304 |
| PRAI | DE 2004-102004014945 | A | 20040326 | | |
| | WO 2005-EP2306 | W | 20050304 | | |
| OS | MARPAT 143:347450 | | | | |
| IT | 865853-89-0P 865853-91-4P 865853-93-6P 865853-95-8P 865853-97-0P 865853-99-2P 865854-02-0P 865854-03-1P | | | | |
| | RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of proline derivs. for treatment of thromboembolic diseases or tumors) | | | | |
| RN | 865853-89-0 CAPLUS | | | | |
| CN | 1,2-Pyrrolidinedicarboxamide, N2-[2'-[(dimethylamino)methyl][1,1'- biphenyl]-4-yl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME) | | | | |


Absolute stereochemistry.



RN 865853-91-4 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-[(dimethylamino)methyl]-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865853-93-6 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]phenyl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865853-95-8 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]phenyl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)

10/712,456-ALW

1-yl]-2-fluorophenyl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865853-97-0 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[(dimethylamino)iminomethyl]phenyl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865853-99-2 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[(dimethylamino)iminomethyl]-2-fluorophenyl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865854-02-0 CAPLUS

10/712,456-ALW

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 865854-03-1 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)-2-fluorophenyl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 14 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:1020451 CAPLUS

DN 143:305710

TI Non-glycosylated/-glycosidic/-peptidic small molecule selectin inhibitors for the treatment of inflammatory disorders

IN Kranich, Remo; Aydt, Ewald Mirko

PA Revotar Biopharmaceuticals A.-G., Germany

SO Eur. Pat. Appl., 43 pp.

CODEN: EPXXDW


DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | EP 1577289 | A1 | 20050921 | EP 2004-6461 | 20040318 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK | | | | |
| | WO 2005090284 | A1 | 20050929 | WO 2005-EP2920 | 20050318 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | EP 1732882 | A1 | 20061220 | EP 2005-716209 | 20050318 |
| | R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |
| PRAI | EP 2004-6461 | A | 20040318 | | |
| | WO 2005-EP2920 | W | 20050318 | | |
| OS | MARPAT 143:305710 | | | | |
| IT | 864518-46-7P | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) | | | | |
| | (preparation of non-glycosylated/-glycosidic/-peptidic small mol. selectin inhibitors for treatment of inflammatory disorders) | | | | |
| RN | 864518-46-7 CAPLUS | | | | |
| CN | L-Proline, 1-[(2,3,4-trihydroxyphenyl)acetyl]- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/712,456-ALW

L4 ANSWER 15 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:983773 CAPLUS
DN 143:286280
TI Preparation of pyrrolizines as modulators of androgen receptor function
IN Li, James J.; Hamann, Lawrence; Augeri, David; Bi, Yingzhi
PA USA
SO U.S. Pat. Appl. Publ., 24 pp.
CODEN: USXXCO

DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|--|----------|-----------------|----------|
| PI | US 2005197367 | A1 | 20050908 | US 2005-70020 | 20050302 |
| | WO 2005089118 | A2 | 20050929 | WO 2005-US6925 | 20050303 |
| | WO 2005089118 | A3 | 20060223 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | EP 1729763 | A2 | 20061213 | EP 2005-724465 | 20050303 |
| | R: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV, MK, YU | | | |
| PRAI | US 2004-550154P | P | 20040304 | | |
| | WO 2005-US6925 | W | 20050303 | | |
| OS | CASREACT 143:286280; MARPAT 143:286280 | | | | |
| IT | 864361-85-3P | | | | |
| | RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) | | | | |
| | (preparation of pyrrolizines for treating, preventing, or inhibiting diseases associated with the androgen receptor) | | | | |
| RN | 864361-85-3 CAPLUS | | | | |
| CN | L-Proline, 1-[(3-chloro-4-cyano-2-methylphenyl)acetyl]-3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, methyl ester, (3S)- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 16 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:983771 CAPLUS

DN 143:286428

TI Preparation of pyrrolo[1,2-c]oxazoles and pyrrolo[1,2-c]imidazoles as modulators of androgen receptor function

IN Nirschl, Alexandra; Sutton, James C.; Hamann, Lawrence; Wang, Tammy; Zou, Yan; Sun, Chongqing

PA USA

SO U.S. Pat. Appl. Publ., 38 pp.

CODEN: USXXCO


DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|--|----------|-----------------|----------|
| PI | US 2005197359 | A1 | 20050908 | US 2005-70808 | 20050302 |
| | WO 2005087232 | A1 | 20050922 | WO 2005-US7229 | 20050303 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | EP 1722793 | A1 | 20061122 | EP 2005-724717 | 20050303 |
| | R: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LV, MK, YU | | | |
| PRAI | US 2004-550042P | P | 20040304 | | |
| | WO 2005-US7229 | W | 20050303 | | |
| OS | MARPAT 143:286428 | | | | |
| IT | 627531-62-8P 627531-64-0P | | | | |
| | RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) | | | | |
| | (preparation of pyrrolo[1,2-c]oxazoles and pyrrolo[1,2-c]imidazoles to treating, preventing, or inhibiting diseases associated with the androgen receptor) | | | | |
| RN | 627531-62-8 CAPLUS | | | | |
| CN | L-Proline, 1-[[[3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-3-hydroxy-, methyl ester, (3S)- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.




RN 627531-64-0 CAPLUS

10/712,456-ALW

CN L-Proline, 1-[[[3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, methyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 17 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:564637 CAPLUS
DN 143:97636
TI Synthesis of prolinylarylacetamides as coagulation factor Xa inhibitors
for use in the prevention or treatment of thromboembolic diseases or
tumors
IN Mederski, Werner; Tsaklakidis, Christos; Dorsch, Dieter; Cezanne, Bertram;
Gleitz, Johannes
PA Merck Patent G.m.b.H., Germany
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|------------------|----------|
| PI | WO 2005058817 | A1 | 20050630 | WO 2004-EP13509 | 20041126 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | DE 10358814 | A1 | 20050721 | DE 2003-10358814 | 20031216 |
| | AU 2004299197 | A1 | 20050630 | AU 2004-299197 | 20041126 |
| | CA 2549589 | A1 | 20050630 | CA 2004-2549589 | 20041126 |
| | EP 1697318 | A1 | 20060906 | EP 2004-820404 | 20041126 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS | | | | |
| | CN 1894210 | A | 20070110 | CN 2004-80037698 | 20041126 |
| | BR 2004017630 | A | 20070327 | BR 2004-17630 | 20041126 |
| | IN 2006KN01579 | A | 20070504 | IN 2006-KN1579 | 20060608 |
| PRAI | DE 2003-10358814 | A | 20031216 | | |
| | WO 2004-EP13509 | W | 20041126 | | |

OS MARPAT 143:97636


IT 855855-42-4 855855-48-0

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of prolinylarylacetamides as coagulation factor Xa inhibitors
for prevention or treatment of thromboembolic diseases or tumors)

RN 855855-42-4 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[4-[[(dimethylamino)acetyl]methylamino]ph
enyl]-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 855855-48-0 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-hydroxy-N2-[4-[(methoxyacetyl)methylamino]phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:430480 CAPLUS

DN 143:133331

TI High-performance liquid chromatographic enantioseparation based on diastereomer formation with new fluorescent chiral quinoxalines

AU Katoh, Akira; Yamamoto, Ryoji; Fujimoto, Takeshi; Saito, Ryota

CS Department of Applied Chemistry, Faculty of Engineering, Seikei University, Tokyo, 180-8633, Japan

SO Heterocycles (2005), 65(5), 1111-1120

CODEN: HTCYAM; ISSN: 0385-5414

PB Japan Institute of Heterocyclic Chemistry

DT Journal

LA English

OS CASREACT 143:133331

IT 858114-47-3P 858114-49-5P

RL: PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)

(preparation of ibuprofen-derived fluorescent chiral quinoxaline derivative


and

study of its high-performance liquid chromatog. enantiosepn.)

RN 858114-47-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2,3-di-4-morpholinyl-6-quinoxaliny)-1-[(2S)-2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 858114-49-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(2,3-di-4-morpholinyl-6-quinoxaliny)-1-[(2R)-2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 19 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:429392 CAPLUS

DN 142:481940

TI Preparation of 3-phenyl-2,4-pyrrolidinediones as herbicides

IN Fischer, Reiner; Lehr, Stefan; Feucht, Dieter; Loesel, Peter; Malsam, Olga; Bojack, Guido; Auler, Thomas; Hills, Martin Jeffrey; Kehne, Heinz; Rosinger, Christopher Hugh

PA Bayer Cropscience Aktiengesellschaft, Germany

SO PCT Int. Appl., 153 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|------------------|--|----------|------------------|----------|
| PI | WO 2005044791 | A2 | 20050519 | WO 2004-EP12444 | 20041104 |
| | WO 2005044791 | A3 | 20050811 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | DE 10351647 | A1 | 20050609 | DE 2003-10351647 | 20031105 |
| | AU 2004287597 | A1 | 20050519 | AU 2004-287597 | 20041104 |
| | CA 2544548 | A1 | 20050519 | CA 2004-2544548 | 20041104 |
| | EP 1682501 | A2 | 20060726 | EP 2004-803102 | 20041104 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS | | | |
| | CN 1874995 | A | 20061206 | CN 2004-80032654 | 20041104 |
| | BR 2004015738 | A | 20061219 | BR 2004-15738 | 20041104 |
| | JP 2007511476 | T | 20070510 | JP 2006-537248 | 20041104 |
| PRAI | DE 2003-10351647 | A | 20031105 | | |
| | WO 2004-EP12444 | W | 20041104 | | |

OS MARPAT 142:481940

IT 852069-60-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of phenylpyrrolidinediones as herbicides)

RN 852069-60-4 CAPLUS

CN L-Proline, 1-[(2-bromo-6-ethyl-4-methylphenyl)acetyl]-, methyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



L4 ANSWER 20 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:409480 CAPLUS

DN 142:463610

TI Preparation of pyridines as inhibitors of dipeptidyl peptidase IV useful for the prophylaxis or treatment of diabetes

IN Oi, Satoru; Maezaki, Hironobu; Suzuki, Nobuhiro

PA Takeda Pharmaceutical Company Limited, Japan

SO PCT Int. Appl., 431 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 2005042488 | A1 | 20050512 | WO 2004-JP16457 | 20041029 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2004285807 | A1 | 20050512 | AU 2004-285807 | 20041029 |
| | CA 2543529 | A1 | 20050512 | CA 2004-2543529 | 20041029 |
| | JP 2006016377 | A | 20060119 | JP 2004-315517 | 20041029 |
| | EP 1678138 | A1 | 20060712 | EP 2004-793377 | 20041029 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| | CN 1886376 | A | 20061227 | CN 2004-80034965 | 20041029 |
| | BR 2004015960 | A | 20070116 | BR 2004-15960 | 20041029 |
| | US 2007037807 | A1 | 20070215 | US 2006-577561 | 20060428 |
| | IN 2006KN01220 | A | 20070427 | IN 2006-KN1220 | 20060510 |
| | NO 2006002516 | A | 20060725 | NO 2006-2516 | 20060531 |
| PRAI | JP 2003-373776 | A | 20031031 | | |
| | JP 2004-30491 | A | 20040206 | | |
| | JP 2004-165977 | A | 20040603 | | |
| | WO 2004-JP16457 | W | 20041029 | | |
| OS | MARPAT 142:463610 | | | | |
| IT | 851585-68-7P, Methyl 1-[[[5-(aminomethyl)-6-isobutyl-2-methyl-4-(4-methylphenyl)pyridin-3-yl]amino]carbonyl]pyrrolidine-2-carboxylate dihydrochloride 851586-53-3P, Methyl 1-[[5-(aminomethyl)-6-isobutyl-2-methyl-4-(4-methylphenyl)pyridin-3-yl]acetyl]prolinate dihydrochloride | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (drug candidate; preparation of pyridines as inhibitors of dipeptidyl peptidase IV useful for prophylaxis or treatment of diabetes) | | | | |
| RN | 851585-68-7 CAPLUS | | | | |
| CN | Proline, 1-[[[5-(aminomethyl)-2-methyl-4-(4-methylphenyl)-6-(2-methylpropyl)-3-pyridinyl]amino]carbonyl]-, methyl ester, dihydrochloride (9CI) (CA INDEX NAME) | | | | |




● 2 HCl

RN 851586-53-3 CAPLUS

CN L-Proline, 1-[[[5-(aminomethyl)-2-methyl-4-(4-methylphenyl)-6-(2-methylpropyl)-3-pyridinyl]acetyl]-, methyl ester, dihydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

IT 851585-69-8P, Methyl 1-[[[5-[[[tert-butoxycarbonyl]amino]methyl]-6-isobutyl-2-methyl-4-(4-methylphenyl)pyridin-3-yl]amino]carbonyl]pyrrolidine-2-carboxylate 851586-54-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyridines as inhibitors of dipeptidyl peptidase IV useful for prophylaxis or treatment of diabetes)

RN 851585-69-8 CAPLUS

CN Proline, 1-[[[5-[[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-methyl-4-(4-methylphenyl)-6-(2-methylpropyl)-3-pyridinyl]amino]carbonyl]-, methyl

10/712,456-ALW


ester (9CI) (CA INDEX NAME)



RN 851586-54-4 CAPLUS

CN L-Proline, 1-[[[5-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]-2-methyl-4-(4-methylphenyl)-6-(2-methylpropyl)-3-pyridinyl]acetyl]-, methyl ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 8


THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 21 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:395446 CAPLUS
DN 142:406543
TI TAO kinase inhibitors for pharmaceutical use and for screening for kinase modulators
IN Xu, Wei; Zheng, Wentao; Baly, Deborah Lynn; Galan, Adam Antoni; Ibrahim, Mohamed Abdulkader; Jaeger, Christopher; Kearney, Patrick; Leahy, James William; Lewis, Gary Lee; McMillan, Kirk; Noguchi, Robin Tammie; Nuss, John M.; Parks, Jason Jevious; Schnepf, Kevin Luke; Shi, Xian; Williams, Matthew Alan
PA Exelixis, Inc., USA
SO PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|--|----------|-----------------|----------|
| PI | WO 2005040355 | A2 | 20050506 | WO 2004-US35469 | 20041022 |
| | WO 2005040355 | A3 | 20050804 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | AU 2004283313 | A1 | 20050506 | AU 2004-283313 | 20041022 |
| | CA 2542064 | A1 | 20050506 | CA 2004-2542064 | 20041022 |
| | EP 1678121 | A2 | 20060712 | EP 2004-796442 | 20041022 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | |
| PRAI | US 2003-514377P | P | 20031024 | | |
| | WO 2004-US35469 | W | 20041022 | | |
| OS | MARPAT 142:406543 | | | | |
| IT | 850467-15-1 850467-20-8 | | | | |
| | RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (TAO kinase inhibitors for pharmaceutical use and for screening for kinase modulators) | | | | |
| RN | 850467-15-1 CAPLUS | | | | |
| CN | 1,2-Pyrrolidinedicarboxamide, N1-(4-butylphenyl)-N2-[(3,4-dichlorophenyl)methyl]-, (2S)- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.




10/712,456-ALW

RN 850467-20-8 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[(3,4-dichlorophenyl)methyl]-N1-[4-(1-methylethyl)phenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 22 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:173614 CAPLUS

DN 143:387223

TI Solid-phase synthesis of model libraries of 3 α ,17 β -dihydroxy-16 α -(N-substituted-aminoethyl)-5 α -androstanes for the development of steroidal therapeutic agents

AU Maltais, Rene; Mercier, Caroline; Labrie, Fernand; Poirier, Donald

CS Oncology and Molecular Endocrinology Research Center (Medicinal Chemistry Division), University Laval, Centre Hospitalier Universitaire de Quebec (CHUQ), QC, G1V 4G2, Can.

SO Molecular Diversity (2005), 9(1-3), 67-79

CODEN: MODIF4; ISSN: 1381-1991

PB Springer

DT Journal

LA English

OS CASREACT 143:387223

IT 866591-57-3P


RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(preparation and antiproliferative activity of; solid-phase synthesis of chemical library of 16 α -(N-substituted-aminoethyl)-5 α -androsterane-3 α ,17 β -diols)

RN 866591-57-3 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[2-[(3 α ,5 α ,16 α ,17 β)-3,17-dihydroxyandrostan-16-yl]ethyl]-1-[[4-[2-(1-piperidinyl)ethoxy]phenyl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 866592-15-6DP, 3-O-PS-DES resin-bound

RL: CPN (Combinatorial preparation); CRT (Combinatorial reactant); RCT (Reactant); SPN (Synthetic preparation); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)


(preparation and removal of, from resin; solid-phase synthesis of chemical library of 16 α -(N-substituted-aminoethyl)-5 α -androsterane-

10/712,456-ALW


3 α ,17 β -diols)
RN 866592-15-6 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[2-[(3 α ,5 α ,16 α ,17 β)-3-hydroxy-17-[(tetrahydro-2H-pyran-2-yl)oxy]androstan-16-yl]ethyl]-1-[[4-[2-(1-piperidinyl)ethoxy]phenyl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




IT 866592-80-5P 866593-33-1P 866593-47-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(solid-phase synthesis of chemical library of 16 α -(N-substituted-aminoethyl)-5 α -androstan-3 α ,17 β -diols)
RN 866592-80-5 CAPLUS
CN Glycinamide, 1-[[4-[2-(1-piperidinyl)ethoxy]phenyl]acetyl]-L-prolyl-N-[2-[(3 α ,5 α ,16 α ,17 β)-3,17-dihydroxyandrostan-16-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 866593-33-1 CAPLUS


CN L-Isoleucinamide, 1-[[4-[2-(1-piperidinyl)ethoxy]phenyl]acetyl]-L-prolyl-N-[2-[(3 α ,5 α ,16 α ,17 β)-3,17-dihydroxyandrost-16-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 866593-47-7 CAPLUS

CN L-Phenylalaninamide, 1-[[4-[2-(1-piperidinyl)ethoxy]phenyl]acetyl]-L-prolyl-N-[2-[(3 α ,5 α ,16 α ,17 β)-3,17-dihydroxyandrost-16-yl]ethyl]- (9CI) (CA INDEX NAME)


10/712,456-ALW

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 23 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:86537 CAPLUS
 DN 143:431977
 TI Identified a morpholinyl-4-piperidinylacetic acid derivative as a potent oral active VLA-4 antagonist. [Erratum to document cited in CA142:085870]
 AU Chiba, Jun; Machinaga, Nobuo; Takashi, Tohru; Ejima, Akio; Takayama, Gensuke; Yokoyama, Mika; Nakayama, Atsushi; Baldwin, John J.; McDonald, Edward; Moriarty, Kevin J.; Sarko, Christopher R.; Saionz, Kurt W.; Swanson, Robert; Hussain, Zahid; Wong, Angela
 CS Medicinal Chemistry Research Laboratory, Daiichi Pharmaceutical Co., Ltd., Edogawa-ku, Tokyo, 134-8630, Japan
 SO Bioorganic & Medicinal Chemistry Letters (2005), 15(4), 1259
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 IT 819078-48-3
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); BIOL (Biological study)
 (morpholinyl-4-piperidinylacetic acid derivative as potent oral active VLA-4 antagonist (Erratum))
 RN 819078-48-3 CAPLUS
 CN Pentanoic acid, 5-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 819078-50-7P 819078-51-8P 819078-52-9P
 819078-53-0P 819078-54-1P 819078-55-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (morpholinyl-4-piperidinylacetic acid derivative as potent oral active VLA-4 antagonist (Erratum))
 RN 819078-50-7 CAPLUS
 CN Glycine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

RN 819078-51-8 CAPLUS

CN β -Alanine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 819078-52-9 CAPLUS

CN Butanoic acid, 4-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 819078-53-0 CAPLUS

CN Hexanoic acid, 6-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 819078-54-1 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]methyl]-, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 819078-55-2 CAPLUS

CN Benzoic acid, 4-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 819078-82-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(morpholinyl-4-piperidinylacetic acid derivative as potent oral active VLA-4 antagonist (Erratum))

RN 819078-82-5 CAPLUS

CN L-Proline, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW


L4 ANSWER 24 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:1124627 CAPLUS
DN 142:74838
TI Preparation of pyrrolidin-1,2-dicarboxylic acids and related compounds as
coagulation factor Xa and factor VIIa inhibitors
IN Mederski, Werner; Tsaklakidis, Christos; Dorsch, Dieter; Cezanne, Bertram;
Gleitz, Johannes
PA Merck Patent G.m.b.H., Germany
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|------------------|----------|
| PI | WO 2004110433 | A1 | 20041223 | WO 2004-EP5717 | 20040527 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | DE 10327428 | A1 | 20050105 | DE 2003-10327428 | 20030618 |
| | DE 10329457 | A1 | 20050120 | DE 2003-10329457 | 20030701 |
| | AU 2004246766 | A1 | 20041223 | AU 2004-246766 | 20040527 |
| | CA 2529453 | A1 | 20041223 | CA 2004-2529453 | 20040527 |
| | EP 1633346 | A1 | 20060315 | EP 2004-735007 | 20040527 |
| | EP 1633346 | B1 | 20060823 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| | BR 2004011466 | A | 20060711 | BR 2004-11466 | 20040527 |
| | CN 1809346 | A | 20060726 | CN 2004-80016955 | 20040527 |
| | AT 337000 | T | 20060915 | AT 2004-735007 | 20040527 |
| | JP 2006527708 | T | 20061207 | JP 2006-515798 | 20040527 |
| | US 2007093472 | A1 | 20070426 | US 2005-561227 | 20051219 |
| PRAI | DE 2003-10327428 | A | 20030618 | | |
| | DE 2003-10329457 | A | 20030701 | | |
| | WO 2004-EP5717 | W | 20040527 | | |
| OS | MARPAT 142:74838 | | | | |
| IT | 814263-98-4P 814263-99-5P 814264-00-1P 814264-01-2P 814264-02-3P 814264-03-4P 814264-04-5P 814264-05-6P 814264-06-7P 814264-07-8P 814264-08-9P 814264-09-0P 814264-10-3P 814264-11-4P 814264-12-5P 814264-13-6P 814264-14-7P 814264-15-8P 814264-16-9P 814264-17-0P 814264-18-1P 814264-19-2P 814264-20-5P 814264-21-6P 814264-22-7P 814264-23-8P 814264-24-9P 814264-25-0P 814264-26-1P 814264-27-2P 814264-28-3P 814264-29-4P 814264-30-7P 814264-31-8P 814264-32-9P 814264-33-0P 814264-34-1P 814264-35-2P 814264-36-3P 814264-37-4P 814264-38-5P 814264-39-6P 814264-40-9P 814264-41-0P 814264-42-1P 814264-43-2P 814264-44-3P 814264-45-4P | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU | | | | |

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

RN 814263-98-4 CAPLUS

Absolute stereochemistry.



CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-methoxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

COC[C@H]1C[C@@H](C(=O)Nc2ccc(N3C(=O)CCOCC3)c2)[C@H](C(=O)Nc4ccc(C#C)cc4)[C@H]1R

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-methoxy-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Chemical structure of compound 10: A morpholine ring substituted with a 4-(4-((4-ethynylphenyl)hydrazono)pyrrolidin-2-yl)-3-methylphenyl group. The pyrrolidine ring has a methyl group at the 4-position and an ethynyl group at the 2-position.

10/712,456-ALW

RN 814264-01-2 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-hydroxy-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-02-3 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-03-4 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-hydroxy-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-04-5 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-hydroxy-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

10/712,456-ALW


Absolute stereochemistry.



RN 814264-05-6 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-06-7 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-07-8 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 814264-08-9 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-methoxy-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-09-0 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-10-3 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 814264-11-4 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-12-5 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-13-6 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[4-(2-oxo-1(2H)-pyrazinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-14-7 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[4-(2-oxo-1-piperidinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-15-8 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[3-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-16-9 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 814264-17-0 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-18-1 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[4-(2-oxo-1(2H)-pyrazinyl)phenyl]-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-19-2 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-hydroxy-N2-[4-(2-oxo-1-piperidiny)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 814264-20-5 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-hydroxy-N2-[4-(2-oxo-1-pyrrolidinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-21-6 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-hydroxy-N2-[3-methyl-4-(2-oxo-1-piperidiny)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-22-7 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-hydroxy-N2-[3-methyl-4-(2-oxo-1-pyrrolidinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 814264-23-8 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-24-9 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-ethoxy-N1-(4-ethynylphenyl)-N2-[3-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-25-0 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-(1-acetyl-2,3-dihydro-1H-indol-5-yl)-N1-(4-ethynylphenyl)-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 814264-26-1 CAPLUS

CN 1H-Indole-2-carboxylic acid, 5-[[[(2R,4R)-1-[[4-ethynylphenyl]amino]carbonyl]-4-hydroxy-2-pyrrolidinyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-27-2 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-methoxy-N2-[3-methoxy-4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-28-3 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-hydroxy-N2-[3-methoxy-4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 814264-29-4 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propenyloxy)-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-30-7 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propenyloxy)-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-31-8 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propenyloxy)-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 814264-32-9 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propynyloxy)-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-33-0 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-34-1 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-methoxy-N2-[3-methyl-4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-35-2 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-4-(2-propynyloxy)-, (2R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-36-3 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, 4-(2,3-dihydroxypropoxy)-N1-(4-ethynylphenyl)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-37-4 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-methoxy-N2-[4-(5-methyl-2-oxo-1(2H)-pyridinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 814264-38-5 CAPLUS

CN L-Proline, 1-[4-[[[(2R,4R)-1-[[4-ethynylphenyl]amino]carbonyl]-4-methoxy-2-pyrrolidinyl]carbonyl]amino]phenyl]-4-hydroxy-, methyl ester, (4R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-39-6 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-methyl-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2S,4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-40-9 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-methyl-2-oxo-1(2H)-pyridinyl)phenyl]-4-methoxy-, (2R,4R)-(9CI) (CA INDEX NAME)

10/712,456-ALW


Absolute stereochemistry.



RN 814264-41-0 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-(2-methoxyethoxy)-N2-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-42-1 CAPLUS

CN Acetic acid, [[[4-(3-oxo-4-morpholinyl)phenyl]amino]carbonyl]-5-[[[(4-ethynylphenyl)amino]carbonyl]-3-pyrrolidinyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 814264-43-2 CAPLUS

CN Acetic acid, [[[4-(3-oxo-4-morpholinyl)phenyl]amino]carbonyl]-5-[[[(4-ethynylphenyl)amino]carbonyl]-3-pyrrolidinyl]oxy]- (9CI) (CA INDEX NAME)

10/712,456-ALW

NAME)


Absolute stereochemistry.



RN 814264-44-3 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-methoxy-N2-[4-(3-methyl-6-oxo-1(6H)-pyridazinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 814264-45-4 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-4-(2-methoxyethoxy)-N2-[2-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 814264-46-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrrolidinyldicarboxylic acids and related compds. as factor Xa and factor VIIa inhibitors)


RN 814264-46-5 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-(4-ethynylphenyl)-N2-[2-fluoro-4-(3-oxo-4-

10/712,456-ALW

morpholinyl)phenyl]-4-(2-methoxyethoxy)-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 25 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:1080794 CAPLUS

DN 142:49214

TI Compounds inhibiting the binding of serum amyloid P component (SAP) for treating osteoarthritis

IN Pepys, Mark B.; Hawkins, Philip Nigel

PA Pentraxin Therapeutics Limited, UK

SO PCT Int. Appl., 51 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004108131 | A1 | 20041216 | WO 2004-GB2445 | 20040610 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2004244815 | A1 | 20041216 | AU 2004-244815 | 20040610 |
| | CA 2528706 | A1 | 20041216 | CA 2004-2528706 | 20040610 |
| | EP 1633345 | A1 | 20060315 | EP 2004-736527 | 20040610 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| | GB 2420498 | A | 20060531 | GB 2006-229 | 20040610 |
| | JP 2006527250 | T | 20061130 | JP 2006-516388 | 20040610 |
| PRAI | GB 2003-13386 | A | 20030610 | | |
| | WO 2004-GB2445 | W | 20040610 | | |
| OS | MARPAT 142:49214 | | | | |
| IT | 224624-85-5, Ro 63-7777 224625-47-2, Ro 64-4383 | | | | |
| | RL: PAC (Pharmacological activity); BIOL (Biological study) | | | | |
| | (compds. inhibiting binding of serum amyloid P component for treating osteoarthritis) | | | | |
| RN | 224624-85-5 CAPLUS | | | | |
| CN | D-Proline, 1,1'-[1,4-phenylenebis(1-oxo-2,1-ethanediyl)]bis- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.




RN 224625-47-2 CAPLUS

CN D-Proline, 1,1'-[(2,5-dihydroxy-1,4-phenylene)bis(1-oxo-2,1-ethanediyl)]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 26 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:1068245 CAPLUS
 DN 142:85870
 TI Identified a morpholinyl-4-piperidinylacetic acid derivative as a potent oral active VLA-4 antagonist
 AU Chiba, Jun; Machinaga, Nobuo; Takashi, Tohru; Ejima, Akio; Takayama, Gensuke; Yokoyama, Mika; Nakayama, Atsushi; Baldwin, John J.; McDonald, Edward; Saionz, Kurt W.; Swanson, Robert; Hussain, Zahid; Wong, Angela
 CS Medicinal Chemistry Research Laboratory, Daiichi Pharmaceutical Co., Ltd., Edogawa-ku, Tokyo, 134-8630, Japan
 SO Bioorganic & Medicinal Chemistry Letters (2005), 15(1), 41-45
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier B.V.
 DT Journal
 LA English
 OS CASREACT 142:85870
 IT 819078-48-3
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); BIOL (Biological study)
 (morpholinyl-4-piperidinylacetic acid derivative as potent oral active VLA-4 antagonist)
 RN 819078-48-3 CAPLUS
 CN Pentanoic acid, 5-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 819078-50-7P 819078-51-8P 819078-52-9P
 819078-53-0P 819078-54-1P 819078-55-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (morpholinyl-4-piperidinylacetic acid derivative as potent oral active VLA-4 antagonist)
 RN 819078-50-7 CAPLUS
 CN Glycine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

RN 819078-51-8 CAPLUS

CN β -Alanine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 819078-52-9 CAPLUS

CN Butanoic acid, 4-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 819078-53-0 CAPLUS

CN Hexanoic acid, 6-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 819078-54-1 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]methyl]-, trans- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 819078-55-2 CAPLUS

CN Benzoic acid, 4-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 819078-82-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(morpholinyl-4-piperidinylacetic acid derivative as potent oral active VLA-4 antagonist)

RN 819078-82-5 CAPLUS

CN L-Proline, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:1037096 CAPLUS

DN 142:23512

TI Preparation of N-acyl proline derivatives and related nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors

IN Ksander, Gary Michael; Vedananda, Thalaththani Ralalage

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SO PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 2004103995 | A1 | 20041202 | WO 2004-EP5434 | 20040519 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2004240754 | A1 | 20041202 | AU 2004-240754 | 20040519 |
| | CA 2525764 | A1 | 20041202 | CA 2004-2525764 | 20040519 |
| | EP 1638963 | A1 | 20060329 | EP 2004-739269 | 20040519 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |
| | BR 2004010779 | A | 20060627 | BR 2004-10779 | 20040519 |
| | CN 1795193 | A | 20060628 | CN 2004-80014021 | 20040519 |
| | JP 2007501263 | T | 20070125 | JP 2006-529884 | 20040519 |
| | US 2006135593 | A1 | 20060622 | US 2005-556988 | 20051115 |
| | NO 2005006056 | A | 20060217 | NO 2005-6056 | 20051220 |
| PRAI | US 2003-472067P | P | 20030520 | | |
| | WO 2004-EP5434 | W | 20040519 | | |
| OS | MARPAT 142:23512 | | | | |
| IT | 799854-62-9P 799854-63-0P 799854-67-4P 799854-68-5P 799854-71-0P 799854-82-3P | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (preparation of N-acyl proline derivs. and related nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors) | | | | |
| RN | 799854-62-9 CAPLUS | | | | |
| CN | D-Proline, 1-[2-methyl-2-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.


10/712,456-ALW



RN 799854-63-0 CAPLUS

CN D-Proline, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 799854-67-4 CAPLUS

CN D-Proline, 1-[2-methyl-2-[4-[[methyl[[4-(trifluoromethyl)phenyl]acetyl]amino]methyl]phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 799854-68-5 CAPLUS

CN D-Proline, 1-[2-[3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]-4-methoxyphenyl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 799854-71-0 CAPLUS


CN D-Proline, 1-[[4-[2-[[[4-(trifluoromethyl)phenyl]acetyl]amino]ethyl]phenyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 799854-82-3 CAPLUS

CN Proline, 1-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)




RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 28 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:857399 CAPLUS
DN 141:343478
TI Use of small molecule compounds for immunopotential
IN Valiante, Nicholas
PA Chiron Corporation, USA
SO PCT Int. Appl., 146 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|--|----------|-----------------|----------|
| PI | WO 2004087153 | A2 | 20041014 | WO 2004-US10331 | 20040329 |
| | WO 2004087153 | A3 | 20050317 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | CA 2520124 | A1 | 20041014 | CA 2004-2520124 | 20040329 |
| | US 2005136065 | A1 | 20050623 | US 2004-814480 | 20040329 |
| | EP 1608369 | A2 | 20051228 | EP 2004-758593 | 20040329 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK | | | |
| PRAI | US 2003-458888P | P | 20030328 | | |
| | WO 2004-US10331 | W | 20040329 | | |
| OS | MARPAT 141:343478 | | | | |
| IT | 774197-06-7 | | | | |
| | RL: | PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | |
| | | (small mol. compds. for immunopotential) | | | |
| RN | 774197-06-7 CAPLUS | | | | |
| CN | 1,2-Pyrrolidinedicarboxamide, N1-(4-methylphenyl)-5-phenyl-N2-[2-(2-pyridinyl)ethyl]-, (2S,5R)- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 29 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:759871 CAPLUS

DN 141:277621

TI Preparation of bicyclic compounds as modulators of androgen receptor function

IN Sun, Chong-Qing; Hamann, Lawrence; Augeri, David; Bi, Yingzhi; Robl, Jeffrey; Huang, Yan-Ting; Wang, Tammy; Holubec, Alexandra; Simpkins, Ligaya; Sutton, James C.; Li, James J.

PA USA

SO U.S. Pat. Appl. Publ., 94 pp., Cont.-in-part of U.S. Pat. Appl. 2004 19,063.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|----------|-----------------|----------|
| PI | US 2004181064 | A1 | 20040916 | US 2004-780415 | 20040217 |
| | US 2004019063 | A1 | 20040129 | US 2003-438722 | 20030515 |
| PRAI | US 2002-381616P | P | 20020517 | | |
| | US 2002-406711P | P | 20020829 | | |
| | US 2003-438722 | A2 | 20030515 | | |

OS MARPAT 141:277621

IT 627531-32-2P 627531-49-1P 627531-62-8P

627531-63-9P 627531-64-0P 627531-67-3P

627531-68-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of bicyclic compds. as modulators of androgen receptor function)

RN 627531-32-2 CAPLUS

CN L-Proline, 1-[[[(7-cyano-1-methyl-1H-benzimidazol-4-yl)amino]carbonyl]-3-hydroxy-, methyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627531-49-1 CAPLUS

CN L-Proline, 1-[[[(3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-3-hydroxy-, methyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 627531-62-8 CAPLUS

CN L-Proline, 1-[[[3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-3-hydroxy-, methyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627531-63-9 CAPLUS

CN L-Proline, 1-[[[3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-3-hydroxy-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627531-64-0 CAPLUS

CN L-Proline, 1-[[[3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, methyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627531-67-3 CAPLUS

CN L-Proline, 1-[[[3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-4-hydroxy-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627531-68-4 CAPLUS

CN L-Proline, 1-[[[3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 30 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:670962 CAPLUS
DN 141:332439
TI Titanium Catalysis in the Ugi Reaction of α -Amino Acids with
Aromatic Aldehydes
AU Godet, Thomas; Bonvin, Yannick; Vincent, Guillaume; Merle, Daphne; Thozet,
Alain; Ciufolini, Marco A.
CS Ecole Supérieure de Chimie, Physique et Electronique de Lyon, Laboratoire
de Synthèse et Methodologie Organiques, CNRS UMR 5181, Centre Commun de
Diffraction, Université Claude Bernard Lyon 1, Villeurbanne, 69622,
Fr.
SO Organic Letters (2004), 6(19), 3281-3284
CODEN: ORLEF7; ISSN: 1523-7060
PB American Chemical Society
DT Journal
LA English
OS CASREACT 141:332439
IT 771586-55-1P 771586-56-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(temperature-dependent uncatalyzed condensation of an aryl aldehyde and an
aryl isocyanide with L-pyrroglutamic acid yields α -
alkoxyarylacetic acid amides)
RN 771586-55-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(2R)-(2,4-dimethoxy-3-
methylphenyl)methoxyacetyl]-N-(2,6-dimethylphenyl)-5-oxo-, (2S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 771586-56-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[(2R)-(2,4-dimethoxy-3-
methylphenyl)ethoxyacetyl]-N-(2,6-dimethylphenyl)-5-oxo-, (2S)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW





RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW



L4 ANSWER 31 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:610128 CAPLUS
DN 141:157478
TI Peptides which target tumor and endothelial cells, compositions and uses thereof
IN Allan, Amy L.; Yoon, Won Hyung; Gladstone, Patricia L.; Ternansky, Robert J.; Parry, Graham; Donate, Fernando; Mazar, Andrew
PA Attenuon, Llc, USA
SO PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|--|----------|------------------|----------|
| PI | WO 2004063213 | A2 | 20040729 | WO 2003-US37895 | 20031125 |
| | WO 2004063213 | A3 | 20050303 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | CA 2506813 | A1 | 20040729 | CA 2003-2506813 | 20031125 |
| | AU 2003298726 | A1 | 20040810 | AU 2003-298726 | 20031125 |
| | US 2004162239 | A1 | 20040819 | US 2003-723144 | 20031125 |
| | US 2005020810 | A1 | 20050127 | US 2003-722843 | 20031125 |
| | EP 1569678 | A2 | 20050907 | EP 2003-796483 | 20031125 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| | BR 2003016550 | A | 20051004 | BR 2003-16550 | 20031125 |
| | CN 1741808 | A | 20060301 | CN 2003-80109204 | 20031125 |
| | CN 1741809 | A | 20060301 | CN 2003-80109205 | 20031125 |
| | JP 2006515866 | T | 20060608 | JP 2005-512876 | 20031125 |
| | NO 2005003112 | A | 20050805 | NO 2005-3112 | 20050624 |
| | IN 2005KN01228 | A | 20070126 | IN 2005-KN1228 | 20050624 |
| PRAI | US 2002-429174P | P | 20021125 | | |
| | US 2003-475539P | P | 20030602 | | |
| | WO 2003-US37895 | W | 20031125 | | |
| OS | MARPAT 141:157478 | | | | |
| IT | 731003-01-3DP, Indium complexes 731003-01-3P | | | | |
| | RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (preparation of peptides which target tumor and endothelial cells) | | | | |
| RN | 731003-01-3 CAPLUS | | | | |
| CN | L-Aspartamide, 1-[[[(4-methylphenyl)amino]thioxomethyl]-L-prolyl-L-histidyl-L-seryl-L-cysteinyl-, mono[N,N-bis[2-[bis(carboxymethyl)amino]ethyl]glycine] deriv. (9CI) (CA INDEX NAME) | | | | |



RN 731003-01-3 CAPLUS


CN L-Aspartamide, 1-[[[(4-methylphenyl)amino]thioxomethyl]-L-prolyl-L-histidyl-L-seryl-L-cysteinyl-, mono[N,N-bis[2-[bis(carboxymethyl)amino]ethyl]glycine] deriv. (9CI) (CA INDEX NAME)




L4 ANSWER 32 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:566894 CAPLUS
 DN 141:273359
 TI Identification of Synthetic Phosphatidylserine Translocases from a
 Combinatorial Library Prepared by Directed Split-and-Pool Synthesis
 AU Shukla, Rameshwer; Sasaki, Yoshihiro; Krchnak, Viktor; Smith, Bradley D.
 CS Department of Chemistry and Biochemistry and the Walther Center for Cancer
 Research, University of Notre Dame, Notre Dame, IN, 46556, USA
 SO Journal of Combinatorial Chemistry (2004), 6(5), 703-709
 CODEN: JCCHFF; ISSN: 1520-4766
 PB American Chemical Society
 DT Journal
 LA English
 IT 757993-84-3P 757993-87-6P 757994-26-6P
 757994-28-8P 757994-98-2P 757995-01-0P
 757995-29-2P 757995-31-6P
 RL: CPN (Combinatorial preparation); RCT (Reactant); CMBI (Combinatorial
 study); PREP (Preparation); RACT (Reactant or reagent)
 (identification of synthetic phosphatidylserine translocases from
 combinatorial library prepared by directed split-and-pool synthesis)
 RN 757993-84-3 CAPLUS
 CN Glycinamide, 2,2'-[[[(2-aminoethyl)imino]di-2,1-ethanediyl]bis[1-[[[(4-
 nitrophenyl)amino]carbonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 757993-87-6 CAPLUS
 CN Glycinamide, 2,2'-[[[(2-aminoethyl)imino]di-2,1-ethanediyl]bis[1-[[[(4-
 methoxyphenyl)amino]carbonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 757994-26-6 CAPLUS


CN L-Lysinamide, 2,2'-[[(2-aminoethyl)imino]di-2,1-ethanediyl]bis[1-[[(4-nitrophenyl)amino]carbonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 757994-28-8 CAPLUS


CN L-Lysinamide, 2,2'-[[(2-aminoethyl)imino]di-2,1-ethanediyl]bis[1-[[(4-methoxyphenyl)amino]carbonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 757994-98-2 CAPLUS

CN L-Threoninamide, 2,2'-[[(2-aminoethyl)imino]di-2,1-ethanediyl]bis[1-[[(4-nitrophenyl)amino]carbonyl]-L-prolyl- (9CI) (CA INDEX NAME)



PAGE 1-A





RN 757995-01-0 CAPLUS

CN L-Threoninamide, 2,2'-[[(2-aminoethyl)imino]di-2,1-ethanediyl]bis[1-[[(4-methoxyphenyl)amino]carbonyl]-L-prolyl- (9CI) (CA INDEX NAME)




RN 757995-29-2 CAPLUS

10/712,456-ALW


CN L-Phenylalaninamide, 2,2'-[[(2-aminoethyl)imino]di-2,1-ethanediyl]bis[1-
[[(4-nitrophenyl)amino]carbonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 757995-31-6 CAPLUS


CN L-Phenylalaninamide, 2,2'-[[(2-aminoethyl)imino]di-2,1-ethanediyl]bis[1-
[[(4-methoxyphenyl)amino]carbonyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RE.CNT 27

THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 33 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:498567 CAPLUS
DN 141:207025
TI Design, synthesis, and biological evaluation of novel T-Type calcium channel antagonists
AU McCalmont, William F.; Heady, Tiffany N.; Patterson, Jaclyn R.; Lindenmuth, Michael A.; Haverstick, Doris M.; Gray, Lloyd S.; Macdonald, Timothy L.
CS Department of Chemistry, University of Virginia, Charlottesville, VA, 22904-4319, USA
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(14), 3691-3695
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 141:207025
IT 106789-32-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzyloxymethyl-substituted pyrrolidines and piperidines as T-type calcium channel antagonists and cancer cell antiproliferative agents)
RN 106789-32-6 CAPLUS
CN L-Proline, 1-[(4-methoxyphenyl)acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE.FORMAT

L4 ANSWER 34 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:493686 CAPLUS
 DN 141:54342
 TI Preparation of 2-(2-hydroxybiphenyl-3-yl)-1H-benzimidazole-5-carboxamide derivatives as factor VIIa inhibitors
 IN Kolesnikov, Aleksandr; Rai, Roopa; Shrader, William Dvorak; Torkelson, Steven M.; Wesson, Kieron E.; Young, Wendy B.
 PA Axys Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 119 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|------------------|----------|
| PI | WO 2004050637 | A2 | 20040617 | WO 2003-US38635 | 20031203 |
| | WO 2004050637 | A3 | 20040902 | | |
| | W: | | | | |
| | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: | | | | |
| | BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2507707 | A1 | 20040617 | CA 2003-2507707 | 20031203 |
| | AU 2003302238 | A1 | 20040623 | AU 2003-302238 | 20031203 |
| | EP 1569912 | A2 | 20050907 | EP 2003-810056 | 20031203 |
| | R: | | | | |
| | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | CN 1745070 | A | 20060308 | CN 2003-80109503 | 20031203 |
| | JP 2006515839 | T | 20060608 | JP 2004-557602 | 20031203 |
| | IN 2005KN01065 | A | 20060818 | IN 2005-KN1065 | 20050603 |
| | US 2006205942 | A1 | 20060914 | US 2006-537115 | 20060320 |
| PRAI | US 2002-430981P | P | 20021203 | | |
| | WO 2003-US38635 | W | 20031203 | | |

OS MARPAT 141:54342

IT 706821-83-2P, (2R)-1-[2-[5-(5-Carbamimidoyl-1H-benzimidazol-2-yl)-6,2'-dihydroxy-5'-sulfamoylbiphenyl-3-yl]acetyl]pyrrolidine-2-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of (hydroxybiphenyl)-1H-benzimidazolecarboxamide derivs. as factor VIIa inhibitors for treating thromboembolic disorders, cancer, or rheumatoid arthritis)

RN 706821-83-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[5-[5-(aminoiminomethyl)-1H-benzimidazol-2-yl]-5'-(aminosulfonyl)-2',6-dihydroxy[1,1'-biphenyl]-3-yl]acetyl]-, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



10/712,456-ALW

L4 ANSWER 35 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:452960 CAPLUS

DN 141:28605

TI Open chain prolyl urea-related modulators of androgen receptor function
therapeutic use for nuclear hormone receptor-associated conditions

IN Hamann, Lawrence G.; Augeri, David J.; Manfredi, Mark C.

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 57 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|--|----------|-----------------|----------|
| PI | WO 2004045518 | A2 | 20040603 | WO 2003-US36331 | 20031113 |
| | WO 2004045518 | A3 | 20041007 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | AU 2003302084 | A1 | 20040615 | AU 2003-302084 | 20031113 |
| | US 2005059652 | A1 | 20050317 | US 2003-712456 | 20031113 |
| | EP 1567487 | A2 | 20050831 | EP 2003-808410 | 20031113 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| PRAI | US 2002-426694P | P | 20021115 | | |
| | WO 2003-US36331 | W | 20031113 | | |
| OS | MARPAT 141:28605 | | | | |
| IT | 496841-10-2P 697228-47-0P 697228-51-6P 697228-52-7P 697228-54-9P | | | | |
| | RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) | | | | |
| | (open chain prolyl urea-related modulators of androgen receptor function therapeutic use for nuclear hormone receptor-associated conditions) | | | | |
| RN | 496841-10-2 CAPLUS | | | | |
| CN | L-Proline, 1-[[[(4-cyano-1-naphthalenyl)amino]carbonyl]-3-hydroxy-, methyl ester, (3R)- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.




10/712,456-ALW

RN 697228-47-0 CAPLUS

CN L-Proline, 1-[[[4-cyano-2-ethyl-3-(trifluoromethyl)phenyl]amino]carbonyl]-3-hydroxy-, methyl ester, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 697228-51-6 CAPLUS

CN L-Proline, 1-[[[4-cyano-2-ethyl-3-(trifluoromethyl)phenyl]amino]carbonyl]-3-hydroxy-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 697228-52-7 CAPLUS

CN L-Proline, 1-[[[5-chloro-6-cyano-3-pyridinyl]amino]carbonyl]-3-hydroxy-, methyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 697228-54-9 CAPLUS

CN L-Proline, 1-[(4-cyano-1-naphthalenyl)acetyl]-3-hydroxy-, methyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



10/712,456-ALW

L4 ANSWER 36 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:143100 CAPLUS

DN 140:199315

TI Preparation of iminothiazolidinone amino acid derivatives as inhibitors of HCV replication

IN Romine, Jeffrey Lee; Martin, Scott W.; Snyder, Lawrence B.; Serrano-Wu, Michael; Deshpande, Milind; Whitehouse, Darren; Lemm, Julie; O'Boyle, Donald; Gao, Min; Colonno, Richard

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 127 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | WO 2004014852 | A2 | 20040219 | WO 2003-US24717 | 20030808 |
| | WO 2004014852 | A3 | 20040422 | | |
| | W: | | | | |
| | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: | | | | |
| | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2003261434 | A1 | 20040225 | AU 2003-261434 | 20030808 |
| | US 2005069522 | A1 | 20050331 | US 2003-637156 | 20030808 |
| | US 2005096364 | A1 | 20050505 | US 2003-637099 | 20030808 |
| | US 7183302 | B2 | 20070227 | | |
| PRAI | US 2002-402661P | P | 20020812 | | |
| | US 2002-403694P | P | 20020815 | | |
| | WO 2003-US24717 | W | 20030808 | | |

OS MARPAT 140:199315

IT 657413-75-7P 657413-78-0P 657413-81-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of iminothiazolidinone amino acid derivs. as inhibitors of HCV replication)

RN 657413-75-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[4-(dimethylamino)phenyl]acetyl]-N-[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




—NMe₂

RN 657413-78-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(4-methoxyphenyl)acetyl]-N-[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




— OMe

RN 657413-81-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]-1-[[4-(trifluoromethyl)phenyl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



—CF₃


10/712,456-ALW

L4 ANSWER 37 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:142910 CAPLUS
DN 140:199742
TI Preparation of iminothiazolidinone amino acid derivatives as combination
pharmaceutical agents for use as inhibitors of HCV replication
IN Colonno, Richard; Lemm, Julie; O'Boyle, Donald; Gao, Min; Romine, Jeffrey
Lee; Martin, Scott W.; Snyder, Lawrence B.; Serrano-Wu, Michael;
Deshpande, Milind; Whitehouse, Darren
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|--|----------|-----------------|----------|
| PI | WO 2004014313 | A2 | 20040219 | WO 2003-US25036 | 20030808 |
| | WO 2004014313 | A3 | 20051215 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | AU 2003264038 | A1 | 20040225 | AU 2003-264038 | 20030808 |
| | US 2005069522 | A1 | 20050331 | US 2003-637156 | 20030808 |
| | US 2005096364 | A1 | 20050505 | US 2003-637099 | 20030808 |
| | US 7183302 | B2 | 20070227 | | |
| PRAI | US 2002-402661P | P | 20020812 | | |
| | US 2002-403694P | P | 20020815 | | |
| | WO 2003-US25036 | W | 20030808 | | |
| OS | MARPAT 140:199742 | | | | |
| IT | 657413-75-7P 657413-78-0P 657413-81-5P | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (preparation of iminothiazolidinone amino acid derivs. as combination pharmaceutical agents for use as inhibitors of HCV replication) | | | | |
| RN | 657413-75-7 CAPLUS | | | | |
| CN | 2-Pyrrolidinecarboxamide, 1-[[4-(dimethylamino)phenyl]acetyl]-N-[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]-, (2S)- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.

Double bond geometry unknown.




NMe₂

RN 657413-78-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(4-methoxyphenyl)acetyl]-N-[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




— OMe

RN 657413-81-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]-1-[[4-(trifluoromethyl)phenyl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.



—CF₃

10/712,456-ALW

L4 ANSWER 38 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:972023 CAPLUS

DN 140:27657

TI Bis(dihydroxyaryl) compounds, pharmaceutical compositions containing them, and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes, and Parkinson's disease.

IN Snow, Alan D.; Nguyen, Beth P.; Castillo, Gerardo M.; Sanders, Virginia J.; Lake, Thomas P.; Larsen, Lesley; Weavers, Rex T.; Lorimer, Stephen D.; Larsen, David S.; Coffen, David L.

PA Proteotech, Inc., USA

SO PCT Int. Appl., 117 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003101927 | A1 | 20031211 | WO 2003-US17288 | 20030530 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2486869 | A1 | 20031211 | CA 2003-2486869 | 20030530 |
| | AU 2003249678 | A1 | 20031219 | AU 2003-249678 | 20030530 |
| | US 2004127555 | A1 | 20040701 | US 2003-452851 | 20030530 |
| | EP 1511710 | A1 | 20050309 | EP 2003-756343 | 20030530 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | JP 2005531596 | T | 20051020 | JP 2004-509622 | 20030530 |
| PRAI | US 2002-385144P | P | 20020531 | | |
| | US 2002-409100P | P | 20020909 | | |
| | US 2002-412272P | P | 20020920 | | |
| | US 2002-435880P | P | 20021220 | | |
| | US 2003-463104P | P | 20030414 | | |
| | WO 2003-US17288 | W | 20030530 | | |

OS MARPAT 140:27657

IT 633699-96-4P, N-(3,4-Dihydroxyphenylacetyl)proline
3,4-dihydroxyanilide


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of bis(dihydroxyaryl) compds. as amyloid fibril disrupters for treatment of Alzheimer's, Parkinson's, and type 2 diabetes)

RN 633699-96-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(3,4-dihydroxyphenyl)-1-[(3,4-dihydroxyphenyl)acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 39 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:971921 CAPLUS
DN 140:19879
TI Drug compositions containing calcium channel antagonists exhibiting
intestinal tract selectivity
IN Hashimoto, Masaki; Takahashi, Kazuyoshi
PA Ajinomoto Co., Inc., Japan
SO PCT Int. Appl., 126 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003101490 | A1 | 20031211 | WO 2003-JP6847 | 20030530 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | JP 2005343790 | A | 20051215 | JP 2002-160187 | 20020531 |
| | AU 2003241991 | A1 | 20031219 | AU 2003-241991 | 20030530 |
| PRAI | JP 2002-160187 | A | 20020531 | | |
| | WO 2003-JP6847 | W | 20030530 | | |
| OS | MARPAT 140:19879 | | | | |
| IT | 477779-14-9P 477779-15-0P 630095-41-9P | | | | |
| | RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) | | | | |
| | (preparation of calcium channel antagonists exhibiting intestinal tract selectivity) | | | | |
| RN | 477779-14-9 CAPLUS | | | | |
| CN | D-Proline, 1-[[4-(dimethylamino)phenyl]acetyl]- (9CI) (CA INDEX NAME) | | | | |


Absolute stereochemistry.



RN 477779-15-0 CAPLUS
CN D-Proline, 1-[[4-(dimethylamino)phenyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 630095-41-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-[(2-bromo-4-chlorophenyl)methoxy]phenyl]-1-[[4-(dimethylamino)phenyl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 98 THERE ARE 98 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 40 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:971920 CAPLUS
DN 140:19878
TI Medicinal compositions containing defined calcium channel antagonists for
treatment for digestive tract disease
IN Yamada, Youji; Takahashi, Kazuyoshi; Hashimoto, Masaki
PA Ajinomoto Co., Inc., Japan
SO PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003101489 | A1 | 20031211 | WO 2003-JP6845 | 20030530 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | JP 2005343791 | A | 20051215 | JP 2002-160188 | 20020531 |
| | AU 2003241987 | A1 | 20031219 | AU 2003-241987 | 20030530 |
| PRAI | JP 2002-160188 | A | 20020531 | | |
| | WO 2003-JP6845 | W | 20030530 | | |
| OS | MARPAT 140:19878 | | | | |
| IT | 477779-14-9P 477779-15-0P 630095-41-9P | | | | |
| | RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) | | | | |
| | (preparation of medicinal compns. containing defined calcium channel antagonists | | | | |
| | for treatment for digestive tract disease) | | | | |
| RN | 477779-14-9 CAPLUS | | | | |
| CN | D-Proline, 1-[[4-(dimethylamino)phenyl]acetyl]- (9CI) (CA INDEX NAME) | | | | |


Absolute stereochemistry.



RN 477779-15-0 CAPLUS
CN D-Proline, 1-[[4-(dimethylamino)phenyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 630095-41-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-[(2-bromo-4-chlorophenyl)methoxy]phenyl]-1-[[4-(dimethylamino)phenyl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 41 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:931118 CAPLUS

DN 140:5047

TI Preparation of pyrrolo[1,2-c]imidazoles as bicyclic modulators of androgen receptor function

IN Sun, Chongqing; Hamann, Lawrence; Augeri, David; Bi, Yingzhi; Robl, Jeffrey; Huang, Yan-ting; Wang, Tammy; Simpkins, Ligaya; Holubec, Alexandra

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 177 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2003096980 | A2 | 20031127 | WO 2003-US15375 | 20030515 |
| | WO 2003096980 | A3 | 20041021 | | |
| | W: | | | | |
| | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: | | | | |
| | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2003234609 | A1 | 20031202 | AU 2003-234609 | 20030515 |
| | EP 1506178 | A2 | 20050216 | EP 2003-728951 | 20030515 |
| | R: | | | | |
| | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | JP 2005531555 | T | 20051020 | JP 2004-504979 | 20030515 |
| | NO 2004004809 | A | 20050214 | NO 2004-4809 | 20041104 |
| PRAI | US 2002-381616P | P | 20020517 | | |
| | US 2002-406711P | P | 20020829 | | |
| | WO 2003-US15375 | W | 20030515 | | |

OS MARPAT 140:5047

IT 627531-32-2P 627531-49-1P 627531-62-8P

627531-63-9P 627531-64-0P 627531-67-3P

627531-68-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; preparation of pyrrolo[1,2-c]imidazoles as bicyclic modulators of androgen receptor function)

RN 627531-32-2 CAPLUS

CN L-Proline, 1-[[[(7-cyano-1-methyl-1H-benzimidazol-4-yl)amino]carbonyl]-3-hydroxy-, methyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 627531-49-1 CAPLUS

CN L-Proline, 1-[[[3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-3-hydroxy-, methyl ester, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 627531-62-8 CAPLUS

CN L-Proline, 1-[[[3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-3-hydroxy-, methyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627531-63-9 CAPLUS

CN L-Proline, 1-[[[3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-3-hydroxy-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627531-64-0 CAPLUS

CN L-Proline, 1-[[[(3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-3-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, methyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 627531-67-3 CAPLUS

CN L-Proline, 1-[[[(3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-4-hydroxy-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 627531-68-4 CAPLUS

CN L-Proline, 1-[[[(3-chloro-4-cyano-2-methylphenyl)amino]carbonyl]-4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, methyl ester, (4R)- (9CI) (CA INDEX NAME)

10/712,456-ALW

Absolute stereochemistry.





L4 ANSWER 42 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:913043 CAPLUS
 DN 139:386340
 TI FAP-activated anti-tumor prodrugs
 IN Patzelt, Erik; Park, John Edward; Peters, Stefan
 PA Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
 SO PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|--|----------|-----------------|----------|
| PI | WO 2003094972 | A2 | 20031120 | WO 2003-EP4713 | 20030506 |
| | WO 2003094972 | A3 | 20040318 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | AU 2003233238 | A1 | 20031111 | AU 2003-233238 | 20030506 |
| | US 2004033957 | A1 | 20040219 | US 2003-430056 | 20030506 |
| | EP 1506221 | A2 | 20050216 | EP 2003-727438 | 20030506 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| PRAI | EP 2002-10552 | A | 20020510 | | |
| | US 2002-386163P | P | 20020605 | | |
| | WO 2003-EP4713 | W | 20030506 | | |
| OS | MARPAT 139:386340 | | | | |
| IT | 623156-76-3P | | | | |
| | RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (FAP-activated anti-tumor prodrugs) | | | | |
| RN | 623156-76-3 CAPLUS | | | | |
| CN | 5,12-Naphthacenedione, 10-[[3-[[1-[[4-(carboxymethyl)phenyl]acetyl]-L-prolyl-L-alanylglycyl-L-prolyl-L-leucyl]amino]-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.

PAGE 1-A






10/712,456-ALW

L4 ANSWER 43 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:887675 CAPLUS
DN 139:381751
TI Preparation of substituted β -alanine derivatives as cell adhesion inhibitors
IN Durette, Philippe L.; Hagmann, William K.; Kopka, Ihor E.; MacCoss, Malcolm; Mills, Sander G.; Mumford, Richard A.; Magriotis, Plato A.
PA Merck & Co., Inc., USA
SO U.S., 45 pp., Cont.-in-part of U.S. Ser. No. 198,680, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 6645939 | B1 | 20031111 | US 1999-317789 | 19990524 |
| | WO 2000071572 | A1 | 20001130 | WO 2000-US14017 | 20000519 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| PRAI | US 1997-66484P | P | 19971124 | | |
| | US 1998-198680 | B2 | 19981124 | | |
| | US 1999-317789 | A2 | 19990524 | | |
| OS | MARPAT 139:381751 | | | | |
| IT | 225515-65-1P | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (preparation of substituted β -alanine derivs. as cell adhesion inhibitors) | | | | |
| RN | 225515-65-1 CAPLUS | | | | |
| CN | β -Alanine, 1-[[4-[[[(2-chlorophenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-3-(1,3-benzodioxol-5-yl)-, (3S)- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.




RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW


L4 ANSWER 44 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:854948 CAPLUS
DN 140:199074
TI Use of S-proline as chiral auxiliary in α -alkylations of carboxylic acids
AU Srivastava, Stuti; Goswami, Lalit N.; Dikshit, Dinesh K.
CS Medicinal Chemistry Division, Central Drug Research Institute, Lucknow, 226 001, India
SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (2003), 42B(10), 2628-2631
CODEN: IJSBDB; ISSN: 0376-4699
PB National Institute of Science Communication
DT Journal
LA English
OS CASREACT 140:199074
IT 662165-79-9P
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(proline chiral auxiliary in asym. alkylation of carboxylic acids)
RN 662165-79-9 CAPLUS
CN L-Proline, 1-[(2R)-2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 662165-78-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(proline chiral auxiliary in asym. alkylation of carboxylic acids)
RN 662165-78-8 CAPLUS
CN L-Proline, 1-[(2S)-2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 45 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:818409 CAPLUS

DN 139:323538

TI Preparation of hydroxamic acid derivatives for use as pharmaceuticals

IN Janser, Philipp; Miltz, Wolfgang; Neumann, Ulf

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SO PCT Int. Appl., 55 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|--|----------|-----------------|----------|
| PI | WO 2003084941 | A2 | 20031016 | WO 2003-EP3644 | 20030408 |
| | WO 2003084941 | A3 | 20040325 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW | | | |
| | RW: | AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR | | | |
| | CA 2481879 | A1 | 20031016 | CA 2003-2481879 | 20030408 |
| | AU 2003236834 | A1 | 20031020 | AU 2003-236834 | 20030408 |
| | EP 1497273 | A2 | 20050119 | EP 2003-735343 | 20030408 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| | BR 2003009135 | A | 20050201 | BR 2003-9135 | 20030408 |
| | CN 1649857 | A | 20050803 | CN 2003-809483 | 20030408 |
| | JP 2005528381 | T | 20050922 | JP 2003-582138 | 20030408 |
| | US 2006063778 | A1 | 20060323 | US 2005-511065 | 20051003 |
| PRAI | GB 2002-8176 | A | 20020409 | | |
| | WO 2003-EP3644 | W | 20030408 | | |
| OS | MARPAT 139:323538 | | | | |
| IT | 612840-78-5P | | | | |
| | RL: | PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | |
| | | (preparation of hydroxamic acid derivs. for use as pharmaceuticals) | | | |
| RN | 612840-78-5 CAPLUS | | | | |
| CN | 1-Pyrrolidinebutanamide, α -ethyl-N-hydroxy- β -(4-methoxyphenyl)- γ -oxo-2-[(phenylamino)carbonyl]-, (α S, β S,2S)- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.



L4 ANSWER 46 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:609509 CAPLUS
DN 139:149931
TI FAP-activated antitumor compounds
IN Peters, Stefan; Breittfelder, Steffen; Park, John Edward; Garin-Chesa,
Pilar; Blech, Stefan Matthias; Lenter, Martin
PA Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G., Germany
SO Eur. Pat. Appl., 29 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | EP 1333033 | A1 | 20030806 | EP 2002-2222 | 20020130 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | US 2003211979 | A1 | 20031113 | US 2003-336378 | 20030103 |
| | CA 2472296 | A1 | 20030807 | CA 2003-2472296 | 20030128 |
| | WO 2003064454 | A1 | 20030807 | WO 2003-EP815 | 20030128 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | EP 1472277 | A1 | 20041103 | EP 2003-734699 | 20030128 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | JP 2005523264 | T | 20050804 | JP 2003-564074 | 20030128 |
| PRAI | EP 2002-2222 | A | 20020130 | | |
| | US 2002-355102P | P | 20020208 | | |
| | WO 2003-EP815 | W | 20030128 | | |

OS MARPAT 139:149931

IT 573690-73-0P 573690-74-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)


(FAP-activated antitumor compds.)

RN 573690-73-0 CAPLUS


CN 5,12-Naphthacenedione, 10-[[3-[[1-[[4-(carboxymethyl)phenyl]acetyl]-L-
prolyl-L-alanylglycyl-L-prolyl]amino]-2,3,6-trideoxy- α -L-lyxo-
hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-
1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 573690-74-1 CAPLUS

CN L-Prolinamide, 1-[[4-(carboxymethyl)phenyl]acetyl]-L-prolyl-L-alanylglycyl-N-(4-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 47 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:434528 CAPLUS
 DN 139:6763
 TI Preparation of pyrrolidinedicarboxamides and related compounds as
 inhibitors of factor Xa useful for thrombotic disorders
 IN Bigge, Christopher Franklin; Dudley, Danette Andrea; Edmunds, Jeremy John;
 Van Huis, Chad Alan; Casimiro-Garcia, Agustin; Filipski, Kevin James;
 Kohrt, Jeffrey Thomas
 PA Warner-Lambert Company L.L.C., USA
 SO PCT Int. Appl., 389 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003045912 | A1 | 20030605 | WO 2002-IB4757 | 20021114 |
| | WO 2003045912 | A8 | 20031002 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 2003162787 | A1 | 20030828 | US 2002-278643 | 20021023 |
| | US 7030141 | B2 | 20060418 | | |
| | CA 2468715 | A1 | 20030605 | CA 2002-2468715 | 20021114 |
| | AU 2002365313 | A1 | 20030610 | AU 2002-365313 | 20021114 |
| | BR 2002014519 | A | 20041013 | BR 2002-14519 | 20021114 |
| | EP 1465864 | A1 | 20041013 | EP 2002-803885 | 20021114 |
| | EP 1465864 | B1 | 20060315 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| | CN 1582274 | A | 20050216 | CN 2002-823837 | 20021114 |
| | HU 200402529 | A2 | 20050329 | HU 2004-2529 | 20021114 |
| | JP 2005515985 | T | 20050602 | JP 2003-547364 | 20021114 |
| | AT 320414 | T | 20060415 | AT 2002-803885 | 20021114 |
| | EP 1671949 | A2 | 20060621 | EP 2006-110738 | 20021114 |
| | EP 1671949 | A3 | 20060719 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| | PT 1465864 | T | 20060630 | PT 2002-803885 | 20021114 |
| | ES 2259113 | T3 | 20060916 | ES 2002-2803885 | 20021114 |
| | NZ 532384 | A | 20061027 | NZ 2002-532384 | 20021114 |
| | ZA 2004004085 | A | 20050905 | ZA 2004-4085 | 20040525 |
| | NO 2004002270 | A | 20040601 | NO 2004-2270 | 20040601 |
| | US 2005267118 | A1 | 20051201 | US 2004-17598 | 20041220 |
| | US 2005250815 | A1 | 20051110 | US 2005-108582 | 20050418 |
| | US 2006264626 | A1 | 20061123 | US 2006-461859 | 20060802 |
| PRAI | US 2001-334168P | P | 20011129 | | |
| | US 2002-384895P | P | 20020531 | | |
| | US 2002-278643 | A3 | 20021023 | | |
| | EP 2002-803885 | A3 | 20021114 | | |
| | WO 2002-IB33416 | A | 20021114 | | |
| | WO 2002-IB4757 | W | 20021114 | | |
| | US 2004-17598 | A3 | 20041220 | | |
| OS | MARPAT 139:6763 | | | | |

IT 536746-37-9P, Pyrrolidine-1,2-dicarboxylic acid
 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 1-p-tolylamide
 536746-38-0P, Pyrrolidine-1,2-dicarboxylic acid
 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 1-[(4-methoxyphenyl)amide]
 536746-43-7P, Pyrrolidine-1,2-dicarboxylic acid
 1-[(3-fluoro-4-methylphenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536746-90-4P, (2R,4R)-4-Hydroxypyrrolidine-1,2-dicarboxylic acid 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 1-p-tolylamide 536748-85-3P, Pyrrolidine-1,2-dicarboxylic acid 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 1-[(4-isopropylphenyl)amide] 536748-86-4P, Pyrrolidine-1,2-dicarboxylic acid 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 1-[(4-trifluoromethylphenyl)amide] 536748-88-6P, Pyrrolidine-1,2-dicarboxylic acid 1-[(4-ethylphenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536749-43-6P, Pyrrolidine-1,2-dicarboxylic acid 1-[(4-cyanophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536749-47-0P, Pyrrolidine-1,2-dicarboxylic acid 1-[(4-dimethylaminophenyl)amide] 2-[(3-fluoro-2'-sulfamoylbiphenyl-4-yl)amide] 536749-51-6P, 4-Hydroxypyrrolidine-1,2-dicarboxylic acid 2-[(3-fluoro-2'-methanesulfonylbiphenyl-4-yl)amide] 1-p-tolylamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of pyrrolidinedicarboxamides and related compds. as inhibitors of factor Xa useful for thrombotic disorders)
 RN 536746-37-9 CAPLUS
 CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 536746-38-0 CAPLUS
 CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 536746-43-7 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(3-fluoro-4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 536746-90-4 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-N1-(4-methylphenyl)-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/712,456-ALW



RN 536748-85-3 CAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 536748-86-4 CAPLUS


CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

10/712,456-ALW




RN 536748-88-6 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-ethylphenyl)- (9CI) (CA INDEX NAME)




RN 536749-43-6 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-(4-cyanophenyl)- (9CI) (CA INDEX NAME)




RN 536749-47-0 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-N1-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)



RN 536749-51-6 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-N1-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RE.CNT 8


THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 48 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:396733 CAPLUS
DN 138:396226
TI Combinatorial library-based protein tyrosine phosphatase 1B (PTP1B)
inhibitor and ligand discovery
IN Zhang, Zhong-Yin; Lawrence, David S.
PA Albert Einstein College of Medicine of Yeshiva University, USA
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003041729 | A1 | 20030522 | WO 2002-US30492 | 20020926 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2461481 | A1 | 20030522 | CA 2002-2461481 | 20020926 |
| | AU 2002363632 | A1 | 20030526 | AU 2002-363632 | 20020926 |
| | EP 1435989 | A1 | 20040714 | EP 2002-803148 | 20020926 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| | JP 2005509008 | T | 20050407 | JP 2003-543616 | 20020926 |
| | US 2004191926 | A1 | 20040930 | US 2004-490836 | 20040325 |
| PRAI | US 2001-325009P | P | 20010926 | | |
| | WO 2002-US30492 | W | 20020926 | | |
| OS | MARPAT 138:396226 | | | | |
| IT | 528550-30-3P | | | | |
| | RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses) | | | | |
| | (combinatorial library-based protein tyrosine phosphatase 1B inhibitor and ligand discovery) | | | | |
| RN | 528550-30-3 CAPLUS | | | | |
| CN | L-Tyrosinamide, 1-[[4-(phosphonooxy)phenyl]acetyl]-L-prolyl-N-(2-mercaptoethyl)-, 24-(dihydrogen phosphate) (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 49 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:376987 CAPLUS

DN 138:385215

TI Preparation of isotopically-coded affinity markers for mass spectrometric analysis of proteins

IN Lerchen, Hans-Georg; Siegmund, Hans-Ulrich; Immler, Dorian; Schumacher, Andreas; Auriel, Daniel

PA Bayer Aktiengesellschaft, Germany

SO PCT Int. Appl., 102 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|------------------|--|----------|------------------|----------|
| PI | WO 2003040288 | A2 | 20030515 | WO 2002-EP12105 | 20021030 |
| | WO 2003040288 | A3 | 20031211 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | DE 10234415 | A1 | 20030522 | DE 2002-10234415 | 20020729 |
| | CA 2466328 | A1 | 20030515 | CA 2002-2466328 | 20021030 |
| | AU 2002340490 | A1 | 20030519 | AU 2002-340490 | 20021030 |
| | EP 1446665 | A2 | 20040818 | EP 2002-774759 | 20021030 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | |
| | EP 1477493 | A1 | 20041117 | EP 2003-9894 | 20030515 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| | US 2005049406 | A1 | 20050303 | US 2004-494999 | 20041029 |
| | US 7132295 | B2 | 20061107 | | |
| PRAI | DE 2001-10154745 | A | 20011109 | | |
| | DE 2002-10234415 | A | 20020729 | | |
| | WO 2002-EP12105 | W | 20021030 | | |

OS MARPAT 138:385215


IT 525586-46-3P

RL: ARG (Analytical reagent use); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); USES (Uses)
(preparation of isotopically-coded affinity markers for mass spectrometric anal. of proteins)

RN 525586-46-3 CAPLUS

CN 1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[[4-[[[(2S)-2-[[[2-[4-[[[3-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxopropyl]amino]acetyl]-1-piperazinyl]-2-oxoethyl]amino]carbonyl]-1-pyrrolidinyl]thioxomethyl]amino]phenyl]methyl]hexahydro-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 50 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:249856 CAPLUS
DN 140:104428
TI Identification of a Selectivity Determinant for Inhibition of Tumor
Necrosis Factor- α Converting Enzyme by Comparative Modeling
AU Wasserman, Zelda R.; Duan, James J.-W.; Voss, Matthew E.; Xue, Chu-Biao;
Cherney, Robert J.; Nelson, David J.; Hardman, Karl D.; Decicco, Carl P.
CS Structural Biology and Molecular Design Group, Bristol-Myers Squibb
Company, Wilmington, DE, 19880, USA
SO Chemistry & Biology (2003), 10(3), 215-223
CODEN: CBOLE2; ISSN: 1074-5521
PB Cell Press
DT Journal
LA English
IT 301162-35-6
RL: PAC (Pharmacological activity); BIOL (Biological study)
(identification of a selectivity determinant for inhibition of tumor
necrosis factor- α converting enzyme by comparative modeling)
RN 301162-35-6 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-hydroxy-1-[[4-[(2-methyl-4-
quinolinyl)methoxy]phenyl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 51 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:117794 CAPLUS

DN 138:153537

TI Preparation of imidazole-containing heterobicyclic modulators of androgen receptor function

IN Sun, Chongqing; Robl, Jeffrey A.; Salvati, Mark E.; Wang, Tammy; Hamann, Lawrence; Augeri, David

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003011824 | A1 | 20030213 | WO 2002-US24185 | 20020731 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2002322794 | A1 | 20030217 | AU 2002-322794 | 20020731 |
| | US 2003055094 | A1 | 20030320 | US 2002-209461 | 20020731 |
| | US 6670386 | B2 | 20031230 | | |
| | EP 1414795 | A1 | 20040506 | EP 2002-756813 | 20020731 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| | US 2004092559 | A1 | 20040513 | US 2003-685020 | 20031014 |
| | US 6992102 | B2 | 20060131 | | |
| PRAI | US 2001-309059P | P | 20010731 | | |
| | US 2002-209461 | A3 | 20020731 | | |
| | WO 2002-US24185 | W | 20020731 | | |

OS MARPAT 138:153537


IT 496840-99-4P, (2S)-1-[[[4-Nitro-1-naphthalenyl)amino]carbonyl]-2-pyrrolidinecarboxylic acid methyl ester 496841-10-2P, (2S,3R)-1-[(4-Cyanonaphthalen-1-yl)carbonyl]-3-hydroxypyrrolidine-2-carboxylic acid methyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazole-containing heterobicyclic modulators of androgen receptor function)

RN 496840-99-4 CAPLUS

CN L-Proline, 1-[[[4-nitro-1-naphthalenyl)amino]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 496841-10-2 CAPLUS

CN L-Proline, 1-[[[(4-cyano-1-naphthalenyl)amino]carbonyl]-3-hydroxy-, methyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 52 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:15497 CAPLUS

DN 138:78430

TI Pharmaceutical compositions containing heterocyclic compounds as $\alpha\beta 2$ integrin-mediated adhesion inhibitors for treatment of inflammatory diseases

IN Sircar, Ila; Furth, Paul; Teegarden, Bradley R.; Morningstar, Marshall; Smith, Nicholas; Griffith, Ronald C.

PA Tanabe Seiyaku Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 72 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | JP 2003002834 | A | 20030108 | JP 2002-117406 | 20020419 |
| PRAI | JP 2001-121235 | A | 20010419 | | |

OS MARPAT 138:78430

IT 336818-26-9P 336818-28-1P 336818-37-2P


336819-04-6P 481704-25-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heterocyclic compds. as $\alpha\beta 2$ integrin-mediated adhesion inhibitors for treatment of inflammatory diseases)

RN 336818-26-9 CAPLUS


CN Proline, 2-[(4-bromophenyl)methyl]-1-[[4-(3,5-dichloro-4-methoxyphenyl)amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 336818-28-1 CAPLUS


CN Proline, 2-[(4-bromophenyl)methyl]-1-[[4-(3-carboxypropoxy)-3,5-dichlorophenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

10/712,456-ALW



RN 336818-37-2 CAPLUS


CN Proline, 2-[(4-bromophenyl)methyl]-1-[[[3,5-dichloro-4-[(1,1-dimethylethoxy)carbonyl]phenyl]amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 336819-04-6 CAPLUS


CN Proline, 1-[[[4-[bis[(phenylmethoxy)carbonyl]amino]-3,5-dichlorophenyl]amino]carbonyl]-2-[(4-cyanophenyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

10/712,456-ALW



RN 481704-25-0 CAPLUS

CN Proline, 2-[(4-bromophenyl)methyl]-1-[[[3,5-dichloro-4-[(1,1-dimethylethoxy)carbonyl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



10/712,456-ALW

L4 ANSWER 53 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:927415 CAPLUS

DN 138:14080

TI Preparation of dihydrodiaryloxazepine derivatives for treatment of functional digestive tract diseases

IN Sakata, Katsutoshi; Tsuji, Takashi; Tokumasu, Munetaka; Takahashi, Kazuyoshi; Hirasawa, Shigeo; Ezaki, Junko

PA Ajinomoto Co., Inc., Japan

SO PCT Int. Appl., 116 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2002096891 | A1 | 20021205 | WO 2002-JP5193 | 20020529 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2002304079 | A1 | 20021209 | AU 2002-304079 | 20020529 |
| | EP 1403258 | A1 | 20040331 | EP 2002-730742 | 20020529 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | US 2004110742 | A1 | 20040610 | US 2003-724179 | 20031201 |
| PRAI | JP 2001-161988 | A | 20010530 | | |
| | WO 2002-JP5193 | W | 20020529 | | |

OS MARPAT 138:14080

IT 477779-14-9P 477779-15-0P 477779-16-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of dihydrodiaryloxazepine derivs. for treatment of functional digestive tract diseases)

RN 477779-14-9 CAPLUS

CN D-Proline, 1-[[4-(dimethylamino)phenyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477779-15-0 CAPLUS

CN D-Proline, 1-[[4-(dimethylamino)phenyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 477779-16-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-[(2-bromo-6-chlorophenyl)methoxy]phenyl]-1-[[4-(dimethylamino)phenyl]acetyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 54 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:834766 CAPLUS
DN 137:295248
TI Novel dipeptide and tripeptide mimic compounds for treating Parkinson's disease
IN Wang, Huei-Bo; Li, Jia-Shuai; Tsai, Ming-Jeng; Lu, Shiau-Hua; Hu, You-Pu
PA Taiwan
SO Taiwan., 34 pp.
CODEN: TWXXA5
DT Patent
LA Chinese
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------|------|----------|------------------|----------|
| PI | TW 387896 | B | 20000421 | TW 1996-85101959 | 19960216 |
| PRAI | TW 1996-85101959 | | 19960216 | | |
| OS | MARPAT 137:295248 | | | | |
| IT | 171860-38-1P | | | | |


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of dipeptide and tripeptide derivs. of L-dopa for treating Parkinson's disease)

RN 171860-38-1 CAPLUS

CN L-Tyrosine, (2R)-2-(4-hydroxyphenyl)glycyl-L-prolyl-3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 146622-05-1P 164353-71-3P 171860-39-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of dipeptide and tripeptide derivs. of L-dopa for treating Parkinson's disease)

RN 146622-05-1 CAPLUS

CN L-Proline, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 164353-71-3 CAPLUS

CN L-Proline, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 171860-39-2 CAPLUS


CN L-Tyrosine, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl-L-prolyl-3-hydroxy-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 55 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:813789 CAPLUS
 DN 138:280734
 TI 3D QSAR (COMFA) of a series of potent and highly selective VLA-4 antagonists
 AU Singh, Juswinder; Van Vlijmen, Herman; Lee, Wen-Cherng; Liao, Yusheng; Lin, Ko-Chung; Ateeq, Humayun; Cuervo, Julio; Zimmerman, Craig; Hammond, Charles; Karpusas, Michael; Palmer, Rex; Chattopadhyay, Tapan; Adams, Steven P.
 CS Biogen Inc, Cambridge, MA, 02142, USA
 SO Journal of Computer-Aided Molecular Design (2002), 16(3), 201-211
 CODEN: JCADEQ; ISSN: 0920-654X
 PB Kluwer Academic Publishers
 DT Journal
 LA English
 IT 187737-36-6 251469-34-8 505082-18-8
 505082-20-2 505082-24-6
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (3D QSAR (COMFA) of a series of potent and highly selective VLA-4 antagonists)
 RN 187737-36-6 CAPLUS
 CN L-Aspartic acid, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251469-34-8 CAPLUS
 CN Butanoic acid, 3-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 505082-18-8 CAPLUS
 CN 5-Hexenoic acid, 3-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 505082-20-2 CAPLUS

CN Butanoic acid, 3-[methyl[[[(2S)-1-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 505082-24-6 CAPLUS

CN β -Alanine, 1-[[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-3-(1,3-benzodioxol-5-yl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 26

THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 56 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:732372 CAPLUS
 DN 138:39451
 TI A multidetachable sulfamate linker successfully used in a solid-phase strategy to generate libraries of sulfamate and phenol derivatives
 AU Poirier, Donald; Ciobanu, Liviu C.; Berube, Marie
 CS Centre Hospitalier Universitaire de Quebec (CHUQ), Pavillon CHUL, Oncology and Molecular Endocrinology Research Center, Medicinal Chemistry Division, Laval University, Quebec, QC, G1V 4G2, Can.
 SO Bioorganic & Medicinal Chemistry Letters (2002), 12(20), 2833-2838
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 OS CASREACT 138:39451
 IT 478415-01-9P
 RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation) (preparation and steroid sulfatase activity of estradiol libraries)
 RN 478415-01-9 CAPLUS
 CN Sulfamic acid, (16 β ,17 β)-16-[3-[[[(2S)-1-[(4-aminophenyl)acetyl]-2-pyrrolidinyl]carbonyl]amino]propyl]-17-hydroxyestra-1,3,5(10)-trien-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



IT 478415-31-5P
 RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation) (preparation of estradiol libraries via solid-phase synthesis using multidetachable sulfamate linker)
 RN 478415-31-5 CAPLUS
 CN 2-Pyrrolidinecarboxamide, 1-[(4-aminophenyl)acetyl]-N-[3-[(16 β ,17 β)-3,17-dihydroxyestra-1,3,5(10)-trien-16-yl]propyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW




RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 57 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:521702 CAPLUS
DN 137:93763
TI Preparation of chiral pyrrolidine derivatives as VLA-4 inhibitors
IN Nakayama, Atsushi; Machinaga, Nobuo; Yoneda, Yoshiyuki; Sugimoto, Yuichi;
Chiba, Jun; Watanabe, Toshiyuki; Iimura, Shin
PA Daiichi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 737 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|--|----------|------------------|----------|
| PI | WO 2002053534 | A1 | 20020711 | WO 2001-JP11641 | 20011228 |
| | WO 2002053534 | A8 | 20020919 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | CN 1483024 | A | 20011228 | CN 2001-821484 | 20011228 |
| | CA 2430978 | A1 | 20020711 | CA 2001-2430978 | 20011228 |
| | AU 2002219555 | A1 | 20020716 | AU 2002-219555 | 20011228 |
| | EP 1346982 | A1 | 20030924 | EP 2001-272548 | 20011228 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | |
| | BR 2001016608 | A | 20040629 | BR 2001-16608 | 20011228 |
| | ZA 2003004059 | A | 20040706 | ZA 2003-4059 | 20011228 |
| | CN 1699363 | A | 20051123 | CN 2005-10073706 | 20011228 |
| | RU 2290403 | C2 | 20061227 | RU 2003-123115 | 20011228 |
| | IN 2003DN00952 | A | 20070316 | IN 2003-DN952 | 20030620 |
| | NO 2003002994 | A | 20030827 | NO 2003-2994 | 20030627 |
| | US 2004110945 | A1 | 20040610 | US 2003-451159 | 20030630 |
| | US 7157487 | B2 | 20070102 | | |
| PRAI | JP 2000-402890 | A | 20001228 | | |
| | JP 2001-149923 | A | 20010518 | | |
| | CN 2001-821484 | A3 | 20011228 | | |
| | WO 2001-JP11641 | W | 20011228 | | |
| OS | MARPAT 137:93763 | | | | |
| IT | 441712-82-9P 441712-83-0P | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (preparation of chiral pyrrolidine derivs. as VLA-4 inhibitors) | | | | |
| RN | 441712-82-9 CAPLUS | | | | |
| CN | Cyclohexanecarboxylic acid, 4-[[[(2S,4S)-1-[[[5-chloro-2-fluoro-4-[[[(1-methyl-1H-indol-3-yl)carbonyl]amino]phenyl]acetyl]-4-fluoro-2-pyrrolidinyl]carbonyl]amino]-, trans- (9CI) (CA INDEX NAME) | | | | |


Absolute stereochemistry.



RN 441712-83-0 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(2S,4S)-1-[[3-chloro-4-[(1-isoquinolin-1-ylcarbonyl)amino]phenyl]acetyl]-4-fluoro-2-pyrrolidinyl]carbonyl]amino]-, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 441716-31-0P 441716-33-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of chiral pyrrolidine derivs. as VLA-4 inhibitors)

RN 441716-31-0 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(2S,4S)-1-[[5-chloro-2-fluoro-4-[(1-methyl-1H-indol-3-yl)carbonyl]amino]phenyl]acetyl]-4-fluoro-2-pyrrolidinyl]carbonyl]amino]-, methyl ester, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 441716-33-2 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(2S,4S)-1-[[[3-chloro-4-[(1-isoquinolinylcarbonyl)amino]phenyl]acetyl]-4-fluoro-2-pyrrolidinyl]carbonyl]amino]-, methyl ester, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RE.CNT 143 THERE ARE 143 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 58 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:503388 CAPLUS
 DN 137:79229
 TI Preparation of cytostatic glycoconjugates having specifically cleavable
 peptidic linking units
 IN Lerchen, Hans-Georg; Baumgarten, Joerg; Lockhoff, Oswald
 PA Bayer Aktiengesellschaft, Germany
 SO Eur. Pat. Appl., 46 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | EP 1219634 | A1 | 20020703 | EP 2000-128402 | 20001227 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | WO 2002051862 | A2 | 20020704 | WO 2001-EP14868 | 20011217 |
| | WO 2002051862 | A3 | 20021010 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2002240841 | A1 | 20020708 | AU 2002-240841 | 20011217 |
| | US 2002173452 | A1 | 20021121 | US 2001-26237 | 20011221 |
| PRAI | EP 2000-128402 | A | 20001227 | | |
| | WO 2001-EP14868 | W | 20011217 | | |
| OS | MARPAT 137:79229 | | | | |
| IT | 439911-62-3P 439911-64-5P 439911-66-7P 439911-68-9P 439911-69-0P 439911-70-3P 439911-71-4P 439911-72-5P 439911-73-6P 439911-74-7P 439911-75-8P 439911-76-9P 439911-77-0P 439911-78-1P 439911-79-2P 439911-80-5P 439911-81-6P 439911-82-7P 439911-83-8P 439911-84-9P 439911-85-0P 439911-86-1P 439911-87-2P 439911-88-3P 439911-89-4P 439911-90-7P | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (preparation of cytostatic glycoconjugates having specifically cleavable peptidic linking units) | | | | |
| RN | 439911-62-3 CAPLUS | | | | |
| CN | L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl- β -L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-histidyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME) | | | | |


Absolute stereochemistry.




RN 439911-64-5 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-histidyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl




RN 439911-66-7 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-histidyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl




RN 439911-68-9 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]carbonyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-histidyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.





● HCl



RN 439911-69-0 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-asparaginyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 439911-70-3 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]carbonyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-asparaginyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN. 439911-71-4 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-α-aspartyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 439911-72-5 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-S-methyl-L-cysteiny-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 439911-73-6 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-tryptophyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 439911-74-7 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-lysyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 439911-75-8 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-D-histidyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 439911-76-9 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-D-leucylglycyl-L-leucyl-L-histidyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl




RN 439911-77-0 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-D-prolyl-L-leucylglycyl-L-leucyl-L-histidyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.





● HCl



RN 439911-78-1 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-D-alanyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 439911-79-2 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-valyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 439911-80-5 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-phenylalanyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 439911-81-6 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-seryl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 439911-82-7 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-isoleucyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 439911-83-8 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-α-glutamyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 439911-85-0 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-prolyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 439911-86-1 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-alanyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 439911-87-2 CAPLUS

CN L-Valine, 1-[[[4-[[3-O-(carboxymethyl)-6-deoxy-β-L-galactopyranosyl]oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-asparaginyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 439911-88-3 CAPLUS

CN L-Valine, 1-[[[4-(β-D-galactopyranosyloxy)phenyl]amino]thioxomethyl]-
L-prolyl-L-leucylglycyl-L-leucyl-L-asparaginyl-, (4S)-4-ethyl-3,4,12,14-
tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 439911-89-4 CAPLUS

CN L-Valine, 1-[[[4-[[6-deoxy-3-O-(2-hydroxyethyl)-β-L-galactopyranosyl]oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-asparaginyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 439911-90-7 CAPLUS

CN L-Valine, 1-[[[4-[[3-O-(2-amino-2-oxoethyl)-6-deoxy-β-L-galactopyranosyl]oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-asparaginyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





IT 439911-98-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)



(preparation of cytostatic glycoconjugates having specifically cleavable peptidic linking units)

RN 439911-98-5 CAPLUS

CN L-Valine, 1-[[[4-[(6-deoxy-3-O-methyl-β-L-galactopyranosyl)oxy]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-N6-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-lysyl-, (4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RE.CNT 11. THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 59 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:503334 CAPLUS
 DN 137:63479
 TI Preparation of conjugates of integrin receptor antagonists and a
 cytostatic agent having specifically cleavable linking units
 IN Lerchen, Hans-Georg; Baumgarten, Joerg; Lockhoff, Oswald; Albers, Markus;
 Schoop, Andreas
 PA Bayer Aktiengesellschaft, Germany
 SO Eur. Pat. Appl., 127 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | EP 1219305 | A1 | 20020703 | EP 2000-128401 | 20001227 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | CA 2433116 | A1 | 20020704 | CA 2001-2433116 | 20011218 |
| | WO 2002051444 | A1 | 20020704 | WO 2001-EP14965 | 20011218 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2002235789 | A1 | 20020708 | AU 2002-235789 | 20011218 |
| | EP 1347783 | A1 | 20031001 | EP 2001-985899 | 20011218 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | JP 2004519449 | T | 20040702 | JP 2002-552585 | 20011218 |
| | US 2002183256 | A1 | 20021205 | US 2001-26408 | 20011221 |
| PRAI | EP 2000-128401 | A | 20001227 | | |
| | WO 2001-EP14965 | W | 20011218 | | |

OS MARPAT 137:63479

IT 439864-66-1P 439864-67-2P 439864-68-3P
 439864-71-8P 439864-73-0P 439864-74-1P
 439864-75-2P 439864-76-3P 439864-77-4P
 439864-78-5P 439864-79-6P 439864-80-9P
 439864-84-3P 439864-85-4P 439864-86-5P
 439864-88-7P 439864-89-8P 439864-90-1P
 439864-93-4P 439864-94-5P 439864-95-6P
 439864-96-7P 439864-97-8P 439864-98-9P
 439864-99-0P 439865-00-6P 439865-01-7P




RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)


(preparation of conjugates of integrin receptor antagonists and a cytostatic
 agent having specifically cleavable linking units)

RN 439864-66-1 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[[[(propylamino)carbonyl]amino]phe
 nyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxome
 thyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-histidyl-, 6-[(4S)-4-ethyl-
 3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-
 b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.








RN 439864-68-3 CAPLUS

CN L-Valine, 1-[[[4-[[[(1S)-2-carboxy-1-[3-[[[3-
 [(propylamino) carbonyl] amino] phenyl] sulfonyl] amino] phenyl] ethyl] amino] car-
 bonyl] amino] phenyl] amino] thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-
 histidyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-
 pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.








RN 439864-71-8 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]carbonyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-histidyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyran-3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

RN 439864-73-0 CAPLUS


CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-, 5-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl]ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B








RN 439864-74-1 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-asparaginyl-,
6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 439864-75-2 CAPLUS


CN L-Valine, 1-[[[4-[[[(1R)-2-carboxy-1-[3-[[[3-
 [(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]car
 bonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-
 asparaginy]-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-
 pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C




10/712,456-ALW

RN 439864-76-3 CAPLUS


CN L-Valine, 1-[[[4-[[[(1S)-2-carboxy-1-[3-[[[3-[[[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-asparaginyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B








RN 439864-77-4 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]carbonyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-asparaginyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.








RN 439864-78-5 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino) carbonyl] amino] phenyl] sulfonyl] amino] phenyl] ethyl] amino] carbonyl] amino] phenyl] amino] thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-S-methyl-L-cysteiny-,
 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439864-79-6 CAPLUS
 CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino) carbonyl] amino]phe

10/712,456-ALW


nyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxome
thyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-tryptophyl-, 6-[(4S)-4-ethyl-
3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-
b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B








RN 439864-80-9 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino) carbonyl] amino] phenyl] sulfonyl] amino] phenyl] ethyl] amino] carbonyl] amino] phenyl] amino] carbonyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-tryptophyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 439864-84-3 CAPLUS
 CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[[(propylamino) carbonyl] amino] phenyl] sulfonyl] amino] phenyl] ethyl] amino] carbonyl] amino] phenyl] amino] thioxomethyl]-L-prolyl-L-leucylglycyl-S-methyl-L-cysteinyl-L-histidyl-,
 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-B



PAGE 1-C




10/712,456-ALW

RN 439864-85-4 CAPLUS


CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-lysyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl]ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B








RN 439864-86-5 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-norvalyl-L-asparaginyl-,
6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 439864-88-7 CAPLUS


CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[[(propylamino) carbonyl] amino] phenyl] sulfonyl] amino] phenyl] ethyl] amino] carbonyl] amino] phenyl] amino] thioxomethyl]-L-prolylglycylglycyl-L-leucyl-L-asparaginy]-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C




10/712,456-ALW

RN 439864-89-8 CAPLUS


CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[[(propylamino) carbonyl] amino] phenyl] sulfonyl] amino] phenyl] ethyl] amino] carbonyl] amino] phenyl] amino] thioxomethyl]-L-prolyl-L-histidylglycyl-L-leucyl-L-asparaginyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A'



PAGE 1-B








RN 439864-90-1 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-histidyl-, 5-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl]ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.








RN 439864-93-4 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino) carbonyl] amino] phenyl] sulfonyl] amino] phenyl] ethyl] amino] carbonyl] amino] phenyl] amino] thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-alanyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439864-94-5 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino) carbonyl] amino] phenyl] sulfonyl] amino] phenyl] ethyl] amino] carbonyl] amino] phenyl] amino] thioxime


thyl]-L-prolyl-L-leucylglycyl-L-leucyl-D-alanyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B








RN 439864-95-6 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-valyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 439864-96-7 CAPLUS


CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[[(propylamino) carbonyl] amino] phenyl] sulfonyl] amino] phenyl] ethyl] amino] carbonyl] amino] phenyl] amino] thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-phenylalanyl-,
6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C




RN 439864-97-8 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino) carbonyl] amino] phe


nyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxome
thyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-seryl-, 6-[(4S)-4-ethyl-3,4,12,14-
tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl]
ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B








RN 439864-98-9 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-isoleucyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 439864-99-0 CAPLUS


CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino) carbonyl] amino] phenyl] sulfonyl] amino] phenyl] ethyl] amino] carbonyl] amino] phenyl] amino] thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L- α -glutamyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


nyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxome
thyl]-L-prolyl-L-leucylglycyl-L-leucylglycyl-, 6-[(4S)-4-ethyl-3,4,12,14-
tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl]
ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B








RN 439865-01-7 CAPLUS

CN L-Valine, 1-[[[4-[[[2-carboxy-1-[3-[[[3-[(propylamino)carbonyl]amino]phenyl]sulfonyl]amino]phenyl]ethyl]amino]carbonyl]amino]phenyl]amino]thioxomethyl]-L-prolyl-L-leucylglycyl-L-leucyl-L-prolyl-, 6-[(4S)-4-ethyl-3,4,12,14-tetrahydro-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 60 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:487548 CAPLUS
DN 137:63475
TI Preparation of proline benzylamide derivatives as thrombin inhibitors
IN Selnick, Harold G.; Barrow, James C.; Nantermet, Philippe G.; Williams, Peter D.; Stauffer, Kenneth J.; Sanderson, Philip E.; Rittle, Kenneth E.; Morrisette, Matthew M.; Wiscount, Catherine M.; Tran, Lekhanh O.; Lyle, Terry A.; Staas, Donnette D.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 157 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2002050056 | A1 | 20020627 | WO 2001-US48321 | 20011214 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2431588 | A1 | 20020627 | CA 2001-2431588 | 20011214 |
| | AU 2002030836 | A5 | 20020701 | AU 2002-30836 | 20011214 |
| | JP 2004516286 | T | 20040603 | JP 2002-551552 | 20011214 |
| PRAI | US 2000-256304P | P | 20001218 | | |
| | US 2001-323184P | P | 20010918 | | |
| | WO 2001-US48321 | W | 20011214 | | |
| OS | MARPAT 137:63475 | | | | |
| IT | 439115-78-3P | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of proline benzylamide derivs. as thrombin inhibitors) | | | | |
| RN | 439115-78-3 CAPLUS | | | | |
| CN | Benzoic acid, 4-[2-[(2S)-2-[[[2-(aminomethyl)-5-chlorophenyl]methyl]amino]carbonyl]-1-pyrrolidinyl]-1-hydroxy-2-oxo-1-phenylethyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME) | | | | |
| CM | 1 | | | | |
| CRN | 439115-77-2 | | | | |
| CMF | C28 H28 Cl N3 O5 | | | | |

Absolute stereochemistry.




10/712,456-ALW

CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 439117-79-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of proline benzylamide derivs. as thrombin inhibitors)

RN 439117-79-0 CAPLUS

CN Benzoic acid, 4-[2-[(2S)-2-[[[5-chloro-2-[[[(1,1-dimethylethoxy) carbonyl] amino] methyl] phenyl] methyl] amino] carbonyl]-1-pyrrolidinyl]-1-hydroxy-2-oxo-1-phenylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 61 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:408632 CAPLUS

DN 137:5933

TI Preparation of substituted 2-phenyl-1-cyclohexanecarboxamides and related compounds their use in the treatment of cardiovascular, urogenital tract or cerebrovascular diseases.

IN Roehrig, Susanne; Stolle, Andreas; Castro-Palomino, Julio; Hanning, Helmut; Handke, Gabriele; Daviu-Folguera, Noemi; Paulsen, Holger; Pernestorfer, Josef; Mueller, Stephan-Nicholas; Steinhagen, Henning; Thielemann, Wolfgang; Bischoff, Erwin; Ebbinghaus-Kintscher, Ulrich; Ellinghaus, Peter; Huetter, Joachim; Krahn, Thomas; Wunder, Frank; Lustig, Klemens; Schuhmacher, Joachim; Suessmeier, Frank

PA Bayer Aktiengesellschaft, Germany

SO PCT Int. Appl., 227 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 2002042257 | A1 | 20020530 | WO 2001-EP13062 | 20011112 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | DE 10058461 | A1 | 20020919 | DE 2000-10058461 | 20001124 |
| | CA 2429328 | A1 | 20020530 | CA 2001-2429328 | 20011112 |
| | AU 200224839 | A | 20020603 | AU 2002-24839 | 20011112 |
| | EP 1339670 | A1 | 20030903 | EP 2001-994647 | 20011112 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | BR 2001015611 | A | 20040106 | BR 2001-15611 | 20011112 |
| | JP 2004522716 | T | 20040729 | JP 2002-544393 | 20011112 |
| | IN 2003MN00496 | A | 20060707 | IN 2003-MN496 | 20030509 |
| | US 2004235830 | A1 | 20041125 | US 2004-432573 | 20040422 |
| PRAI | DE 2000-10058461 | A | 20001124 | | |
| | WO 2001-EP13062 | W | 20011112 | | |

OS MARPAT 137:5933

IT 432044-76-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of 2-phenyl-1-cyclohexanecarboxamide derivs. for treatment of cardiovascular, urogenital tract or cerebrovascular diseases)

RN 432044-76-3 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N1-[4-(dimethylamino)phenyl]-N1-[[4-[(1R,2R)-2-[[[(1R)-2-hydroxy-1-phenylethyl]amino]carbonyl]cyclohexyl]phenyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 62 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:368495 CAPLUS
 DN 136:370002
 TI FAP α -activated antitumor compounds
 IN Peters, Stefan; Mack, Juergen; Leipert, Dietmar; Eickmeier, Christian;
 Park, John-Edward; Lenter, Martin; Garin-Chesa, Pilar
 PA Boehringer Ingelheim Pharma K.-G., Germany
 SO PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2002038590 | A1 | 20020516 | WO 2001-EP12812 | 20011106 |
| | W: | | | | |
| | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, | | | | |
| | CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, | | | | |
| | GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, | | | | |
| | LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, | | | | |
| | PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, | | | | |
| | US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, | | | | |
| | DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, | | | | |
| | BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2002020684 | A5 | 20020521 | AU 2002-20684 | 20011106 |
| | US 2003232742 | A1 | 20031218 | US 2001-36224 | 20011109 |
| PRAI | GB 2000-27552 | A | 20001110 | | |
| | US 2001-262323P | P | 20010117 | | |
| | WO 2001-EP12812 | W | 20011106 | | |
| OS | MARPAT 136:370002 | | | | |
| IT | 423757-45-3P 423757-47-5P | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU | | | | |
| | (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES | | | | |
| | (Uses) | | | | |
| | (FAP α -activated antitumor compds.) | | | | |
| RN | 423757-45-3 CAPLUS | | | | |
| CN | L-Prolinamide, 1-[[4-(aminomethyl)phenyl]acetyl]-L-prolyl-L-alanylglycyl-N- | | | | |
| | (4-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.

PAGE 1-A






RN 423757-47-5 CAPLUS

CN L-Prolinamide, 1-[(4-hydroxyphenyl)acetyl]-L-prolyl-L-alanylglycyl-N-(4-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 63 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:332684 CAPLUS
DN 136:340999
TI Preparation of amino acid derivatives as rotamase enzyme activity
inhibitors
IN Steiner, Joseph P.; Hamilton, Gregory S.
PA Gpi Nil Holdings, Inc., USA
SO U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S. Ser. No. 359,351.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 8

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 2002052410 | A1 | 20020502 | US 2001-805249 | 20010314 |
| | US 7056935 | B2 | 20060606 | | |
| | US 5614547 | A | 19970325 | US 1995-479436 | 19950607 |
| | US 2002013344 | A1 | 20020131 | US 1995-551026 | 19951031 |
| | RU 2269514 | C2 | 20060210 | RU 2000-115383 | 19960605 |
| | US 6509477 | B1 | 20030121 | US 1999-359351 | 19990721 |
| PRAI | US 1995-479436 | A1 | 19950607 | | |
| | US 1995-551026 | A2 | 19951031 | | |
| | US 1996-693003 | B1 | 19960806 | | |
| | US 1999-359351 | A2 | 19990721 | | |
| | RU 1997-111860 | A3 | 19960605 | | |
| OS | MARPAT 136:340999 | | | | |
| IT | 391669-36-6P | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of glyoxalylprolinate and -pipecolate derivs. as rotamase inhibitors) | | | | |
| RN | 391669-36-6 CAPLUS | | | | |
| CN | L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 3-phenylpropyl ester (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.




RE.CNT 232 THERE ARE 232 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L4 ANSWER 64 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:325632 CAPLUS
 DN 137:125380
 TI Synthesis of nucleopeptides by employing an enzyme-labile urethane protecting group
 AU Jeyaraj, Duraiswamy A.; Prinz, Heino; Waldmann, Herbert
 CS Abteilung Chemische Biologie, Max-Planck-Institut für molekulare Physiologie, Dortmund, 44227, Germany
 SO Chemistry--A European Journal (2002), 8(8), 1879-1887
 CODEN: CEUJED; ISSN: 0947-6539
 PB Wiley-VCH Verlag GmbH
 DT Journal
 LA English
 OS CASREACT 137:125380
 IT 444343-91-3P
 RL: BPN (Biosynthetic preparation); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of in the preparation of nucleopeptides by enzyme-labile protecting group synthesis techniques)
 RN 444343-91-3 CAPLUS
 CN L-Alanine, 1-[[4-[(phenylacetyl)oxy]phenyl]acetyl]-L-prolyl-L-valyl-O-[3'-O-acetyl-2'-deoxy-P-2-propenyl-N-[(2-propenyloxy)carbonyl]-5'-cytidyl]-L-seryl-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 444343-87-7P 444343-90-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of in the preparation of nucleopeptides by enzyme-labile protecting group synthesis techniques)

RN 444343-87-7 CAPLUS

CN L-Alanine, 1-[[4-[(phenylacetyl)oxy]phenyl]acetyl]-L-prolyl-L-seryl-, 2-propenyl ester (9CI) (CA. INDEX NAME)

Absolute stereochemistry. Rotation (-).





RN 444343-90-2 CAPLUS

CN L-Alanine, 1-[[4-[(phenylacetyl)oxy]phenyl]acetyl]-L-prolyl-O-[3'-O-acetyl-2'-deoxy-P-2-propenyl-N-[(2-propenyloxy)carbonyl]-5'-cytidyl]-L-seryl-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





IT 444343-74-2


RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of in the preparation of nucleopeptides by enzyme-labile protecting group synthesis techniques)

RN 444343-74-2 CAPLUS

CN L-Proline, 1-[[4-[(phenylacetyl)oxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 65 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:312019 CAPLUS

DN 136:325828

TI Preparation of dipeptide derivatives as cell adhesion inhibitors

IN Adams, Steven P.; Lin, Ko-Chung; Lee, Wen-Cherng; Castro, Alfredo C.;
Zimmerman, Craig N.; Hammond, Charles E.; Liao, Yu-Sheng; Cuervo, Julio
Hernan; Singh, Juswinder

PA Biogen, Inc., USA

SO U.S., 50 pp., Cont.-in-part of U.S. 6,306,840.

CODEN: USXXAM

DT Patent


LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 6376538 | B1 | 20020423 | US 1997-875321 | 19970919 |
| | US. 6306840 | B1 | 20011023 | US 1995-376372 | 19950123 |
| | WO 9622966 | A1 | 19960801 | WO 1996-US1349 | 19960118 |
| | W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE | | | | |
| EP | 1142867 | A2 | 20011010 | EP 2001-107877 | 19960118 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI | | | | |
| | AU 766538 | B2 | 20031016 | AU 2000-62432 | 20001002 |
| | US 2003018016 | A1 | 20030123 | US 2001-2341 | 20011023 |
| | US 6630512 | B2 | 20031007 | | |
| | US 7001921 | B1 | 20060221 | US 2003-625626 | 20030724 |
| | US 2006166866 | A1 | 20060727 | US 2003-679478 | 20031007 |
| PRAI | US 1995-376372 | A2 | 19950123 | | |
| | WO 1996-US1349 | W | 19960118 | | |
| | AU 1996-49115 | A3 | 19960118 | | |
| | EP 1996-905316 | A3 | 19960118 | | |
| | US 1997-875321 | A3 | 19970919 | | |
| | US 2001-935461 | A1 | 20010822 | | |
| | US 2001-2341 | A1 | 20011023 | | |
| OS | MARPAT 136:325828 | | | | |
| IT | 181519-89-1P | | | | |
| | RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of β -amino acid dipeptide derivs. as cell adhesion inhibitors) | | | | |
| RN | 181519-89-1 CAPLUS | | | | |
| CN | 1,3-Benzodioxole-5-propanoic acid, β -[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]-, methyl ester, (β S)- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.

10/712,456-ALW



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 66 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:276523 CAPLUS
DN 136:295090
TI Preparation of amino acid derivatives for use as thrombin inhibitors
IN Gustafsson, David; Nystrom, Jan-erik
PA Astra AB, Swed.
SO U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of Appl. No. PCT/SE96/00878.
CODEN: USXXCO

DT Patent
LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|-------|----------|------------------|----------|
| | ----- | ----- | ----- | ----- | ----- |
| PI | US 2002042396 | A1 | 20020411 | US 2001-995564 | 20011129 |
| | US 6617320 | B2 | 20030909 | | |
| | ZA 9605344 | A | 19970106 | ZA 1996-5344 | 19960624 |
| | TW 585853 | B | 20040501 | TW 1996-85107577 | 19960624 |
| | WO 9702284 | A1 | 19970123 | WO 1996-SE878 | 19960702 |
| | W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA | | | | |
| | ES 2197240 | T3 | 20040101 | ES 1996-922355 | 19960702 |
| | RU 2262508 | C2 | 20051020 | RU 2000-128495 | 19960702 |
| | US 6337343 | B1 | 20020108 | US 2000-537344 | 20000329 |
| | US 2004087647 | A1 | 20040506 | US 2003-606349 | 20030626 |
| | US 6921758 | B2 | 20050726 | | |
| PRAI | SE 1995-2487 | A | 19950706 | | |
| | SE 1995-2504 | A | 19950707 | | |
| | SE 1995-2505 | A | 19950707 | | |
| | SE 1995-3923 | A | 19951107 | | |
| | SE 1995-4349 | A | 19951205 | | |
| | GB 1995-26411 | A | 19951222 | | |
| | WO 1996-SE878 | A2 | 19960702 | | |
| | RU 1998-102188 | A | 19960702 | | |
| | US 1996-687466 | A3 | 19960807 | | |
| | US 2000-537344 | A1 | 20000329 | | |
| | US 2001-995564 | A1 | 20011129 | | |

OS MARPAT 136:295090

IT 187751-57-1P 407626-97-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of amino acid derivative as thrombin inhibitors)

RN 187751-57-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[hydroxy(4-hydroxy-3-methoxyphenyl)acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 407626-97-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(3-chloro-4-hydroxyphenyl)hydroxyacetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 187752-83-6P 187753-36-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of amino acid derivative as thrombin inhibitors)

RN 187752-83-6 CAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[hydroxy(4-hydroxy-3-methoxyphenyl)acetyl]-2-pyrrolidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 187753-36-2 CAPLUS

10/712,456-ALW

CN Carbamic acid, [[4-[[[(2S)-1-[(3-chloro-4-hydroxyphenyl)hydroxyacetyl]-2-pyrrolidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

L4 ANSWER 67 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:276521 CAPLUS
DN 136:310178
TI Preparation of amino acid derivatives as rotamase enzyme activity
inhibitors
IN Steiner, Joseph P.; Hamilton, Gregory S.
PA USA
SO U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U.S. Ser. No. 551,026.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 8


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | US 2002042377 | A1 | 20020411 | US 2001-873298 | 20010605 |
| | US 5614547 | A | 19970325 | US 1995-479436 | 19950607 |
| | US 2002013344 | A1 | 20020131 | US 1995-551026 | 19951031 |
| | RU 2269514 | C2 | 20060210 | RU 2000-115383 | 19960605 |
| | US 6509477 | B1 | 20030121 | US 1999-359351 | 19990721 |
| PRAI | US 1995-479436 | A1 | 19950607 | | |
| | US 1995-551026 | A2 | 19951031 | | |
| | US 1996-693003 | B1 | 19960806 | | |
| | US 1999-359351 | A2 | 19990721 | | |
| | RU 1997-111860 | A3 | 19960605 | | |
| OS | MARPAT 136:310178 | | | | |
| IT | 391669-36-6P | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of glyoxalylprolinate and -pipecolinate derivs. as rotamase inhibitors) | | | | |
| RN | 391669-36-6 CAPLUS | | | | |
| CN | L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 3-phenylpropyl ester (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.




L4 ANSWER 68 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:836875 CAPLUS
DN 136:118718
Ti 2-Aryl-2,2-difluoroacetamide FKBP12 Ligands: Synthesis and X-ray
Structural Studies
AU Dubowchik, Gene M.; Vrudhula, Vivekananda M.; Dasgupta, Bireshwar; Ditta,
Jonathan; Chen, Ti; Sheriff, Steven; Sipman, Karin; Witmer, Mark; Tredup,
Jeffrey; Vyas, Dolatrai M.; Verdoorn, Todd A.; Bollini, Sagarika;
Vinitsky, Alexander
CS Bristol-Myers Squibb Pharm. Res. Inst., Wallingford, CT, 06492-7660, USA
SO Organic Letters (2001), 3(25), 3987-3990
CODEN: ORLEF7; ISSN: 1523-7060
PB American Chemical Society
DT Journal
LA English
OS CASREACT 136:118718
IT 251909-01-0P 251909-02-1P 391669-22-0P
391669-24-2P 391669-26-4P 391669-28-6P
391669-31-1P 391669-33-3P 391669-35-5P
391669-36-6P 391669-37-7P 391669-38-8P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);
BIOL (Biological study); PREP (Preparation)
(preparation, crystal structure and rotamase inhibition activity of
(aryl)difluoroacetamides as ligands of FKBP12)
RN 251909-01-0 CAPLUS
CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-, 3-phenylpropyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 251909-02-1 CAPLUS
CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-,
3-(3-pyridinyl)propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 391669-22-0 CAPLUS
CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-,

10/712,456-ALW

1-phenyl-3-(3-pyridinyl)propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 391669-24-2 CAPLUS

CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-,
1-(phenylmethyl)-3-(3-pyridinyl)propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 391669-26-4 CAPLUS

CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-,
1-(2-phenylethyl)-3-(3-pyridinyl)propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 391669-28-6 CAPLUS

CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-,
4-phenyl-1-[2-(3-pyridinyl)ethyl]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 391669-31-1 CAPLUS

CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-,
1-(2-phenylethyl)-4-(3-pyridinyl)butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 391669-33-3 CAPLUS

CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-,
1-(3-phenylpropyl)-4-(3-pyridinyl)butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 391669-35-5 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 3-(3-pyridinyl)propyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 391669-36-6 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 3-phenylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 391669-37-7 CAPLUS

CN L-Proline, 1-[(3,4,5-trimethoxyphenyl)acetyl]-, 3-(3-pyridinyl)propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 391669-38-8 CAPLUS

CN L-Proline, 1-[(3,4,5-trimethoxyphenyl)acetyl]-, 3-phenylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 69 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:713304 CAPLUS

DN 135:257472

TI Preparation of peptidomimetic ligands for cellular receptors and ion channels

IN Persons, Paul E.; Holland, Joanne M.; Hauske, James R.

PA Sepracor, Inc., USA

SO PCT Int. Appl., 109 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 2001070684 | A2 | 20010927 | WO 2001-US6173 | 20010227 |
| | WO 2001070684 | A3 | 20020307 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | US 2005080271 | A1 | 20050414 | US 2003-203279 | 20030304 |
| | US 7115664 | B2 | 20061003 | | |
| | US 2007093522 | A1 | 20070426 | US 2006-512056 | 20060829 |
| PRAI | US 2000-190133P | P | 20000316 | | |
| | WO 2001-US6173 | W | 20010227 | | |
| | US 2003-203279 | A1 | 20030304 | | |

OS MARPAT 135:257472


IT 361347-63-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptidomimetic ligands for cellular receptors and ion channels)

RN 361347-63-9 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-[2-(dimethylamino)ethyl]-N2-(phenylmethyl)-N1-[4-(trifluoromethoxy)phenyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

L4 ANSWER 70 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:615529 CAPLUS
DN 135:180704
TI Synthesis alkylamidoheteroacylamide derivatives as Bax-a inhibitors for
the treatment of apoptosis
IN Halazy, Serge; Schwarz, Matthias; Antonsson, Bruno; Bombrun, Agnes;
Martinou, Jean-claude; Church, Dennis
PA Applied Research Systems Ars Holding N.V., Neth. Antilles
SO Eur. Pat. Appl., 57 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | EP 1125925 | A1 | 20010822 | EP 2000-810128 | 20000215 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | CA 2397651 | A1 | 20010823 | CA 2001-2397651 | 20010213 |
| | WO 2001060798 | A1 | 20010823 | WO 2001-EP1579 | 20010213 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | EP 1263730 | A1 | 20021211 | EP 2001-927666 | 20010213 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | JP 2003523332 | T | 20030805 | JP 2001-560184 | 20010213 |
| | AU 784086 | B2 | 20060202 | AU 2001-54640 | 20010213 |
| | US 2003216427 | A1 | 20031120 | US 2002-182745 | 20021226 |
| | US 6770656 | B2 | 20040803 | | |
| PRAI | EP 2000-810128 | A | 20000215 | | |
| | WO 2001-EP1579 | W | 20010213 | | |
| OS | MARPAT 135:180704 | | | | |
| IT | 355139-04-7P 355139-29-6P 355139-57-0P 355139-83-2P 355140-04-4P 355140-21-5P | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (Synthesis alkylamidoheteroacylamide derivs. as Bax-a inhibitors for the treatment of apoptosis) | | | | |
| RN | 355139-04-7 CAPLUS | | | | |
| CN | 2-Pyrrolidinecarboxamide, N-(6-aminohexyl)-1-[[4- (phenylmethoxy)phenyl]acetyl]- (9CI) (CA INDEX NAME) | | | | |

10/712,456-ALW




RN 355139-29-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(5-aminopentyl)-1-[[4-(phenylmethoxy)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 355139-57-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(7-aminoheptyl)-1-[[4-(phenylmethoxy)phenyl]acetyl]- (9CI) (CA INDEX NAME)




RN 355139-83-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-1-[[4-


10/712,456-ALW

(phenylmethoxy)phenyl]acetyl]- (9CI) (CA INDEX NAME)




RN 355140-04-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-methyl-N-[2-[2-(methylamino)ethoxy]ethyl]-1-[[4-(phenylmethoxy)phenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 355140-21-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-methyl-N-[6-(methylamino)hexyl]-1-[[4-(phenylmethoxy)phenyl]acetyl]- (9CI) (CA INDEX NAME)



10/712,456-ALW

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 71 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:564780 CAPLUS
DN 135:147400
TI Preparation of hydroxyproline derivatives as anthelmintics and nematocides
IN Chalquest, Richard R.
PA Akkadix Corporation, USA
SO PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 7

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2001054498 | A1 | 20010802 | WO 2001-US2871 | 20010129 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 2001049373 | A1 | 20011206 | US 2001-770121 | 20010126 |
| | US 2002002171 | A1 | 20020103 | US 2001-771067 | 20010126 |
| | AU 2001033089 | A5 | 20010807 | AU 2001-33089 | 20010129 |
| | US 2002016330 | A1 | 20020207 | US 2001-772262 | 20010129 |
| PRAI | US 2000-179005P | P | 20000128 | | |
| | WO 2001-US2871 | W | 20010129 | | |

OS MARPAT 135:147400


IT 352236-90-9P 352236-91-0P 352237-47-9P
352237-75-3P 352238-03-0P

RL: AGR (Agricultural use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation as anthelmintics and nematocide)

RN 352236-90-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, 4-(cyclohexylmethoxy)-1-[(3,4-dimethoxyphenyl)acetyl]-N-[[4-(1,1-dimethylethyl)phenyl]methyl]-, (2S,4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352236-91-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[1,1'-bicyclohexyl]-2-yl-4-(cyclohexylmethoxy)-1-[(3,4-dimethoxyphenyl)acetyl]-, (2S,4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 352237-47-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[1,1'-bicyclohexyl]-2-yl-1-[(3,4-dimethoxyphenyl)acetyl]-4-[[4-(1,1-dimethylethyl)phenyl]methoxy]-, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 352237-75-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[1,1'-bicyclohexyl]-2-yl-1-[(3,4-dimethoxyphenyl)acetyl]-4-(phenylmethoxy)-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352238-03-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[1,1'-bicyclohexyl]-2-yl-1-[(3,4-dimethoxyphenyl)acetyl]-4-[(3-methoxyphenyl)methoxy]-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 72 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:489369 CAPLUS

DN 135:92538

TI Preparation of N-arylcyanomethylprolineamides and analogs as cathepsin K inhibitors

IN Gabriel, Tobias; Pech, Michael; Wallbaum, Sabine

PA F. Hoffmann-La Roche A.-G., Switz.

SO PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2001047886 | A1 | 20010705 | WO 2000-EP12646 | 20001213 |
| | W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2395179 | A1 | 20010705 | CA 2000-2395179 | 20001213 |
| | EP 1244621 | A1 | 20021002 | EP 2000-990733 | 20001213 |
| | EP 1244621 | B1 | 20060913 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | BR 2000016699 | A | 20021105 | BR 2000-16699 | 20001213 |
| | JP 2003519125 | T | 20030617 | JP 2001-549358 | 20001213 |
| | JP 3808772 | B2 | 20060816 | | |
| | AU 783145 | B2 | 20050929 | AU 2001-30106 | 20001213 |
| | AT 339404 | T | 20061015 | AT 2000-990733 | 20001213 |
| | US 2001008901 | A1 | 20010719 | US 2000-745675 | 20001221 |
| | US 6531612 | B2 | 20030311 | | |
| | ZA 2002004397 | A | 20030901 | ZA 2002-4397 | 20020531 |
| PRAI | EP 1999-125857 | A | 19991224 | | |
| | WO 2000-EP12646 | W | 20001213 | | |

OS MARPAT 135:92538

IT 348143-28-2P 348143-35-1P 348143-46-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-arylcyanomethylprolineamides and analogs as cathepsin K inhibitors)

RN 348143-28-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(3-chlorophenyl)cyanomethyl]-1-[(3,4,5-trimethoxyphenyl)acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

RN 348143-35-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-(1,3-benzodioxol-5-ylcyanomethyl)-1-[(4-ethoxyphenyl)acetyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348143-46-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[cyano(3,4-dimethoxyphenyl)methyl]-1-[(4-ethoxyphenyl)acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3


THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 73 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:319894 CAPLUS
DN 134:326532
TI Preparation of 3-(hetero)aryl-1,3-diazabicyclo[3.3.0]octane-2,4-diones and
analogues as inhibitors of $\alpha 1\beta 2$ mediated cell adhesion
IN Sircar, Ila; Furth, Paul; Teegarden, Bradley R.; Morningstar, Marshall;
Smith, Nicholas; Griffith, Ronald C.
PA Tanabe Seiyaku Co., Ltd., Japan
SO PCT Int. Appl., 195 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|--|----------|------------------|----------|
| PI | WO 2001030781 | A2 | 20010503 | WO 2000-US29273 | 20001019 |
| | WO 2001030781 | A3 | 20011122 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | CA 2388639 | A1 | 20010503 | CA 2000-2388639 | 20001019 |
| | BR 2000014651 | A | 20020618 | BR 2000-14651 | 20001019 |
| | JP 2003512468 | T | 20030402 | JP 2001-533134 | 20001019 |
| | EP 1307455 | A2 | 20030507 | EP 2000-976625 | 20001019 |
| | EP 1307455 | B1 | 20050406 | | |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | |
| | NZ 518369 | A | 20030926 | NZ 2000-518369 | 20001019 |
| | AU 778757 | B2 | 20041216 | AU 2001-14370 | 20001019 |
| | AT 292634 | T | 20050415 | AT 2000-976625 | 20001019 |
| | PT 1307455 | T | 20050630 | PT 2000-976625 | 20001019 |
| | CN 1651431 | A | 20050810 | CN 2004-10096397 | 20001019 |
| | ES 2240201 | T3 | 20051016 | ES 2000-976625 | 20001019 |
| | TW 250984 | B | 20060311 | TW 2001-90108415 | 20010409 |
| | US 6897225 | B1 | 20050524 | US 2002-111110 | 20021016 |
| | HK 1053473 | A1 | 20050909 | HK 2003-105854 | 20030814 |
| | US 2005148602 | A1 | 20050707 | US 2005-70335 | 20050303 |
| PRAI | US 1999-160629P | P | 19991020 | | |
| | US 2000-209847P | P | 20000607 | | |
| | WO 2000-US29273 | W | 20001019 | | |
| | US 2002-111110 | A3 | 20021016 | | |
| OS | MARPAT 134:326532 | | | | |
| IT | 336818-26-9P 336818-28-1P 336818-37-2P 336819-04-6P | | | | |
| | RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) | | | | |
| | (intermediate; preparation of 3-(hetero)aryl-1,3-diazabicyclo[3.3.0]octane-2,4-diones and analogues as inhibitors of $\alpha 1\beta 2$ mediated cell adhesion by cyclization and reaction of N-[(hetero)arylcarbamoyl]proline derivs.) | | | | |
| RN | 336818-26-9 CAPLUS | | | | |
| CN | Proline, 2-[(4-bromophenyl)methyl]-1-[[[(3,5-dichloro-4-methoxyphenyl)amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME) | | | | |

10/712,456-ALW




RN 336818-28-1 CAPLUS

CN Proline, 2-[(4-bromophenyl)methyl]-1-[[[4-(3-carboxypropoxy)-3,5-dichlorophenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 336818-37-2 CAPLUS


CN Proline, 2-[(4-bromophenyl)methyl]-1-[[[3,5-dichloro-4-[(1,1-dimethylethoxy)carbonyl]phenyl]amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



10/712,456-ALW

RN 336819-04-6 CAPLUS

CN Proline, 1-[[[4-[bis[(phenylmethoxy)carbonyl]amino]-3,5-dichlorophenyl]amino]carbonyl]-2-[(4-cyanophenyl)methyl]-, methyl ester
(9CI) (CA INDEX NAME)



10/712,456-ALW

L4 ANSWER 74 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:228855 CAPLUS

DN 134:252658

TI Preparation of tyrosine derivatives as inhibitors of $\alpha 4$ containing integrin-mediated binding to ligands VCAM-1 and MAdCAM.

IN Jackson, David Y.; Sailes, Frederick C.; Sutherlin, Daniel P.

PA Genentech, Inc., USA

SO PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2001021584 | A1 | 20010329 | WO 2000-US26326 | 20000925 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2385882 | A1 | 20010329 | CA 2000-2385882 | 20000925 |
| | EP 1214292 | A1 | 20020619 | EP 2000-965417 | 20000925 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| | US 6469047 | B1 | 20021022 | US 2000-669779 | 20000925 |
| | JP 2003509488 | T | 20030311 | JP 2001-524964 | 20000925 |
| | AU 780385 | B2 | 20050317 | AU 2000-76138 | 20000925 |
| | US 2004110753 | A1 | 20040610 | US 2002-198328 | 20020716 |
| | US 2004158076 | A1 | 20040812 | US 2004-772678 | 20040204 |
| PRAI | US 1999-156062P | P | 19990924 | | |
| | US 2000-669779 | A1 | 20000925 | | |
| | WO 2000-US26326 | W | 20000925 | | |
| | US 2002-198328 | A1 | 20020716 | | |

OS MARPAT 134:252658


IT 331471-51-3P 331471-52-4P 331471-53-5P
331471-54-6P 331471-57-9P 331471-73-9P
331471-89-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tyrosine derivs. as inhibitors of $\alpha 4$ containing integrin-mediated binding to ligands VCAM-1 and MAdCAM.)

RN 331471-51-3 CAPLUS

CN L-Tyrosine, 1-[(4-aminophenyl)acetyl]-L-prolyl-, 4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331471-52-4 CAPLUS

CN L-Tyrosine, 1-[[4-(acetilamino)phenyl]acetyl]-L-prolyl-,
4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 331471-53-5 CAPLUS

CN L-Tyrosine, (2S)-2-(4-hydroxyphenyl)glycyl-4-aminobenzeneacetyl-L-prolyl-,
4-(4-morpholinecarboxylate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 331471-54-6 CAPLUS

CN L-Tyrosine, (2S)-N-acetyl-2-(4-hydroxyphenyl)glycyl-4-aminobenzeneacetyl-L-prolyl-, 4-(4-morpholinecarboxylate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331471-57-9 CAPLUS


CN L-Tyrosine, 1-[[4-[2-[(2-carboxyethyl)amino]-2-oxoethyl]phenyl]acetyl]-L-prolyl-, 4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 331471-73-9 CAPLUS

CN L-Tyrosine, 1-[[4-[2-[(carboxymethyl)amino]-2-oxoethyl]phenyl]acetyl]-L-propyl-, 4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 331471-89-7 CAPLUS

CN L-Tyrosine, 1-[[4-(carboxymethyl)phenyl]acetyl]-L-propyl-, 4-morpholinecarboxylate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 75 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:185738 CAPLUS

DN 134:222732

TI Novel processes for preparing oxazepine derivatives via cyclization of 2-(2-bromobenzyloxy)aniline derivative

IN Sekiyama, Takaaki; Matsuzawa, Toshihiro; Yamamoto, Takashi; Yatagai, Masanobu; Ezaki, Junko

PA Ajinomoto Co., Inc., Japan

SO PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2001017980 | A1 | 20010315 | WO 2000-JP5967 | 20000901 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2000068689 | A | 20010410 | AU 2000-68689 | 20000901 |
| | EP 1219611 | A1 | 20020703 | EP 2000-956884 | 20000901 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| | US 2002133004 | A1 | 20020919 | US 2002-86781 | 20020304 |
| PRAI | JP 1999-250298 | A | 19990903 | | |
| | WO 2000-JP5967 | W | 20000901 | | |

OS CASREACT 134:222732; MARPAT 134:222732

IT 329329-16-0P 329329-17-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(novel processes for preparing oxazepine derivs. via cyclization of (bromobenzyloxy)aniline derivative)

RN 329329-16-0 CAPLUS

CN D-Proline, 1-[(4-methoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 329329-17-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-[(2-bromophenyl)methoxy]phenyl]-1-[(4-methoxyphenyl)acetyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 76 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2001:137020 CAPLUS
 DN 134:193741
 TI Preparation of peptide derivatives as cell adhesion inhibitors
 IN Lee, Wen-Cherng; Scott, Daniel; Cornebise, Mark; Petter, Russell
 PA Biogen, Inc., USA
 SO PCT Int. Appl., 144 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2001012186 | A1 | 20010222 | WO 2000-US22285 | 20000814 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2380817 | A1 | 20010222 | CA 2000-2380817 | 20000814 |
| | BR 2000013248 | A | 20020723 | BR 2000-13248 | 20000814 |
| | HU 200202469 | A2 | 20021128 | HU 2002-2469 | 20000814 |
| | EP 1265606 | A1 | 20021218 | EP 2000-959232 | 20000814 |
| | EP 1265606 | B1 | 20061025 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| | JP 2003506491 | T | 20030218 | JP 2001-516532 | 20000814 |
| | EE 200200070 | A | 20030415 | EE 2002-70 | 20000814 |
| | US 6630503 | B1 | 20031007 | US 2000-638652 | 20000814 |
| | NZ 517011 | A | 20040227 | NZ 2000-517011 | 20000814 |
| | AU 780610 | B2 | 20050407 | AU 2000-70586 | 20000814 |
| | AT 343383 | T | 20061115 | AT 2000-959232 | 20000814 |
| | EP 1741428 | A2 | 20070110 | EP 2006-21333 | 20000814 |
| | EP 1741428 | A3 | 20070509 | | |
| | R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| | IN 2002DN00160 | A | 20061229 | IN 2002-DN160 | 20020207 |
| | ZA 2002001158 | A | 20030512 | ZA 2002-1158 | 20020211 |
| | NO 2002000725 | A | 20020408 | NO 2002-725 | 20020213 |
| | BG 106510 | A | 20021031 | BG 2002-106510 | 20020311 |
| | HK 1051500 | A1 | 20070202 | HK 2003-103786 | 20030527 |
| | US 2004132809 | A1 | 20040708 | US 2003-677756 | 20031003 |
| | US 7034043 | B2 | 20060425 | | |
| | US 2006166961 | A1 | 20060727 | US 2006-362043 | 20060227 |
| PRAI | US 1999-148845P | P | 19990813 | | |
| | EP 2000-959232 | A3 | 20000814 | | |
| | US 2000-638652 | A1 | 20000814 | | |
| | WO 2000-US22285 | W | 20000814 | | |
| | US 2003-677756 | A1 | 20031003 | | |
| OS | MARPAT 134:193741 | | | | |
| IT | 327612-34-0P 327612-97-5P 327613-59-2P | | | | |
| | RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (preparation of peptide derivs. as cell adhesion inhibitors) | | | | |
| RN | 327612-34-0 CAPLUS | | | | |
| CN | L-Alanine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-3-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2- | | | | |

10/712,456-ALW


pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 327612-97-5 CAPLUS



CN L-Lysine, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-N6-[1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 327613-59-2 CAPLUS
 CN Butanoic acid, 1-[(3,5-dichlorophenyl)sulfonyl]-L-prolyl-N4-[1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl]-2,4-diamino-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 78 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2001:12266 CAPLUS

DN 134:86149

TI Preparation of diphenyl ureas as VLA-4 inhibitors

IN Baldwin, John J.; McDonald, Edward; Moriarty, Kevin Joseph; Sarko, Christopher Ronald; Machinaga, Nobuo; Nakayama, Atsushi; Chiba, Jun; Iimura, Shin; Yoneda, Yoshiyuki

PA Daiichi Pharmaceutical Co., Ltd., Japan; Pharmacopeia, Inc.

SO PCT Int. Appl., 511 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2001000206 | A1 | 20010104 | WO 2000-US18079 | 20000630 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2369308 | A1 | 20010104 | CA 2000-2369308 | 20000630 |
| | EP 1189612 | A1 | 20020327 | EP 2000-945035 | 20000630 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | BR 2000012068 | A | 20020514 | BR 2000-12068 | 20000630 |
| | JP 2003503350 | T | 20030128 | JP 2001-505915 | 20000630 |
| | AU 781438 | B2 | 20050526 | AU 2000-59031 | 20000630 |
| | RU 2264386 | C2 | 20051120 | RU 2001-135856 | 20000630 |
| | ZA 2001009203 | A | 20030207 | ZA 2001-9203 | 20011107 |
| | NO 2001006319 | A | 20020228 | NO 2001-6319 | 20011221 |
| | US 2003078249 | A1 | 20030424 | US 2001-34585 | 20011228 |
| | US 6756378 | B2 | 20040629 | | |
| | US 2004229858 | A1 | 20041118 | US 2004-787905 | 20040226 |
| | US 7179819 | B2 | 20070220 | | |
| | US 2007054909 | A1 | 20070308 | US 2006-594432 | 20061108 |
| PRAI | US 1999-141601P | P | 19990630 | | |
| | US 1999-141602P | P | 19990630 | | |
| | US 1999-141692P | P | 19990630 | | |
| | WO 2000-US18079 | W | 20000630 | | |
| | US 2001-34585 | A3 | 20011228 | | |
| | US 2004-787905 | A3 | 20040226 | | |

OS MARPAT 134:86149


IT 317353-65-4P 317353-66-5P 317360-89-7P
317360-90-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of di-Ph ureas as VLA-4 inhibitors)

RN 317353-65-4 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[(2S)-1-[[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]-, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 317353-66-5 CAPLUS



CN Cyclohexanecarboxylic acid, 4-[[[1-[[4-[[[(2-chlorophenyl)amino]carbonyl]amino]-3-methoxyphenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]-, cis- (9CI)
(CA INDEX NAME)

Relative stereochemistry.





RN 317360-89-7 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[1-[[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 317360-90-0 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[[[1-[[4-[[[(2-chlorophenyl)amino]carbonyl]amino]-3-methoxyphenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



IT 317358-44-4P 317358-45-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of di-Ph ureas as VLA-4 inhibitors)
 RN 317358-44-4 CAPLUS
 CN Cyclohexanecarboxylic acid, 4-[[[(2S)-1-[[3-methoxy-4-[[[(2-
 methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-
 pyrrolidinyl]carbonyl]amino]-, phenylmethyl ester, cis- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




10/712,456-ALW

RN 317358-45-5 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[1-[[4-[[[(2-chlorophenyl)amino]carbonyl]amino]-3-methoxyphenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]-, phenylmethyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 79 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:725611 CAPLUS
DN 133:276333
TI Anticancer calcium channel blockers
IN Gray, Lloyd S.; Macdonald, Timothy L.; Haverstick, Doris M.; Heady,
Tiffany N.
PA USA
SO PCT Int. Appl., 125 pp.
CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2000059882 | A1 | 20001012 | WO 2000-US9310 | 20000407 |
| | W: CA, JP | | | | |
| | RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | CA 2369588 | A1 | 20001012 | CA 2000-2369588 | 20000407 |
| | EP 1165508 | A1 | 20020102 | EP 2000-921867 | 20000407 |
| | EP 1165508 | B1 | 20040623 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | JP 2002541142 | T | 20021203 | JP 2000-609394 | 20000407 |
| | AT 269848 | T | 20040715 | AT 2000-921867 | 20000407 |
| | US 6946475 | B1 | 20050920 | US 2000-544968 | 20000407 |
| PRAI | US 1999-128143P | P | 19990407 | | |
| | WO.2000-US9310 | W | 20000407 | | |
| OS | MARPAT 133:276333 | | | | |
| IT | 106789-32-6P | | | | |
| | RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) | | | | |
| | (anticancer calcium channel blockers) | | | | |
| RN | 106789-32-6 CAPLUS | | | | |
| CN | L-Proline, 1-[(4-methoxyphenyl)acetyl]-, methyl ester (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/712,456-ALW

L4 ANSWER 80 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:725603 CAPLUS
DN 133:296654
TI Preparation of N-acyl- α -aminohydroxamic acids as matrix
metalloproteinase, TNF- α , and aggrecanase inhibitors
IN Duan, Jingwu
PA Du Pont Pharmaceuticals Company, USA
SO PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2000059874 | A1 | 20001012 | WO 2000-US8362 | 20000330 |
| | W: AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | CA 2366264 | A1 | 20001012 | CA 2000-2366264 | 20000330 |
| | EP 1165500 | A1 | 20020102 | EP 2000-921500 | 20000330 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | JP 2002541138 | T | 20021203 | JP 2000-609387 | 20000330 |
| | US 6376665 | B1 | 20020423 | US 2000-540057 | 20000331 |
| | US 2003032803 | A1 | 20030213 | US 2002-74357 | 20020212 |
| | US 6689771 | B2 | 20040210 | | |
| PRAI | US 1999-127635P | P | 19990402 | | |
| | WO 2000-US8362 | W | 20000330 | | |
| | US 2000-540057 | A3 | 20000331 | | |
| OS | MARPAT 133:296654 | | | | |
| IT | 301162-35-6P 301162-36-7P 301162-55-0P 301162-56-1P | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of N-acyl- α -aminohydroxamic acids as matrix metalloproteinase, TNF- α , and aggrecanase inhibitors) | | | | |
| RN | 301162-35-6 CAPLUS | | | | |
| CN | 2-Pyrrolidinecarboxamide, N-hydroxy-1-[[4-[(2-methyl-4-quinolinyloxy)methoxy]phenyl]acetyl]-, (2R)- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.


10/712,456-ALW



RN 301162-36-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-hydroxy-1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 301162-55-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-hydroxy-1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]-, (2R)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 301162-35-6

10/712,456-ALW

CMF C24 H25 N3 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 301162-56-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-hydroxy-1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]-, (2S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 301162-36-7

CMF C24 H25 N3 O4

Absolute stereochemistry.


10/712,456-ALW



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 301162-84-5P 301162-85-6P 301162-86-7P

301163-20-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of N-acyl- α -aminohydroxamic acids as matrix metalloproteinase, TNF- α , and aggrecanase inhibitors)

RN 301162-84-5 CAPLUS

CN L-Proline, 1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 301162-85-6 CAPLUS

CN D-Proline, 1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 301162-86-7 CAPLUS

CN D-Proline, 1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 301163-20-2 CAPLUS

CN L-Proline, 1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 13

THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 81 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2000:457018 CAPLUS

DN 133:89793

TI Preparation of 4-(4-hydroxyphenoxy)phenylacetyl amino acids and related compounds as novel thyroid receptor ligands

IN Hangeland, Jon; Zhang, Minsheng; Caringal, Yolanda; Ryono, Denis; Li, Yi-lin; Malm, Johan; Liu, Ye; Garg, Neeraj; Litten, Chris; Garcia Collazo, Ana Maria; Koehler, Konrad

PA Karo Bio AB, Swed.; et al.

SO PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|--|----------|-------------------|----------|
| PI | WO 2000039077 | A2 | 20000706 | WO 1999-IB2084 | 19991223 |
| | WO 2000039077 | A3 | 20000921 | | |
| | W: | AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | |
| | RW: | GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | CA 2356319 | A1 | 20000706 | CA 1999-2356319 | 19991223 |
| | BR 9916851 | A | 20011016 | BR 1999-16851 | 19991223 |
| | EP 1144370 | A2 | 20011017 | EP 1999-962486 | 19991223 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | |
| | TR 200101834 | T2 | 20011221 | TR 2001-200101834 | 19991223 |
| | HU 200104666 | A2 | 20020328 | HU 2001-4666 | 19991223 |
| | JP 2002533432 | T | 20021008 | JP 2000-590990 | 19991223 |
| | AU 758202 | B2 | 20030320 | AU 2000-18855 | 19991223 |
| | NZ 512422 | A | 20040227 | NZ 1999-512422 | 19991223 |
| | NO 2001002931 | A | 20010821 | NO 2001-2931 | 20010613 |
| | ZA 2001004932 | A | 20030115 | ZA 2001-4932 | 20010615 |
| | IN 2001KN00754 | A | 20050311 | IN 2001-KN754 | 20010720 |
| | US 6989402 | B1 | 20060124 | US 2001-868889 | 20010914 |
| | US 2005282872 | A1 | 20051222 | US 2005-189654 | 20050726 |
| PRAI | GB 1998-28442 | A | 19981224 | | |
| | WO 1999-IB2084 | W | 19991223 | | |
| | US 2001-868889 | A3 | 20010914 | | |
| OS | MARPAT 133:89793 | | | | |
| IT | 280777-20-OP 280777-26-6P | | | | |
| | RL: | SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | |
| | | (preparation of (hydroxyphenoxy)phenylacetyl amino acids and related compds. as novel thyroid receptor ligands) | | | |
| RN | 280777-20-0 CAPLUS | | | | |
| CN | D-Proline, 1-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.


10/712,456-ALW



RN 280777-26-6 CAPLUS

CN L-Proline, 1-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 82 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:384175 CAPLUS
DN 133:30959
TI Preparation of prolinylalkanediones and related compounds for treating neurological disease, vision disorders, and alopecia.
IN Hamilton, Gregory S.; Norman, Mark H.; Wu, Yong-qian
PA GPI Nil Holdings, Inc., USA; Amgen, Inc.
SO PCT Int. Appl., 166 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | WO 2000032588 | A2 | 20000608 | WO 1999-US28663 | 19991203 |
| | WO 2000032588 | A3 | 20010222 | | |
| | W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 6331537 | B1 | 20011218 | US 1999-453571 | 19991202 |
| | CA 2353460 | A1 | 20000608 | CA 1999-2353460 | 19991203 |
| | BR 9916461 | A | 20010904 | BR 1999-16461 | 19991203 |
| | EP 1135370 | A2 | 20010926 | EP 1999-961930 | 19991203 |
| | EP 1135370 | B1 | 20031015 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | AU 767468 | B2 | 20031113 | AU 2000-18413 | 19991203 |
| | AT 252078 | T | 20031115 | AT 1999-961930 | 19991203 |
| | NZ 511673 | A | 20040326 | NZ 1999-511673 | 19991203 |
| | ZA 2001004397 | A | 20030829 | ZA 2001-4397 | 20010529 |
| | NO 2001002765 | A | 20010720 | NO 2001-2765 | 20010605 |
| | NO 318909 | B1 | 20050523 | | |
| | BG 105643 | A | 20020228 | BG 2001-105643 | 20010625 |
| | AU 2004200797 | A1 | 20040325 | AU 2004-200797 | 20040227 |
| PRAI | US 1998-204237 | A | 19981203 | | |
| | US 1999-453571 | A | 19991202 | | |
| | US 1998-87788P | P | 19980603 | | |
| | AU 1999-17081 | A3 | 19981203 | | |
| | WO 1999-US28663 | W | 19991203 | | |

OS MARPAT 133:30959

IT 251949-15-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of prolinylalkanediones and related compds. for treating neurol. disease, vision disorders, and alopecia)

RN 251949-15-2 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethylphenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



10/712,456-ALW

L4 ANSWER 83 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2000:209094 CAPLUS

DN 133:72574

TI Fluoresceinated FKBP12 ligands for a high-throughput fluorescence polarization assay

AU Dubowchik, Gene M.; Ditta, Jonathan L.; Herbst, John J.; Bollini, Sagarika; Vinitsky, Alexander

CS Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT, 06492-7660, USA

SO Bioorganic & Medicinal Chemistry Letters (2000), 10(6), 559-562
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science Ltd.

DT Journal

LA English

IT 278612-52-5P 278612-54-7P

RL: ARG (Analytical reagent use); PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); PROC (Process); USES (Uses)
(fluoresceinated FKBP12 ligands for a high-throughput fluorescence polarization assay)


RN 278612-52-5 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 4-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)amino]thioxomethyl]amino]butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A

HO—



PAGE 1-B




10/712,456-ALW

RN 278612-54-7 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 278612-50-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(fluoresceinated FKBP12 ligands for a high-throughput fluorescence polarization assay)

RN 278612-50-3 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 84 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2000:133508 CAPLUS
DN 132:166514
TI heterocyclic carboxylic acid ureas or carbamates for vision and memory disorders.
IN Ross, Douglas T.; Sauer, Hansjorg; Hamilton, Gregory S.; Steiner, Joseph P.
PA Guilford Pharmaceuticals Inc., USA
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2000009125 | A1 | 20000224 | WO 1999-US18234 | 19990812 |
| | W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2336152 | A1 | 20000224 | CA 1999-2336152 | 19990812 |
| | AU 9954778 | A1 | 20000306 | AU 1999-54778 | 19990812 |
| | EP 1107754 | A1 | 20010620 | EP 1999-941054 | 19990812 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | JP 2002522494 | T | 20020723 | JP 2000-564628 | 19990812 |
| PRAI | US 1998-134420 | A | 19980814 | | |
| | WO 1999-US18234 | W | 19990812 | | |

OS MARPAT 132:166514

IT 251574-40-0


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(heterocyclic carboxylic acid ureas or carbamates for vision and memory disorders)

RN 251574-40-0 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-hydroxy-N1-(4-methylphenyl)-N2-propyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 85 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:819360 CAPLUS

DN 132:64524

TI Preparation of N-thiazolidinylcarbonylphenylalanine derivatives and analogs as inhibitors of $\alpha 4\beta 1$ mediated cell adhesion

IN Blinn, James R.; Chrusciel, Robert A.; Fisher, Jed F.; Tanis, Steven P.; Thomas, Edward William; Lobl, Thomas J.; Teegarden, Bradley R.

PA Pharmacia and Upjohn Company, USA; Tanabe Seiyaku Co., Ltd.

SO PCT Int. Appl., 308 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 9967230 | A1 | 19991229 | WO 1999-US14233 | 19990623 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | TW 591026 | B | 20040611 | TW 1999-88110444 | 19990622 |
| | CA 2342778 | A1 | 19991229 | CA 1999-2342778 | 19990623 |
| | AU 9947116 | A | 20000110 | AU 1999-47116 | 19990623 |
| | AU 764553 | B2 | 20030821 | | |
| | EP 1089989 | A1 | 20010411 | EP 1999-930614 | 19990623 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | JP 2002518491 | T | 20020625 | JP 2000-555884 | 19990623 |
| | NZ 509010 | A | 20021025 | NZ 1999-509010 | 19990623 |
| | US 6685617 | B1 | 20040203 | US 2001-720088 | 20010309 |
| PRAI | US 1998-90421P | P | 19980623 | | |
| | WO 1999-US14233 | W | 19990623 | | |

OS MARPAT 132:64524

IT 253154-47-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(target compound; preparation of N-thiazolidinylcarbonylphenylalanine derivs.

and analogs as inhibitors of $\alpha 4\beta 1$ mediated cell adhesion)

RN 253154-47-1 CAPLUS

CN L-Phenylalanine, 1-[[[(4-carboxyphenyl)amino]carbonyl]-L-prolyl-4-[(2,6-dichlorobenzoyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 86 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:784078 CAPLUS

DN 132:22860

TI Preparation of aza-heterocyclic compounds used to treat neurological disorders and hair loss

IN Hamilton, Gregory S.; Norman, Mark H.; Wu, Yong-Qian; Steiner, Joseph P.

PA Guilford Pharmaceuticals Inc., USA; Amgen, Inc.

SO PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 5

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 9962881 | A1 | 19991209 | WO 1998-US25573 | 19981203 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW. | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2333963 | A1 | 19991209 | CA 1998-2333963 | 19981203 |
| | AU 9917081 | A | 19991220 | AU 1999-17081 | 19981203 |
| | AU 772472 | B2 | 20040429 | | |
| | ZA 9811063 | A | 20000707 | ZA 1998-11063 | 19981203 |
| | BR 9815920 | A | 20010220 | BR 1998-15920 | 19981203 |
| | EP 1084107 | A1 | 20010321 | EP 1998-961866 | 19981203 |
| | EP 1084107 | B1 | 20070411 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY | | | | |
| | HU 200102923 | A2 | 20011228 | HU 2001-2923 | 19981203 |
| | HU 200102923 | A3 | 20020128 | | |
| | JP 2002516905 | T | 20020611 | JP 2000-552093 | 19981203 |
| | NZ 508462 | A | 20040227 | NZ 1998-508462 | 19981203 |
| | AT 359267 | T | 20070515 | AT 1998-961866 | 19981203 |
| | NO 2000005903 | A | 20010202 | NO 2000-5903 | 20001121 |
| | NO 320643 | B1 | 20060109 | | |
| | BG 105015 | A | 20010831 | BG 2000-105015 | 20001201 |
| | AU 2004200797 | A1 | 20040325 | AU 2004-200797 | 20040227 |
| PRAI | US 1998-87788P | P | 19980603 | | |
| | US 1998-101077P | P | 19980918 | | |
| | AU 1999-17081 | A3 | 19981203 | | |
| | WO 1998-US25573 | W | 19981203 | | |
| OS | MARPAT 132:22860 | | | | |
| IT | 251949-15-2P 251950-15-9P | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (preparation of aza-heterocyclic compds. used to treat neurol. disorders and hair loss) | | | | |
| RN | 251949-15-2 CAPLUS | | | | |
| CN | L-Proline, 1-[oxo(3,4,5-trimethylphenyl)acetyl]- (9CI) (CA INDEX NAME) | | | | |


Absolute stereochemistry.

10/712,456-ALW



RN 251950-15-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-cyano-N-ethyl-1-[(4-methylphenyl)oxoacetyl]-
(9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 87 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:784076 CAPLUS

DN 132:22867

TI Preparation of urea and carbamate derivatives of N-heterocyclic carboxylic acids and carboxylic acid isosteres for the treatment of neurodegenerative diseases and alopecia

IN Hamilton, Gregory S.; Norman, Mark H.; Wu, Yong-Qian; Steiner, Joseph P.

PA Guilford Pharmaceuticals Inc., USA; Amgen, Inc.

SO PCT Int. Appl., 102 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9962879 | A1 | 19991209 | WO 1998-US25570 | 19981203 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | ZA 9811061 | A | 19991203 | ZA 1998-11061 | 19981203 |
| | CA 2333960 | A1 | 19991209 | CA 1998-2333960 | 19981203 |
| | AU 9916204 | A | 19991220 | AU 1999-16204 | 19981203 |
| | EP 1082301 | A1 | 20010314 | EP 1998-960656 | 19981203 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | HU 200102847 | A2 | 20011228 | HU 2001-2847 | 19981203 |
| | BR 9815881 | A | 20020723 | BR 1998-15881 | 19981203 |
| | NO 2000006111 | A | 20010201 | NO 2000-6111 | 20001201 |
| | BG 105014 | A | 20010831 | BG 2000-105014 | 20001201 |
| | US 2002007075 | A1 | 20020117 | US 2001-771686 | 20010130 |
| | US 2002042442 | A1 | 20020411 | US 2001-847432 | 20010503 |
| PRAI | US 1998-87844P | P | 19980603 | | |
| | US 1998-204235 | A3 | 19981203 | | |
| | WO 1998-US25570 | W | 19981203 | | |

OS MARPAT 132:22867

IT 251574-40-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of urea and carbamate derivs. of N-heterocyclic carboxylic acids and carboxylic acid isosteres for the treatment of neurodegenerative diseases and alopecia)

RN 251574-40-0 CAPLUS

CN 1,2-Pyrrolidinedicarboxamide, N2-hydroxy-N1-(4-methylphenyl)-N2-propyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 88 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:783930 CAPLUS
DN 132:23195
TI Preparation of neurotrophic amino acid difluoroamide agents
IN Vrudhula, Vivekananda M.; Dubowchik, Gene M.; Dasgupta, Bireshwar; Vyas, Dolatrai M.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9962511 | A1 | 19991209 | WO 1999-US11348 | 19990521 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2333997 | A1 | 19991209 | CA 1999-2333997 | 19990521 |
| | AU 9941975 | A | 19991220 | AU 1999-41975 | 19990521 |
| | AU 743199 | B2 | 20020124 | | |
| | US 6096762 | A | 20000801 | US 1999-316792 | 19990521 |
| | EP 1087763 | A1 | 20010404 | EP 1999-925749 | 19990521 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | JP 2002516857 | T | 20020611 | JP 2000-551767 | 19990521 |
| | US 6239146 | B1 | 20010529 | US 2000-590808 | 20000609 |
| PRAI | US 1998-87642P | P | 19980602 | | |
| | US 1999-316792 | A3 | 19990521 | | |
| | WO 1999-US11348 | W | 19990521 | | |
| OS | MARPAT 132:23195 | | | | |
| IT | 251909-01-0P 251909-02-1P 251909-03-2P 251909-05-4P 251909-06-5P 251909-08-7P 251909-18-9P | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of neurotrophic amino acid difluoroamide agents) | | | | |
| RN | 251909-01-0 CAPLUS | | | | |
| CN | L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-, 3-phenylpropyl ester (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.




10/712,456-ALW

RN 251909-02-1 CAPLUS

CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-,
3-(3-pyridinyl)propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251909-03-2 CAPLUS

CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-,
(1S)-1-(3-phenylpropyl)-4-(3-pyridinyl)butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251909-05-4 CAPLUS

CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-,
1,1-dimethyl-3-phenylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251909-06-5 CAPLUS

CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-, 1,3-diphenylpropyl
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 251909-08-7 CAPLUS

CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-,
3-(3,4,5-trimethoxyphenyl)propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 251909-18-9 CAPLUS

CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-,
(1R)-1-(3-phenylpropyl)-4-(3-pyridinyl)butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 251909-15-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of neurotrophic amino acid difluoroamide agents)

RN 251909-15-6 CAPLUS

CN L-Proline, 1-[difluoro(3,4,5-trimethoxyphenyl)acetyl]- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.

10/712,456-ALW



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 89 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:764020 CAPLUS

DN 132:12508

TI Preparation of novel VLA-4 inhibitor (R)-N-[[4-[[[2-methylphenylamino)carbonyl]amino]phenyl]acetyl]-L-prolyl]-3-methyl- β -alanine

IN Lee, Wen-Cherng; Gill, Alan

PA Biogen, Inc., USA

SO PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-------------------|----------|
| PI | WO 9961421 | A1 | 19991202 | WO 1999-US11924 | 19990528 |
| | W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2333656 | A1 | 19991202 | CA 1999-2333656 | 19990528 |
| | AU 9942192 | A | 19991213 | AU 1999-42192 | 19990528 |
| | AU 764108 | B2 | 20030807 | | |
| | EP 1082302 | A1 | 20010314 | EP 1999-926019 | 19990528 |
| | EP 1082302 | B1 | 20031217 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | TR 200100190 | T2 | 20010521 | TR 2001-200100190 | 19990528 |
| | HU 200102255 | A2 | 20011128 | HU 2001-2255 | 19990528 |
| | JP 2002516309 | T | 20020604 | JP 2000-550827 | 19990528 |
| | EE 200000698 | A | 20020617 | EE 2000-698 | 19990528 |
| | EE 4639 | B1 | 20060615 | | |
| | NZ 509199 | A | 20031031 | NZ 1999-509199 | 19990528 |
| | AT 256659 | T | 20040115 | AT 1999-926019 | 19990528 |
| | PT 1082302 | T | 20040430 | PT 1999-926019 | 19990528 |
| | ES 2211096 | T3 | 20040701 | ES 1999-926019 | 19990528 |
| | IL 139967 | A | 20051120 | IL 1999-139967 | 19990528 |
| | SK 285280 | B6 | 20061005 | SK 2000-1810 | 19990528 |
| | NO 2000006023 | A | 20010117 | NO 2000-6023 | 20001128 |
| | NO 317990 | B1 | 20050117 | | |
| | US 6495525 | B1 | 20021217 | US 2000-724107 | 20001128 |
| | ZA 2000007300 | A | 20020227 | ZA 2000-7300 | 20001208 |
| | BG 105060 | A | 20010831 | BG 2000-105060 | 20001218 |
| | BG 65021 | B1 | 20061229 | | |
| | HK 1035726 | A1 | 20040930 | HK 2001-106420 | 20010911 |
| PRAI | US 1998-87064P | P | 19980528 | | |
| | WO 1999-US11924 | W | 19990528 | | |
| IT | 251469-34-8P | | | | |

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of novel VLA-4 inhibitor [(((methylphenylamino)carbonyl]amino)phenyl]acetyl]prolyl]methyl- β -alanine)

RN 251469-34-8 CAPLUS

CN Butanoic acid, 3-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]-, (3R)- (9CI) (CA INDEX NAME)

10/712,456-ALW

Absolute stereochemistry.



IT 251469-33-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of novel VLA-4 inhibitor [(((methylphenylamino)carbonyl)amino)phenyl]acetyl]prolyl]methyl-β-alanine)

RN 251469-33-7 CAPLUS

CN Butanoic acid, 3-[[[(2S)-1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]-, phenylmethyl ester, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 90 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:708726 CAPLUS
DN 131:322422
TI Preparation of aminomethyl benzoic ester derivatives as tryptase
inhibitors
IN Waszkowycz, Bohdan; Lively, Sarah Elizabeth; Harrison, Martin James
PA Proteus Molecular Design Limited, UK
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|--|----------|-----------------|----------|
| PI | WO 9955661 | A1 | 19991104 | WO 1999-GB1263 | 19990423 |
| | W: | AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | AU 9936200 | A | 19991116 | AU 1999-36200 | 19990423 |
| | EP 1073624 | A1 | 20010207 | EP 1999-918168 | 19990423 |
| | R: | CH, DE, ES, FR, GB, IT, LI, SE | | | |
| PRAI | GB 1998-8813 | A | 19980424 | | |
| | GB 1998-22432 | A | 19981014 | | |
| | WO 1999-GB1263 | W | 19990423 | | |

OS MARPAT 131:322422

IT 248587-06-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of aminomethyl benzoic ester derivs. as tryptase inhibitors for treatment of asthma)

RN 248587-06-6 CAPLUS


CN L-Proline, 1-[[4-[[4-(aminomethyl)benzoyl]oxy]phenyl]acetyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 248587-05-5

CMF C21 H22 N2 O5


Absolute stereochemistry.



CM 2

10/712,456-ALW


CRN 76-05-1
CMF C2 H F3 O2



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 91 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1999:467152 CAPLUS
 DN 131:228993
 TI Synthesis and evaluation of anti-inflammatory activity of
 2-(4-isobutylphenyl)propionyl derivatives of amino acids and peptides
 AU Belagali, S. L.; Himaja, M.
 CS Department of P.G. Studies and Research in Chemistry, Mangalore
 University, Mangalagangothri, 574 199, India
 SO Indian Journal of Chemistry, Section B: Organic Chemistry Including
 Medicinal Chemistry (1999), 38B(4), 505-507
 CODEN: IJSBDB; ISSN: 0376-4699
 PB National Institute of Science Communication, CSIR
 DT Journal
 LA English
 IT 243868-53-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); BIOL (Biological
 study); PREP (Preparation)
 (preparation and evaluation of anti-inflammatory activity of
 (isobutylphenyl)propionyl derivs. of amino acids and peptides)
 RN 243868-53-3 CAPLUS
 CN L-Proline, 1-[2-[4-(2-methylpropyl)phenyl]-1-oxopropyl]-L-prolyl-L-leucyl-
 L-threonyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 92 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1999:440760 CAPLUS
 DN 131:199967
 TI Novel protocol for the solid-phase synthesis of peptidyl and
 peptidomimetic P1-argininal derivatives
 AU Siev, Daniel V.; Gaudette, John A.; Semple, J. Edward
 CS Department of Medicinal Chemistry, Corvas International, Inc., San Diego,
 CA, 92121, USA
 SO Tetrahedron Letters (1999), 40(28), 5123-5127
 CODEN: TELEAY; ISSN: 0040-4039
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 OS CASREACT 131:199967
 IT 241146-30-5DP, resin-bound 241146-32-7DP, resin-bound
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (solid-phase synthesis of peptidyl and peptidomimetic P1-argininal
 derivs.)
 RN 241146-30-5 CAPLUS
 CN Hexanoic acid, 6-[[[(3S)-3-[[[(2S,4R)-1-[(3,4-dihydroxyphenyl)acetyl]-4-
 (phenylmethoxy)-2-pyrrolidinyl]carbonyl]amino]-1-[imino[[(2-
 propenyloxy)carbonyl]amino]methyl]-2-piperidinyl]oxy]- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



RN 241146-32-7 CAPLUS
 CN Hexanoic acid, 6-[[[(3S)-3-[[[(2S,4R)-1-[(4-butoxyphenyl)acetyl]-4-
 (phenylmethoxy)-2-pyrrolidinyl]carbonyl]amino]-1-[imino[[(2-
 propenyloxy)carbonyl]amino]methyl]-2-piperidinyl]oxy]- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



IT 241145-97-1P 241145-99-3P

10/712,456-ALW

RL: SPN (Synthetic preparation); PREP (Preparation)
(solid-phase synthesis of peptidyl and peptidomimetic Pl-argininal
derivs.)

RN 241145-97-1 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[(3S)-1-(aminoiminomethyl)-2-hydroxy-3-
piperidinyl]-1-[(3,4-dihydroxyphenyl)acetyl]-4-(phenylmethoxy)-, (2S,4R)-,
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 241145-96-0

CMF C26 H33 N5 O6


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 241145-99-3 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[(3S)-1-(aminoiminomethyl)-2-hydroxy-3-
piperidinyl]-1-[(4-butoxyphenyl)acetyl]-4-(phenylmethoxy)-, (2S,4R)-,
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 241145-98-2

CMF C30 H41 N5 O5

Absolute stereochemistry.




10/712,456-ALW

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RE.CNT 43

THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 93 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:375282 CAPLUS
DN 131:44656
TI Preparation of N-(4-amidinophenyl)phenylglycineamides as factor
VIIa/tissue factor inhibitors
IN Grobke, Katrin; Ji, Yu-hua; Wallbaum, Sabine; Weber, Lutz
PA F. Hoffmann-La Roche A.-G., Switz.
SO Eur. Pat. Appl., 46 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|------------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | EP 921116 | A1 | 19990609 | EP 1998-122169 | 19981126 |
| | EP 921116 | B1 | 20030618 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | AT 243192 | T | 20030715 | AT 1998-122169 | 19981126 |
| | PT 921116 | T | 20031128 | PT 1998-122169 | 19981126 |
| | ES 2201396 | T3 | 20040316 | ES 1998-122169 | 19981126 |
| | CA 2255180 | A1 | 19990604 | CA 1998-2255180 | 19981202 |
| | NZ 333126 | A | 20000623 | NZ 1998-333126 | 19981202 |
| | US 6140353 | A | 20001031 | US 1998-204373 | 19981202 |
| | IL 127361 | A | 20020912 | IL 1998-127361 | 19981202 |
| | ZA 9811077 | A | 19990604 | ZA 1998-11077 | 19981203 |
| | NO 9805646 | A | 19990607 | NO 1998-5646 | 19981203 |
| | AU 9895210 | A | 19990624 | AU 1998-95210 | 19981203 |
| | AU 739769 | B2 | 20011018 | | |
| | MX 9810201 | A | 20000831 | MX 1998-10201 | 19981203 |
| | RU 2202539 | C2 | 20030420 | RU 1998-122314 | 19981203 |
| | CZ 295105 | B6 | 20050518 | CZ 1998-3969 | 19981203 |
| | HU 9802808 | A2 | 19990628 | HU 1998-2808 | 19981204 |
| | CN 1224714 | A | 19990804 | CN 1998-126979 | 19981204 |
| | CN 1115330 | B | 20030723 | | |
| | JP 11246507 | A | 19990914 | JP 1998-345875 | 19981204 |
| | JP 3236267 | B2 | 20011210 | | |
| | BR 9805320 | A | 20000411 | BR 1998-5320 | 19981204 |
| | HR 980614 | B1 | 20030228 | HR 1998-614 | 19981204 |
| | PL 193297 | B1 | 20070131 | PL 1998-330104 | 19981204 |
| | TW 544446 | B | 20030801 | TW 1999-88102291 | 19990212 |
| | HK 1020941 | A1 | 20031107 | HK 1999-106072 | 19991223 |
| PRAI | EP 1997-121285 | A | 19971204 | | |
| | EP 1998-121374 | A | 19981110 | | |
| OS | MARPAT 131:44656 | | | | |
| IT | 227022-04-0P | | | | |

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(4-amidinophenyl)phenylglycineamides as factor VIIa/tissue factor inhibitors)


RN 227022-04-0 CAPLUS
CN L-Proline, N-[4-(aminoiminomethyl)phenyl]-2-[3-methoxy-4-(phenylmethoxy)phenyl]glycyl-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 227022-03-9
CMF C28 H30 N4 O5

Absolute stereochemistry.


10/712,456-ALW



CM 2

CRN 64-19-7

CMF C2 H4 O2



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 94 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:354478 CAPLUS

DN 131:5529

TI Preparation of substituted β -alanine derivatives as cell adhesion inhibitors

IN Durette, Philippe L.; Hagmann, William K.; Kopka, Ihor E.; MacCoss, Malcolm; Mills, Sander G.; Mumford, Richard A.; Magriotis, Plato A.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 109 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9926921 | A1 | 19990603 | WO 1998-US24898 | 19981124 |
| | W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2309341 | A1 | 19990603 | CA 1998-2309341 | 19981124 |
| | AU 9915327 | A | 19990615 | AU 1999-15327 | 19981124 |
| | AU 751950 | B2 | 20020905 | | |
| | EP 1034164 | A1 | 20000913 | EP 1998-959547 | 19981124 |
| | EP 1034164 | B1 | 20040519 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO | | | | |
| | JP 2001524465 | T | 20011204 | JP 2000-522079 | 19981124 |
| | AT 267168 | T | 20040615 | AT 1998-959547 | 19981124 |
| | ES 2221227 | T3 | 20041216 | ES 1998-959547 | 19981124 |
| PRAI | US 1997-66484P | P | 19971124 | | |
| | GB 1997-27215 | A | 19971223 | | |
| | WO 1998-US24898 | W | 19981124 | | |
| OS | MARPAT 131:5529 | | | | |
| IT | 225515-65-1P | | | | |
| | RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (preparation of substituted β -alanine derivs. as cell adhesion inhibitors) | | | | |
| RN | 225515-65-1 CAPLUS | | | | |
| CN | β -Alanine, 1-[[4-[[[(2-chlorophenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-3-(1,3-benzodioxol-5-yl)-, (3S)- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.



10/712,456-ALW

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 95 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:343650 CAPLUS

DN 130:352548

TI Synthesis of D-proline derivatives for treatment of amyloidosis

IN Hertel, Cornelia; Hoffmann, Torsten; Jakob-Roetne, Roland; Norcross, Roger David

PA F. Hoffmann-La Roche A.-G., Switz.

SO Eur. Pat. Appl., 77 pp.

CODEN: EPXXDW

DT Patent


LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | EP 915088 | A1 | 19990512 | EP 1998-119986 | 19981022 |
| | EP 915088 | B1 | 20020918 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | AT 224366 | T | 20021015 | AT 1998-119986 | 19981022 |
| | PT 915088 | T | 20030131 | PT 1998-119986 | 19981022 |
| | ES 2182203 | T3 | 20030301 | ES 1998-119986 | 19981022 |
| | HU 9802465 | A1 | 20001228 | HU 1998-2465 | 19981026 |
| | US 6103910 | A | 20000815 | US 1998-179652 | 19981027 |
| | CA 2252163 | A1 | 19990430 | CA 1998-2252163 | 19981028 |
| | NZ 332530 | A | 20000526 | NZ 1998-332530 | 19981028 |
| | IL 126787 | A | 20031210 | IL 1998-126787 | 19981028 |
| | ZA 9809889 | A | 19990430 | ZA 1998-9889 | 19981029 |
| | AU 9889599 | A | 19990520 | AU 1998-89599 | 19981029 |
| | AU 750734 | B2 | 20020725 | | |
| | JP 11209343 | A | 19990803 | JP 1998-307719 | 19981029 |
| | JP 3048558 | B2 | 20000605 | | |
| | TW 585854 | B | 20040501 | TW 1998-87117984 | 19981029 |
| | CZ 296252 | B6 | 20060215 | CZ 1998-3463 | 19981029 |
| | NO 9805059 | A | 19990503 | NO 1998-5059 | 19981030 |
| | NO 312064 | B1 | 20020311 | | |
| | CN 1217327 | A | 19990526 | CN 1998-123674 | 19981030 |
| | BR 9804378 | A | 20000613 | BR 1998-4378 | 19981030 |
| | SG 74094 | A1 | 20000718 | SG 1998-4381 | 19981030 |
| | RU 2201937 | C2 | 20030410 | RU 1998-120057 | 19981030 |
| | HR 980572 | B1 | 20040630 | HR 1998-572 | 19981030 |
| | US 6262089 | B1 | 20010717 | US 2000-505375 | 20000216 |
| | US 6512001 | B1 | 20030128 | US 2000-636076 | 20000810 |
| | US 2003100770 | A1 | 20030529 | US 2002-186781 | 20020701 |
| | US 6740760 | B2 | 20040525 | | |
| PRAI | EP 1997-119031 | A | 19971031 | | |
| | EP 1998-113851 | A | 19980724 | | |
| | US 1998-179652 | A3 | 19981027 | | |
| | US 2000-505375 | A3 | 20000216 | | |
| | US 2000-636076 | A3 | 20000810 | | |
| OS | MARPAT 130:352548 | | | | |
| IT | 224626-74-8P 224626-82-8P 224626-85-1P | | | | |
| | 224627-09-2P 224627-32-1P | | | | |
| | RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) | | | | |
| | (synthesis of D-proline derivs. for treatment of amyloidosis) | | | | |
| RN | 224626-74-8 CAPLUS | | | | |
| CN | D-Proline, 1,1'-[(2,5-dihydroxy-1,4-phenylene)bis(1-oxo-2,1-ethanediyl)]bis-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.


10/712,456-ALW



RN 224626-82-8 CAPLUS

CN L-Proline, 1,1'-[1,4-phenylenebis(1-oxo-2,1-ethanediyl)]bis-,
bis(phenylmethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 224626-85-1 CAPLUS

CN D-Proline, 1,1'-[1,4-naphthalenediylbis(1-oxo-2,1-ethanediyl)]bis-,
bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 224627-09-2 CAPLUS

CN D-Proline, 1,1'-[1,4-phenylenebis(2-methyl-1-oxo-2,1-ethanediyl)]bis-,
bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 224627-32-1 CAPLUS

CN D-Proline, 1,1'-[1,4-phenylenebis(1-oxo-2,1-ethanediyl)]bis[4,4-difluoro-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 224624-85-5P 224625-47-2P 224625-54-1P

224625-56-3P 224625-66-5P 224625-98-3P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis of D-proline derivs. for treatment of amyloidosis)

RN 224624-85-5 CAPLUS

CN D-Proline, 1,1'-[1,4-phenylenebis(1-oxo-2,1-ethanediyl)]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 224625-47-2 CAPLUS

CN D-Proline, 1,1'-[(2,5-dihydroxy-1,4-phenylene)bis(1-oxo-2,1-ethanediyl)]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 224625-54-1 CAPLUS

CN L-Proline, 1,1'-[1,4-phenylenebis(1-oxo-2,1-ethanediyl)]bis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 224625-56-3 CAPLUS

CN D-Proline, 1,1'-[1,4-phenylenebis(1-oxo-2,1-ethanediyl)]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 224625-66-5 CAPLUS

CN D-Proline, 1,1'-[1,4-phenylenebis(2-methyl-1-oxo-2,1-ethanediyl)]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 224625-98-3 CAPLUS

CN D-Proline, 1,1'-[1,4-phenylenebis(1-oxo-2,1-ethanediyl)]bis[4,4-difluoro-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 96 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1999:141228 CAPLUS

DN 130:182769

TI Preparation of heterocyclic peptide derivatives as growth hormone secretagogues

IN Dodge, Jeffrey Alan; Hauser, Kenneth Lee; Heiman, Mark Louis; Jones, Scott Alan; Alt, Charles Arthur; Bryant, Henry Uhlman; Cohen, Jeffrey Daniel; Copp, James Densmore; Fahey, Kennan Joseph; Gritton, William Harlan; Jungheim, Louis Nickolaus; Kennedy, Joseph Henry; Lugar, Charles Willis, III; Muehl, Brian Stephen; Palkowitz, Alan David; Ratz, Andrew Michael; Rhodes, Gary Anthony; Robey, Robert Lewis; Seyler, David Edward; Shepherd, Timothy Alan; Thrasher, Kenneth Jeff; Trankle, William George

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 876 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-------------------|----------|
| PI | WO 9908699 | A1 | 19990225 | WO 1998-US17229 | 19980819 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | IN 1998CA01422 | A | 20050325 | IN 1998-CA1422 | 19980807 |
| | ZA 9807385 | A | 20000418 | ZA 1998-7385 | 19980817 |
| | EP 933365 | A2 | 19990804 | EP 1998-306622 | 19980818 |
| | EP 933365 | A3 | 20030319 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | TW 577879 | B | 20040301 | TW 1998-87113593 | 19980818 |
| | CA 2302467 | A1 | 19990225 | CA 1998-2302467 | 19980819 |
| | AU 9890256 | A | 19990308 | AU 1998-90256 | 19980819 |
| | AU 738204 | B2 | 20010913 | | |
| | BR 9811948 | A | 20000822 | BR 1998-11948 | 19980819 |
| | HU 200002392 | A2 | 20001028 | HU 2000-2392 | 19980819 |
| | TR 200000930 | T2 | 20001121 | TR 2000-200000930 | 19980819 |
| | JP 2001515046 | T | 20010918 | JP 2000-509436 | 19980819 |
| | CA 2340344 | A1 | 20000302 | CA 1999-2340344 | 19990219 |
| | WO 2000010565 | A1 | 20000302 | WO 1999-US3525 | 19990219 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 9926868 | A | 20000314 | AU 1999-26868 | 19990219 |
| | EP 1112071 | A1 | 20010704 | EP 1999-907136 | 19990219 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | JP 2002523368 | T | 20020730 | JP 2000-565886 | 19990219 |
| | HR 2000000090 | A1 | 20010430 | HR 2000-90 | 20000217 |
| | NO 2000000823 | A | 20000412 | NO 2000-823 | 20000218 |
| | MX 200001738 | A | 20001211 | MX 2000-1738 | 20000218 |

10/712,456-ALW

| | | | | | | |
|------|---|--------|----------|----|-------------|----------|
| US | 6639076 | B1 | 20031028 | US | 2001-762529 | 20010417 |
| US | 2004122234 | A1 | 20040624 | US | 2003-453833 | 20030603 |
| US | 6992097 | B2 | 20060131 | | | |
| PRAI | US 1997-56142P | P | 19970819 | | | |
| EP | 1998-306621 | A | 19980818 | | | |
| EP | 1998-306622 | A | 19980818 | | | |
| WO | 1998-US17229 | W | 19980819 | | | |
| WO | 1999-US3525 | W | 19990219 | | | |
| US | 2001-762529 | A3 | 20010417 | | | |
| OS | MARPAT 130:182769 | | | | | |
| IT | 220536-67-4P | | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | | |
| | (preparation of heterocyclic peptide derivs. as growth hormone secretagogues) | | | | | |
| RN | 220536-67-4 | CAPLUS | | | | |
| CN | D-Proline, 2-methylalanyl-O-(phenylmethyl)-D-seryl-4-amino- α -(4-methoxyphenyl)-1H-imidazole-1-acetyl-, methyl ester, dihydrochloride (9CI) | | | | | |
| | (CA INDEX NAME) | | | | | |

Absolute stereochemistry.




●2 HCl

IT 220530-00-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic peptide derivs. as growth hormone secretagogues)
RN 220530-00-7 CAPLUS
CN D-Proline, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-O-(phenylmethyl)-D-seryl-4-amino- α -(4-methoxyphenyl)-1H-imidazole-1-acetyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW




RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 97 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1999:141226 CAPLUS
 DN 130:209977
 TI Treatment of congestive heart failure with growth hormone secretagogues
 IN Kauffman, Raymond Francis; Palkowitz, Alan David
 PA Eli Lilly and Company, USA
 SO PCT Int. Appl., 775 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9908697 | A1 | 19990225 | WO 1998-US17201 | 19980819 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | ZA 9807383 | A | 20000217 | ZA 1998-7383 | 19980817 |
| | EP 898963 | A2 | 19990303 | EP 1998-306621 | 19980818 |
| | EP 898963 | A3 | 20030709 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | BR 9803168 | A | 20000111 | BR 1998-3168 | 19980818 |
| | CA 2300848 | A1 | 19990225 | CA 1998-2300848 | 19980819 |
| | AU 9894715 | A | 19990308 | AU 1998-94715 | 19980819 |
| | JP 2001515045 | T | 20010918 | JP 2000-509434 | 19980819 |
| | JP 2002523368 | T | 20020730 | JP 2000-565886 | 19990219 |
| | US 6329342 | B1 | 20011211 | US 2000-485924 | 20000218 |
| | US 2004122234 | A1 | 20040624 | US 2003-453833 | 20030603 |
| | US 6992097 | B2 | 20060131 | | |
| PRAI | US 1997-56135P | P | 19970819 | | |
| | EP 1998-306621 | A | 19980818 | | |
| | EP 1998-306622 | A | 19980818 | | |
| | WO 1998-US17201 | W | 19980819 | | |
| | WO 1999-US3525 | W | 19990219 | | |
| | US 2001-762529 | A3 | 20010417 | | |
| OS | MARPAT 130:209977 | | | | |
| IT | 220536-67-4P | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (treatment of congestive heart failure with growth hormone secretagogues) | | | | |
| RN | 220536-67-4 CAPLUS | | | | |
| CN | D-Proline, 2-methylalanyl-O-(phenylmethyl)-D-seryl-4-amino- α -(4-methoxyphenyl)-1H-imidazole-1-acetyl-, methyl ester, dihydrochloride (9CI) | | | | |
| | (CA INDEX NAME) | | | | |


Absolute stereochemistry.



●2 HCl

IT 220530-00-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (treatment of congestive heart failure with growth hormone secretagogues)
 RN 220530-00-7 CAPLUS
 CN D-Proline, N-[(1,1-dimethylethoxy)carbonyl]-2-methylalanyl-O-(phenylmethyl)-D-seryl-4-amino- α -(4-methoxyphenyl)-1H-imidazole-1-acetyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 98 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1998:799992 CAPLUS

DN 130:52724

TI Preparation of heterocyclic dipeptide derivatives as cell adhesion inhibitors

IN Durette, Philippe L.; Hagmann, William K.; Maccoss, Malcolm; Mills, Sander G.; Mumford, Richard A.; Van Riper, Gail M.; Schmidt, Jack A.; Kevin, Nancy J.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 129 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9853814 | A1 | 19981203 | WO 1998-US10940 | 19980529 |
| | W: CA, JP, US | | | | |
| | RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | US 6903075 | B1 | 20050607 | US 1998-86327 | 19980528 |
| | CA 2291778 | A1 | 19981203 | CA 1998-2291778 | 19980529 |
| | EP 1001764 | A1 | 20000524 | EP 1998-926122 | 19980529 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI | | | | |
| | JP 2002512625 | T | 20020423 | JP 1999-500934 | 19980529 |
| | WO 9964395 | A1 | 19991216 | WO 1998-US11623 | 19980611 |
| | W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | AU 9880595 | A | 19991230 | AU 1998-80595 | 19980611 |
| PRAI | US 1997-48017P | P | 19970529 | | |
| | GB 1997-14314 | A | 19970707 | | |
| | US 1997-66525P | P | 19971125 | | |
| | GB 1998-686 | A | 19980114 | | |
| | US 1997-47856P | P | 19970529 | | |
| | WO 1998-US10940 | W | 19980529 | | |
| | WO 1998-US11623 | A | 19980611 | | |
| OS | MARPAT 130:52724 | | | | |
| IT | 217452-38-5P | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (preparation of heterocyclic dipeptide derivs. as cell adhesion inhibitors) | | | | |
| RN | 217452-38-5 CAPLUS | | | | |
| CN | L-Norleucine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.




10/712,456-ALW

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 99 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:749736 CAPLUS
DN 130:110572
TI Self-Immolative Nitrogen Mustard Prodrugs for Suicide Gene Therapy
AU Niculescu-Duvaz, Dan; Niculescu-Duvaz, Ion; Friedlos, Frank; Martin, Janet; Spooner, Robert; Davies, Lawrence; Marais, Richard; Springer, Caroline J.
CS UK
SO Journal of Medicinal Chemistry (1998), 41(26), 5297-5309
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
IT 219591-73-8P
RL: BYP (Byproduct); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(preparation of self-immolative nitrogen mustard prodrugs for suicide gene therapy)
RN 219591-73-8 CAPLUS
CN L-Proline, 1-[[[4-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]phenyl]amino]carbonyl]-5-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 219591-75-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of self-immolative nitrogen mustard prodrugs for suicide gene therapy)
RN 219591-75-0 CAPLUS
CN L-Proline, 1-[[[4-(hydroxymethyl)phenyl]amino]carbonyl]-5-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 100 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1998:709057 CAPLUS
 DN 129:343718
 TI Preparation of heterocyclic derivatives as antithrombotic agents
 IN Van Boeckel, Constant Adriaan Anton; Van Galen, Philippus Johannes Marie;
 Rewinkel, Johannes Bernardus Maria
 PA Akzo Nobel N.V., Neth.
 SO PCT Int. Appl., 208 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 9847876 | A1 | 19981029 | WO 1998-EP2455 | 19980421 |
| | W: AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, TT, UA, US, UZ, VN, AZ, BY, KZ, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | TW 228123 | B | 20050221 | TW 1998-87105306 | 19980408 |
| | ZA 9803176 | A | 19981021 | ZA 1998-3176 | 19980415 |
| | IN 1998MA00835 | A | 20050304 | IN 1998-MA835 | 19980420 |
| | CA 2287558 | A1 | 19981029 | CA 1998-2287558 | 19980421 |
| | AU 9876486 | A | 19981113 | AU 1998-76486 | 19980421 |
| | EP 975600 | A1 | 20000202 | EP 1998-924206 | 19980421 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | JP 2001523240 | T | 20011120 | JP 1998-545041 | 19980421 |
| | EP 1505062 | A1 | 20050209 | EP 2004-105699 | 19980421 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY | | | | |
| | US 6194409 | B1 | 20010227 | US 1999-403327 | 19991019 |
| | US 6444672 | B1 | 20020903 | US 2000-550954 | 20000417 |
| | US 6432955 | B1 | 20020813 | US 2000-679232 | 20001004 |
| | US 2003130270 | A1 | 20030710 | US 2002-178441 | 20020620 |
| | US 6797710 | B2 | 20040928 | | |
| PRAI | EP 1997-201227 | A | 19970424 | | |
| | EP 1998-924206 | A3 | 19980421 | | |
| | WO 1998-EP2455 | W | 19980421 | | |
| | US 1999-403327 | A3 | 19991019 | | |
| | US 2000-679232 | A3 | 20001004 | | |
| OS | MARPAT 129:343718 | | | | |
| IT | 215450-75-2P 215450-76-3P 215450-77-4P 215450-83-2P 215450-93-4P | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of heterocyclic derivs. as antithrombotic agents) | | | | |
| RN | 215450-75-2 CAPLUS | | | | |
| CN | L-Prolinamide, N-acetyl-2-[4-(methoxycarbonyl)phenyl]glycyl-N-[(1-amino-6-isoquinolinyl)methyl]- (9CI) (CA INDEX NAME) | | | | |


Absolute stereochemistry.



RN 215450-76-3 CAPLUS

CN L-Prolinamide, N-acetyl-2-(4-cyanophenyl)glycyl-N-[(1-amino-6-isoquinolinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 215450-77-4 CAPLUS

CN L-Prolinamide, N-acetyl-2-[4-(trifluoromethyl)phenyl]glycyl-N-[(1-amino-6-isoquinolinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 215450-83-2 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(acetyloxy)[4-(trifluoromethyl)phenyl]acetyl]-N-[(1-amino-6-isoquinolinyl)methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 215450-93-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(acetyloxy)(4-methoxyphenyl)acetyl]-N-[(1-amino-6-isoquinoliny)methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW


L4 ANSWER 101 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:572297 CAPLUS
DN 129:203270
TI Preparation of prolinamide derivatives as thrombin inhibitors
IN Lumma, William C.; Tucker, Thomas J.; Witherup, Keith M.; Brady, Stephen F.; Whitter, Willie L.; Vacca, Joseph P.; Coburn, Craig; Shafer, Jules A.
PA Merck and Co., Inc., USA
SO U.S., 24 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------|------|----------|-----------------|----------|
| PI | US 5798377 | A | 19980825 | US 1996-734148 | 19961021 |
| PRAI | US 1996-734148 | | 19961021 | | |
| OS | MARPAT 129:203270 | | | | |
| IT | 190509-75-2P | | | | |

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of prolinamide derivs. as thrombin inhibitors)

RN 190509-75-2 CAPLUS
CN L-Prolinamide, (2R)-2-(4-hydroxy-3-methoxyphenyl)glycyl-N-[(2,5-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 102 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1998:505485 CAPLUS

DN 129:230962

TI 2-Nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-naphthyl)alanyl-N-benzyl-N-methylamide (SDZ NKT 343), a Potent Human NK1 Tachykinin Receptor Antagonist with Good Oral Analgesic Activity in Chronic Pain Models

AU Walpole, C.; Ko, S. Y.; Brown, M.; Beattie, D.; Campbell, E.; Dickenson, F.; Ewan, S.; Hughes, G. A.; Lemaire, M.; Lerpiniere, J.; Patel, S.; Urban, L.

CS Novartis Institute for Medical Sciences, London, WC1E 6BN, UK

SO Journal of Medicinal Chemistry (1998), 41(17), 3159-3173

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

IT 180047-07-8P 212700-34-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

.(preparation of potent human NK1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models)

RN 180047-07-8 CAPLUS

CN L-Alaninamide, 1-[[[4-nitrophenyl]amino]carbonyl]-L-prolyl-N-methyl-3-(2-naphthalenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 212700-34-0 CAPLUS

CN L-Alaninamide, 1-[[[4-cyanophenyl]amino]carbonyl]-L-prolyl-N-methyl-3-(2-naphthalenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 103 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:157415 CAPLUS
DN 128:205136
TI Preparation of acylated amino acid derivatives for multi-drug resistance
therapies and immune suppression.
IN Armistead, David M.; Harding, Matthew W.; Saunders, Jeffrey O.; Boger,
Joshua S.
PA Vertex Pharmaceuticals Inc., USA
SO U.S., 34 pp., Cont.-in-part of U.S. 5,620,971.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | US 5723459 | A | 19980303 | US 1995-377315 | 19950124 |
| | US 5620971 | A | 19970415 | US 1994-217982 | 19940325 |
| PRAI | US 1991-697785 | B2 | 19910509 | | |
| | US 1992-881152 | B2 | 19920511 | | |
| | US 1992-952299 | B2 | 19920928 | | |
| | US 1993-127814 | B2 | 19930928 | | |
| | US 1994-217982 | A2 | 19940325 | | |

OS MARPAT 128:205136


IT 145913-35-5P 159997-77-0P 159997-78-1P
159997-95-2P 160072-11-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylated amino acid esters for multi-drug resistance
therapies and immune suppression.)

RN 145913-35-5 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 1-(3-phenylpropyl)-4-(2-
pyridinyl)butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159997-77-0 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, (1S)-1-[3,4,5-tris(4-
pyridinylmethoxy)phenyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 159997-78-1 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, (1R)-1-[3,4,5-tris(4-pyridinylmethoxy)phenyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159997-95-2 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 4-(3-pyridinyl)-1-[3-(3-pyridinyl)propyl]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160072-11-7 CAPLUS


CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 2-(phenylmethoxy)-1-[(phenylmethoxy)phenyl]ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



D1-O-CH₂-Ph

PAGE 2-A



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 104 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1998:106085 CAPLUS

DN 128:176149

TI Molecular model for VLA-4 inhibitors, and inhibitor identification

IN Singh, Juswinder; Zheng, Zhongli; Sprague, Peter; Van Vlijmen, Herman W. T.; Castro, Alfredo C.; Adams, Steven P.

PA Biogen, Inc., USA

SO PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|--------------------|----------|
| PI | WO 9804913 | A1 | 19980205 | WO 1997-US13008 | 19970724 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW | | | | |
| | RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2261974 | A1 | 19980205 | CA 1997-2261974 | 19970724 |
| | AU 9737385 | A | 19980220 | AU 1997-37385 | 19970724 |
| | CN 1230110 | A | 19990929 | CN 1997-197953 | 19970724 |
| | HU 9903142 | A2 | 20000128 | HU 1999-3142 | 19970724 |
| | HU 9903142 | A3 | 20000628 | | |
| | CN 1478472 | A | 20040303 | CN 2003-2003146679 | 19970724 |
| | SG 124234 | A1 | 20060830 | SG 2001-200100382 | 19970724 |
| | AT 339196 | T | 20061015 | AT 1997-934289 | 19970724 |
| | KR 2000029538 | A | 20000525 | KR 1999-700595 | 19990125 |
| | US 6552216 | B1 | 20030422 | US 1999-236784 | 19990125 |
| | BG 64470 | B1 | 20050430 | BG 1999-103193 | 19990222 |
| | BG 108806 | A | 20050430 | BG 1999-108806 | 19990222 |
| | BG 64902 | B1 | 20060831 | | |
| | AU 759063 | B2 | 20030403 | AU 2001-91330 | 20011114 |
| PRAI | US 1996-22890P | P | 19960725 | | |
| | US 1996-32786P | P | 19961206 | | |
| | US 1997-57002P | P | 19970630 | | |
| | AU 1997-37386 | A3 | 19970724 | | |
| | WO 1997-US13008 | W | 19970724 | | |
| OS | MARPAT 128:176149 | | | | |
| IT | 203181-31-1 | | | | |
| | RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (mol. model for VLA-4 inhibitors, and inhibitor identification) | | | | |
| RN | 203181-31-1 CAPLUS | | | | |
| CN | Butanoic acid, 3-[[[1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-pyrrolidinyl]carbonyl]amino]-, [R-(R*,R*)]]- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.

10/712,456-ALW



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 105 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1998:45153 CAPLUS

DN 128:97538

TI Discovery and Development of the Novel Potent Orally Active Thrombin Inhibitor N-(9-Hydroxy-9-fluorene-carboxy)prolyl trans-4-Aminocyclohexylmethyl Amide (L-372,460): Coapplication of Structure-Based Design and Rapid Multiple Analog Synthesis on Solid Support

AU Brady, Stephen F.; Stauffer, Kenneth J.; Lumma, William C.; Smith, Graham M.; Ramjit, Harri G.; Lewis, S. Dale; Lucas, Bobby J.; Gardell, Steven J.; Lyle, Elizabeth A.; Appleby, Sandra D.; Cook, Jacquelyn J.; Holahan, Marie A.; Stranieri, Maria T.; Lynch, Joseph J., Jr.; Lin, Jiunn H.; Chen, I.-Wu; Vastag, Kari; Naylor-Olsen, Adel M.; Vacca, Joseph P.

CS Departments of Medicinal Chemistry Biological Chemistry Pharmacology Drug Metabolism and Molecular Design and Diversity, Merck Research Laboratories, West Point, PA, 19486, USA

SO Journal of Medicinal Chemistry (1998), 41(3), 401-406
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

IT 201211-44-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(isolation of the potent orally active thrombin inhibitor N-(9-Hydroxy-9-fluorene-carboxy)prolyl trans-4-Aminocyclohexylmethyl Amide (L-372,460) and coapplication of structure-based design and rapid multiple analog synthesis)

RN 201211-44-1 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(4-aminocyclohexyl)methyl]-1-[(3,4,5-trimethoxyphenyl)acetyl]-, [1(S)-trans]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 106 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1998:1496 CAPLUS

DN 128:75673

TI Preparation of amino acid derivatives and their use as thrombin inhibitors

IN Gustafsson, David; Nystrom, Jan-erik

PA Astra Aktiebolag, Swed.

SO PCT Int. Appl., 136 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9746577 | A1 | 19971211 | WO 1997-SE989 | 19970605 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU | | | | |
| | RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | IN 1996DE01427 | A | 20050311 | IN 1996-DE1427 | 19960627 |
| | ZA 9704542 | A | 19971208 | ZA 1997-4542 | 19970523 |
| | IN 1997DE01389 | A | 20050311 | IN 1997-DE1389 | 19970526 |
| | CA 2255625 | A1 | 19971211 | CA 1997-2255625 | 19970605 |
| | AU 9731140 | A | 19980105 | AU 1997-31140 | 19970605 |
| | AU 723420 | B2 | 20000824 | | |
| | EP 910573 | A1 | 19990428 | EP 1997-926356 | 19970605 |
| | EP 910573 | B1 | 20030129 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | BR 9709560 | A | 19990810 | BR 1997-9560 | 19970605 |
| | CN 1226895 | A | 19990825 | CN 1997-196864 | 19970605 |
| | CN 1129604 | B | 20031203 | | |
| | NZ 332964 | A | 20000825 | NZ 1997-332964 | 19970605 |
| | JP 2000512631 | T | 20000926 | JP 1998-500502 | 19970605 |
| | HU 200002404 | A2 | 20001028 | HU 2000-2404 | 19970605 |
| | HU 200002404 | A3 | 20010228 | | |
| | AT 231883 | T | 20030215 | AT 1997-926356 | 19970605 |
| | ES 2191840 | T3 | 20030916 | ES 1997-926356 | 19970605 |
| | US 6255301 | B1 | 20010703 | US 1997-860871 | 19970714 |
| | NO 9805700 | A | 19990205 | NO 1998-5700 | 19981204 |
| | NO 317135 | B1 | 20040823 | | |
| | KR 2000016401 | A | 20000325 | KR 1998-709975 | 19981205 |
| | US 2002019371 | A1 | 20020214 | US 2001-844427 | 20010430 |
| | US 6838478 | B2 | 20050104 | | |
| PRAI | SE 1996-2263 | A | 19960607 | | |
| | WO 1997-SE989 | W | 19970605 | | |
| | US 1997-860871 | A1 | 19970714 | | |
| OS | MARPAT 128:75673 | | | | |
| IT | 200213-43-0P 200213-92-9P 200213-93-0P | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (preparation of amino acid derivs. as thrombin inhibitors) | | | | |
| RN | 200213-43-0 CAPLUS | | | | |
| CN | 2-Pyrrolidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[3-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-1-oxopropyl]-, monohydrochloride, (2S)- (9CI) (CA INDEX NAME) | | | | |

10/712,456-ALW

Absolute stereochemistry.




● HCl

RN 200213-92-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[3-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-1-oxopropyl]-, [S-(R*,S*)]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 200213-93-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[3-hydroxy-2-(4-hydroxy-3-methoxyphenyl)-1-oxopropyl]-, [S-(R*,R*)]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



IT 200215-27-6P 200215-28-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of amino acid derivs. as thrombin inhibitors)

RN 200215-27-6 CAPLUS

CN Carbamic acid, [[4-[[[1-[3-hydroxy-2-[3-methoxy-4-(phenylmethoxy)phenyl]-1-oxopropyl]-2-pyrrolidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, phenylmethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200215-28-7 CAPLUS

CN Carbamic acid, [[4-[[[1-[3-hydroxy-2-[3-methoxy-4-(phenylmethoxy)phenyl]-1-oxopropyl]-2-pyrrolidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, phenylmethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



L4 ANSWER 107 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:735919 CAPLUS

DN 127:346664

TI Preparation of di-and tripeptide L-dopa mimetics as compounds for treatment of Parkinson's disease

IN Wang, Hui-po; Lee, Jia-shuai; Tsai, Ming-cheng; Lu, Hsiao-hwa; Hu, Oliver Yoa-pu; Luo, Wen-lin

PA Department of Health, the Executive Yuan, Republic of China, Taiwan

SO U.S., 12 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------|------|----------|-----------------|----------|
| PI | US 5686423 | A | 19971111 | US 1996-602361 | 19960216 |
| PRAI | US 1996-602361 | | 19960216 | | |
| OS | MARPAT 127:346664 | | | | |
| IT | 171860-38-1P | | | | |


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of di-and tripeptide L-dopa mimetics as compds. for treatment of Parkinson's disease)

RN 171860-38-1 CAPLUS

CN L-Tyrosine, (2R)-2-(4-hydroxyphenyl)glycyl-L-prolyl-3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 146622-05-1P 164353-71-3P 171860-39-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of di-and tripeptide L-dopa mimetics as compds. for treatment of Parkinson's disease)

RN 146622-05-1 CAPLUS

CN L-Proline, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 164353-71-3 CAPLUS

CN L-Proline, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 171860-39-2 CAPLUS

CN L-Tyrosine, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl-L-prolyl-3-hydroxy-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 108 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:594714 CAPLUS

DN 127:247960

TI Synthetic derivatives of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains

IN Holt, Dennis A.; Keenan, Terence P.; Guo, Tao; Laborde, Edgardo; Wu, Yang

PA Ariad Gene Therapeutics, Inc., USA

SO PCT Int. Appl., 116 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9731898 | A1 | 19970904 | WO 1997-US3137 | 19970228 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU | | | | |
| | RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2244363 | A1 | 19970904 | CA 1997-2244363 | 19970228 |
| | CA 2244363 | C | 20061114 | | |
| | AU 9719809 | A | 19970916 | AU 1997-19809 | 19970228 |
| | AU 731826 | B2 | 20010405 | | |
| | EP 888303 | A1 | 19990107 | EP 1997-907937 | 19970228 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | JP 2000505475 | T | 20000509 | JP 1997-531139 | 19970228 |
| | US 6133456 | A | 20001017 | US 1997-808276 | 19970228 |
| | US 6150527 | A | 20001121 | US 1997-808274 | 19970228 |
| | US 2002161240 | A1 | 20021031 | US 2002-86506 | 20020228 |
| | US 2003036654 | A1 | 20030220 | US 2002-86770 | 20020228 |
| | US 2004006233 | A1 | 20040108 | US 2003-461705 | 20030613 |
| PRAI | US 1996-12432P | P | 19960228 | | |
| | US 1996-24861P | P | 19960828 | | |
| | US 1996-33035P | P | 19961210 | | |
| | US 1994-292598 | B2 | 19940818 | | |
| | US 1995-479694 | A2 | 19950607 | | |
| | US 1995-793016 | B2 | 19950818 | | |
| | US 1997-808274 | A1 | 19970228 | | |
| | US 1997-808276 | A1 | 19970228 | | |
| | WO 1997-US3137 | W | 19970228 | | |
| | US 1997-793016 | B1 | 19971201 | | |
| | US 2000-690581 | B1 | 20001017 | | |
| | US 2000-690797 | B1 | 20001017 | | |
| | US 2002-86770 | A1 | 20020228 | | |
| OS | MARPAT 127:247960 | | | | |
| IT | 195514-55-7P, AP 1972 | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (synthetic derivs. of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains) | | | | |
| RN | 195514-55-7 CAPLUS | | | | |
| CN | L-Proline, 1-[(2S)-1-oxo-2-(3,4,5-trimethoxyphenyl)butyl]-, (1R)-1-[3-(carboxymethoxy)phenyl]-3-(3,4-dimethoxyphenyl)propyl ester (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.


10/712,456-ALW



10/712,456-ALW

L4 ANSWER 109 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1997:564959 CAPLUS
DN 127:156266
TI Molecular Modeling and 3D-QSAR Studies on the Interaction Mechanism of
Tripeptidyl Thrombin Inhibitors with Human α -Thrombin
AU Jiang, Hualiang; Chen, Kaixian; Tang, Yun; Chen, Jianzhong; Li, Quan;
Wang, Qinmi; Ji, Ruyun
CS Shanghai Institute of Materia Medica, Chinese Academy of Sciences,
Shanghai, 200031, Peop. Rep. China
SO Journal of Medicinal Chemistry (1997), 40(19), 3085-3090
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
IT 141972-92-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); PRP (Properties); BIOL (Biological study)
(tripeptidyl thrombin inhibitors interaction with human
 α -thrombin)
RN 141972-92-1 CAPLUS
CN L-Prolinamide, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-
hydroxyphenyl)glycyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-formylbutyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/712,456-ALW

L4 ANSWER 110 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:400089 CAPLUS

DN 127:13457

TI Peptide derivative thrombin inhibitors, preparation and activity thereof,
and pharmaceutical compositions

IN Lumma, William C.; Tucker, Thomas J.; Witherup, Keith M.; Brady, Stephen
F.; Whitter, Willie L.; Vacca, Joseph P.; Coburn, Craig; Shafer, Jules A.

PA Merck and Co., Inc., USA

SO PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | WO 9715190 | A1 | 19970501 | WO 1996-US16865 | 19961021 |
| | W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2233860 | A1 | 19970501 | CA 1996-2233860 | 19961021 |
| | AU 9674634 | A | 19970515 | AU 1996-74634 | 19961021 |
| | AU 709088 | B2 | 19990819 | | |
| | EP 858262 | A1 | 19980819 | EP 1996-936804 | 19961021 |
| | EP 858262 | B1 | 20021204 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI | | | | |
| | JP 11514378 | T | 19991207 | JP 1996-516702 | 19961021 |
| | AT 228760 | T | 20021215 | AT 1996-936804 | 19961021 |
| | ES 2186807 | T3 | 20030516 | ES 1996-936804 | 19961021 |
| PRAI | US 1995-6076P | P | 19951024 | | |
| | GB 1996-5163 | A | 19960312 | | |
| | US 1996-23164P | P | 19960805 | | |
| | WO 1996-US16865 | W | 19961021 | | |

OS MARPAT 127:13457

IT 190509-75-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)


(peptide derivative thrombin inhibitors, preparation and activity thereof,
and pharmaceutical compns.)

RN 190509-75-2 CAPLUS

CN L-Prolinamide, (2R)-2-(4-hydroxy-3-methoxyphenyl)glycyl-N-[(2,5-
dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



10/712,456-ALW

L4 ANSWER 111 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1997:307496 CAPLUS
DN 126:272378
TI Methods and compositions for stimulating neurite growth using compounds
with affinity for FKBP12 in combination with neurotrophic factors
IN Armistead, David M.
PA Vertex Pharmaceuticals Incorporated, USA
SO S. African, 54 pp.
CODEN: SFXAB
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | ZA 9604852 | A | 19960729 | ZA 1996-4852 | 19960607 |
| | US 6037370 | A | 20000314 | US 1995-486004 | 19950608 |
| | CA 2222430 | A1 | 19961227 | CA 1996-2222430 | 19960606 |
| | WO 9641609 | A2 | 19961227 | WO 1996-US10123 | 19960606 |
| | W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN | | | | |
| | AU 9661119 | A | 19970109 | AU 1996-61119 | 19960606 |
| | EP 831812 | A2 | 19980401 | EP 1996-918469 | 19960606 |
| | EP 831812 | B1 | 20051207 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | CN 1202104 | A | 19981216 | CN 1996-195690 | 19960606 |
| | BR 9609333 | A | 19991013 | BR 1996-9333 | 19960606 |
| | NZ 310339 | A | 20000327 | NZ 1996-310339 | 19960606 |
| | NZ 501709 | A | 20001027 | NZ 1996-501709 | 19960606 |
| | JP 2002502355 | T | 20020122 | JP 1997-503275 | 19960606 |
| | IL 122346 | A | 20020523 | IL 1996-122346 | 19960606 |
| | IL 136118 | A | 20021201 | IL 1996-136118 | 19960606 |
| | RU 2197240 | C2 | 20030127 | RU 1998-100456 | 19960606 |
| | PL 185798 | B1 | 20030731 | PL 1996-328723 | 19960606 |
| | AT 311875 | T | 20051215 | AT 1996-918469 | 19960606 |
| | EP 1666037 | A2 | 20060607 | EP 2005-26521 | 19960606 |
| | EP 1666037 | A3 | 20060621 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | ES 2255077 | T3 | 20060616 | ES 1996-918469 | 19960606 |
| | US 6124328 | A | 20000926 | US 1997-795956 | 19970228 |
| | AU 2000043801 | A | 20000907 | AU 2000-43801 | 20000703 |
| | AU 757406 | B2 | 20030220 | | |
| | US 6326387 | B1 | 20011204 | US 2000-616539 | 20000714 |
| PRAI | US 1995-486004 | A | 19950608 | | |
| | AU 1996-61119 | A3 | 19960606 | | |
| | EP 1996-918469 | A3 | 19960606 | | |
| | IL 1996-122346 | A3 | 19960606 | | |
| | NZ 1996-310339 | A1 | 19960606 | | |
| | WO 1996-US10123 | W | 19960606 | | |
| | US 1997-795956 | A3 | 19970228 | | |

OS MARPAT 126:272378

IT 145913-35-5 159997-77-0 159997-78-1
159997-95-2 188615-72-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


10/712,456-ALW

(comps. with affinity for FKBP12 in combination with neurotrophic factors for stimulating neurite growth)

RN 145913-35-5 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 1-(3-phenylpropyl)-4-(2-pyridinyl)butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159997-77-0 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, (1S)-1-[3,4,5-tris(4-pyridinylmethoxy)phenyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159997-78-1 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, (1R)-1-[3,4,5-tris(4-pyridinylmethoxy)phenyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 159997-95-2 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 4-(3-pyridinyl)-1-[3-(3-pyridinyl)propyl]butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188615-72-7 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 2-(phenylmethoxy)-1-[(phenylmethoxy)methyl]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 112 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:276774 CAPLUS

DN 126:343875

TI Preparation of acylated amino acid derivatives for multi-drug resistance therapies and immune suppression.

IN Armistead, David M.; Saunders, Jeffrey O.; Boger, Joshua S.

PA Vertex Pharmaceuticals Incorporated, USA

SO U.S., 35 pp., Cont.-in-part of U.S. Ser. No. 881,152, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 4

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | US 5620971 | A | 19970415 | US 1994-217982 | 19940325 |
| | US 5723459 | A | 19980303 | US 1995-377315 | 19950124 |
| PRAI | US 1991-697785 | B2 | 19910509 | | |
| | US 1992-881152 | B2 | 19920511 | | |
| | US 1992-952299 | B2 | 19920928 | | |
| | US 1993-127814 | B2 | 19930928 | | |
| | US 1994-217982 | A2 | 19940325 | | |

OS MARPAT 126:343875

IT 145913-35-5P 159997-77-0P 159997-78-1P


159997-95-2P 160072-11-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylated amino acid esters for multi-drug resistance therapies and immune suppression.)

RN 145913-35-5 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 1-(3-phenylpropyl)-4-(2-pyridinyl)butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159997-77-0 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, (1S)-1-[3,4,5-tris(4-pyridinylmethoxy)phenyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159997-78-1 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, (1R)-1-[3,4,5-tris(4-pyridinylmethoxy)phenyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159997-95-2 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 4-(3-pyridinyl)-1-[3-(3-pyridinyl)propyl]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160072-11-7 CAPLUS


CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 2-(phenylmethoxy)-1-[(phenylmethoxy)phenyl]ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



D1-O-CH₂-Ph

PAGE 2-A



10/712,456-ALW

L4 ANSWER 113 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:207658 CAPLUS

DN 126:199840

TI Preparation of peptide derivatives as cell adhesion inhibitors

IN Lin, Ko-Chung; Adams, Steven P.; Castro, Alfredo C.; Zimmerman, Craig N.; Cuervo, Julio Hernan; Lee, Wen-Cherng; Hammond, Charles E.; Carter, Mary Beth; Almquist, Ronald G.; Ensinger, Carol Lee

PA Biogen, Inc., USA; Lin, Ko-Chung; Adams, Steven, P.; Castro, Alfredo, C.; Zimmerman, Craig, N.; Cuervo, Julio, Hernan; Lee, Wen-Cherng; Hammond, Charles, E.; Carter, Mary, Beth; et al.

SO PCT Int. Appl., 117 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|--------------|--------------|------------------|----------|
| PI | WO 9703094 | A1 | 19970130 | WO 1996-US11570 | 19960711 |
| | W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA | | | | |
| | US 6248713 | B1 | 20010619 | US 1995-498237 | 19950711 |
| | CA 2226868 | A1 | 19970130 | CA 1996-2226868 | 19960711 |
| | AU 9664894 | A | 19970210 | AU 1996-64894 | 19960711 |
| | AU 716276 | B2 | 20000224 | | |
| | EP 842196 | A1 | 19980520 | EP 1996-924444 | 19960711 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI | | | | |
| | CN 1193325 | A | 19980916 | CN 1996-196380 | 19960711 |
| | HU 9802202 | A2 | 19990128 | HU 1998-2202 | 19960711 |
| | BR 9609782 | A | 19990309 | BR 1996-9782 | 19960711 |
| | JP 11511124 | T | 19990928 | JP 1996-505989 | 19960711 |
| | NZ 312950 | A | 20000128 | NZ 1996-312950 | 19960711 |
| | EE 3694 | B1 | 20020415 | EE 1997-362 | 19960711 |
| | EE 200200384 | A | 20021015 | EE 2002-384 | 19960711 |
| | PL 188446 | B1 | 20050228 | PL 1996-324491 | 19960711 |
| | IL 122783 | A | 20050831 | IL 1996-122783 | 19960711 |
| | RO 121032 | B1 | 20061130 | RO 1998-33 | 19960711 |
| | TW 570927 | B | 20040111 | TW 1996-85108493 | 19960712 |
| | FI 9800033 | A | 19980305 | FI 1998-33 | 19980109 |
| | NO 9800097 | A | 19980311 | NO 1998-97 | 19980109 |
| | BG 63876 | B1 | 20030430 | BG 1998-102241 | 19980210 |
| | US 6239108 | B1 | 20010529 | US 1998-983391 | 19980810 |
| | US 6596687 | B1 | 20030722 | US 2000-482296 | 20000113 |
| | AU 758886 | B2 | 20030403 | AU 2000-36445 | 20000525 |
| | US 6875743 | B1 | 20050405 | US 2000-724139 | 20001128 |
| PRAI | US 1995-498237 | A | 19950711 | | |
| | AU 1996-64894 | A3 | 19960711 | | |
| | WO 1996-US11570 | W | 19960711 | | |
| | US 1998-983391 | A1 | 19980810 | | |
| OS | MARPAT 126:199840 | | | | |
| IT | 187736-26-1P | 187736-27-2P | 187736-28-3P | | |
| | 187736-29-4P | 187736-30-7P | 187736-31-8P | | |
| | 187736-32-9P | 187736-33-0P | 187736-34-1P | | |
| | 187736-35-2P | 187736-36-3P | 187736-97-6P | | |
| | 187736-98-7P | 187737-36-6P | 187738-01-8P | | |
| | 187738-02-9P | 187738-03-0P | 187738-05-2P | | |
| | 187738-06-3P | 187738-07-4P | 187738-08-5P | | |


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptide derivs. as cell adhesion inhibitors)

RN 187736-26-1 CAPLUS

CN L- α -Asparagine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187736-27-2 CAPLUS

CN L-Leucinamide, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187736-28-3 CAPLUS

CN L-Valinamide, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187736-29-4 CAPLUS

CN L-Isoleucinamide, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187736-30-7 CAPLUS

CN L- α -Glutamine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187736-31-8 CAPLUS

CN L-Threoninamide, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 187736-32-9 CAPLUS

CN L-Methioninamide, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 187736-33-0 CAPLUS

CN D-Aspartamide, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187736-34-1 CAPLUS

CN D- α -Glutamine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 187736-35-2 CAPLUS


CN L-Tryptophanamide, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 187736-36-3 CAPLUS

CN D-Serinamide, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187736-97-6 CAPLUS

CN L- α -Asparagine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -glutamyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187736-98-7 CAPLUS

CN L-Valinamide, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -glutamyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187737-36-6 CAPLUS

CN L-Aspartic acid, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 187738-01-8 CAPLUS

CN L-Isoleucinamide, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 187738-02-9 CAPLUS

CN L-Isoleucine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl-, 3-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187738-03-0 CAPLUS

CN L-Isoleucine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 187738-05-2 CAPLUS

CN L- α -Glutamine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 187738-06-3 CAPLUS

CN L-Isoleucinamide, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -glutamyl-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187738-07-4 CAPLUS

CN L-Isoleucine, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl-L- α -glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 187738-08-5 CAPLUS

CN L-Glutamic acid, 1-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



L4 ANSWER 114 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1997:205101 CAPLUS
 DN 126:199834
 TI Preparation of amino acid derivatives as thrombin inhibitors
 IN Gustafsson, David; Nystroem, Jan-Erik
 PA Astra Aktiebolag, Swed.; Gustafsson, David; Nystroem, Jan-Erik
 SO PCT Int. Appl., 105 pp.
 CODEN: PIXXD2


DT Patent
 LA English
 FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | WO 9702284 | A1 | 19970123 | WO 1996-SE878 | 19960702 |
| | W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA | | | | |
| | ZA 9605344 | A | 19970106 | ZA 1996-5344 | 19960624 |
| | TW 585853 | B | 20040501 | TW 1996-85107577 | 19960624 |
| | CA 2226256 | A1 | 19970123 | CA 1996-2226256 | 19960702 |
| | AU 9663253 | A | 19970205 | AU 1996-63253 | 19960702 |
| | AU 709710 | B2 | 19990902 | | |
| | EP 836615 | A1 | 19980422 | EP 1996-922355 | 19960702 |
| | EP 836615 | B1 | 20030423 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI | | | | |
| | CN 1195354 | A | 19981007 | CN 1996-196781 | 19960702 |
| | HU 9802315 | A2 | 19990128 | HU 1998-2315 | 19960702 |
| | BR 9609447 | A | 19990302 | BR 1996-9447 | 19960702 |
| | JP 11508591 | T | 19990727 | JP 1996-505071 | 19960702 |
| | NZ 311854 | A | 20000623 | NZ 1996-311854 | 19960702 |
| | RU 2176645 | C2 | 20011210 | RU 1998-102188 | 19960702 |
| | AT 238342 | T | 20030515 | AT 1996-922355 | 19960702 |
| | PL 185606 | B1 | 20030630 | PL 1996-324483 | 19960702 |
| | PT 836615 | T | 20030930 | PT 1996-922355 | 19960702 |
| | ES 2197240 | T3 | 20040101 | ES 1996-922355 | 19960702 |
| | EE 4500 | B1 | 20050615 | EE 1997-354 | 19960702 |
| | NZ 509474 | A | 20050826 | NZ 1996-509474 | 19960702 |
| | SK 284695 | B6 | 20050908 | SK 1997-1804 | 19960702 |
| | RU 2262508 | C2 | 20051020 | RU 2000-128495 | 19960702 |
| | US 6051568 | A | 20000418 | US 1996-687466 | 19960807 |
| | NO 9800015 | A | 19980225 | NO 1998-15 | 19980102 |
| | HK 1008995 | A1 | 20030905 | HK 1998-109754 | 19980807 |
| | US 6337343 | B1 | 20020108 | US 2000-537344 | 20000329 |
| | US 2002042396 | A1 | 20020411 | US 2001-995564 | 20011129 |
| | US 6617320 | B2 | 20030909 | | |
| | US 2004087647 | A1 | 20040506 | US 2003-606349 | 20030626 |
| | US 6921758 | B2 | 20050726 | | |
| PRAI | SE 1995-2487 | A | 19950706 | | |
| | SE 1995-2504 | A | 19950707 | | |
| | SE 1995-2505 | A | 19950707 | | |
| | SE 1995-3923 | A | 19951107 | | |
| | SE 1995-4349 | A | 19951205 | | |
| | GB 1995-26411 | A | 19951222 | | |
| | RU 1998-102188 | A | 19960702 | | |
| | WO 1996-SE878 | W | 19960702 | | |
| | US 1996-687466 | A3 | 19960807 | | |
| | US 2000-537344 | A1 | 20000329 | | |

10/712,456-ALW

US 2001-995564 A1 20011129
OS MARPAT 126:199834
IT 187751-57-1P 187751-58-2P 187751-93-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid derivs. as thrombin inhibitors)
RN 187751-57-1 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[hydroxy(4-hydroxy-3-methoxyphenyl)acetyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 187751-58-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[hydroxy(4-hydroxy-3-methoxyphenyl)acetyl]-, (2S)-, monoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 187751-57-1
CMF C22 H26 N4 O5


Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2


10/712,456-ALW



RN 187751-93-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[[4-(aminoiminomethyl)phenyl]methyl]-1-[(3-chloro-4-hydroxyphenyl)hydroxyacetyl]-, monohydrochloride, (2S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



● HCl


IT 187752-83-6P 187753-36-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of amino acid derivs. as thrombin inhibitors)

RN 187752-83-6 CAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[hydroxy(4-hydroxy-3-methoxyphenyl)acetyl]-2-pyrrolidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 187753-36-2 CAPLUS

CN Carbamic acid, [[4-[[[(2S)-1-[(3-chloro-4-hydroxyphenyl)hydroxyacetyl]-2-pyrrolidinyl]carbonyl]amino]methyl]phenyl]iminomethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

10/712,456-ALW

Absolute stereochemistry.



L4 ANSWER 115 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:151521 CAPLUS

DN 126:157396

TI Preparation of 3-phenylheterocycloalkyl-2,4-dione enols as pesticides and herbicides

IN Lieb, Folker; Hagemann, Hermann; Widdig, Arno; Ruther, Michael; Fischer, Reiner; Bretschneider, Thomas; Erdelen, Christoph; Wachendorff-Neumann, Ulrike; Dahmen, Peter; Dollinger, Markus; Santel, Hans-Joachim; Graff, Alan; Andersch, Wolfram

PA Bayer A.-G., Germany

SO Ger. Offen., 135 pp.

CODEN: GWXXBX


DT Patent

LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|------------------|----------|
| PI | DE 19603332 | A1 | 19970102 | DE 1996-19603332 | 19960131 |
| | CA 2225830 | A1 | 19970123 | CA 1996-2225830 | 19960617 |
| | CA 2532743 | A1 | 19970123 | CA 1996-2532743 | 19960617 |
| | WO 9702243 | A1 | 19970123 | WO 1996-EP2601 | 19960617 |
| | W: AU, BB, BG, BR, BY, CA, CN, CZ, HU, JP, KR, KZ, LK, MX, NO, NZ, PL, RO, RU, SK, TR, UA, US | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | AU 9663561 | A | 19970205 | AU 1996-63561 | 19960617 |
| | AU 707357 | B2 | 19990708 | | |
| | EP 835243 | A1 | 19980415 | EP 1996-922817 | 19960617 |
| | EP 835243 | B1 | 20030129 | | |
| | R: BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL | | | | |
| | CN 1193960 | A | 19980923 | CN 1996-196456 | 19960617 |
| | HU 9802279 | A2 | 19990128 | HU 1998-2279 | 19960617 |
| | BR 9609301 | A | 19990525 | BR 1996-9301 | 19960617 |
| | JP 11510481 | T | 19990914 | JP 1996-504750 | 19960617 |
| | ES 2189877 | T3 | 20030716 | ES 1996-922817 | 19960617 |
| | IN 1996DE01384 | A | 20050701 | IN 1996-DE1384 | 19960624 |
| | ZA 9605516 | A | 19970206 | ZA 1996-5516 | 19960628 |
| | TW 410141 | B | 20001101 | TW 1996-85107798 | 19960628 |
| | US 5994274 | A | 19991130 | US 1997-981610 | 19971223 |
| | US 6251830 | B1 | 20010626 | US 1999-360510 | 19990726 |
| | US 2002022575 | A1 | 20020221 | US 2001-839481 | 20010420 |
| | US 6469196 | B2 | 20021022 | | |
| | CN 1362397 | A | 20020807 | CN 2001-138493 | 20011114 |
| | US 2003144504 | A1 | 20030731 | US 2002-197720 | 20020718 |
| | US 6759548 | B2 | 20040706 | | |
| PRAI | DE 1995-19523850 | A1 | 19950630 | | |
| | DE 1996-19603332 | A | 19960131 | | |
| | CA 1996-2225830 | A3 | 19960617 | | |
| | WO 1996-EP2601 | W | 19960617 | | |
| | US 1997-981610 | A3 | 19971223 | | |
| | US 1999-360510 | A3 | 19990726 | | |
| | US 2001-839481 | A3 | 20010420 | | |
| OS | MARPAT 126:157396 | | | | |
| IT | 186748-83-4P | | | | |
| | RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) | | | | |
| | (preparation of 3-phenylheterocycloalkyl-2,4-dione enols as pesticides and herbicides) | | | | |
| RN | 186748-83-4 CAPLUS | | | | |
| CN | Proline, 1-[(2-bromo-4,6-dimethylphenyl)acetyl]-4,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME) | | | | |


10/712,456-ALW




L4 ANSWER 116 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1997:127734 CAPLUS
 DN 126:220788
 TI The conformational change responsible for AT1 receptor activation is dependent upon two Juxtaposed asparagine residues on transmembrane helixes III and VII
 AU Balmforth, Anthony J.; Lee, Alison J.; Warburton, Philip; Donnelly, Dan; Ball, Stephen G.
 CS Inst. Cardiovascular Res., Univ. Leeds, Leeds, LS2 9JT, UK
 SO Journal of Biological Chemistry (1997), 272(7), 4245-4251
 CODEN: JBCHA3; ISSN: 0021-9258
 PB American Society for Biochemistry and Molecular Biology
 DT Journal
 LA English
 IT 188013-77-6
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (conformational change responsible for AT1 receptor activation is dependent upon two Juxtaposed asparagine residues on transmembrane helixes III and VII)
 RN 188013-77-6 CAPLUS
 CN Angiotensin II, 5-L-isoleucine-6-[(2S)-2-(4-aminophenyl)glycine]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L4 ANSWER 117 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:41800 CAPLUS

DN 126:74741

TI Alkyl dihalogenated phenyl-substituted keto enols useful as pesticides and herbicides

IN Lieb, Folker; Hagemann, Hermann; Widdig, Arno; Ruther, Michael; Fischer, Reiner; Bretschneider, Thomas; Erdelen, Christoph; Wachendorff-Neumann, Ulrike; Dahmen, Peter; Dollinger, Markus; Santel, Hans-Joachim; et al.

PA Bayer A.-G., Germany; Lieb, Folker; Hagemann, Hermann; Widdig, Arno; Ruther, Michael; Fischer, Reiner; Bretschneider, Thomas; Erdelen, Christoph; Wachendorff-Neumann, Ulrike; et al.

SO PCT Int. Appl., 231 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|--------------------|----------|
| PI | WO 9635664 | A1 | 19961114 | WO 1996-EP1781 | 19960429 |
| | W: AU, BB, BG, BR, BY, CA, CN, CZ, HU, JP, KR, KZ, LK, MX, NO, NZ, PL, RO, RU, SK, TR, UA, US | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | DE 19545467 | A1 | 19961114 | DE 1995-19545467 | 19951206 |
| | IN 1996DE00865 | A | 20050311 | IN 1996-DE865 | 19960423 |
| | CA 2220440 | A1 | 19961114 | CA 1996-2220440 | 19960429 |
| | AU 9657626 | A | 19961129 | AU 1996-57626 | 19960429 |
| | EP 825982 | A1 | 19980304 | EP 1996-914146 | 19960429 |
| | EP 825982 | B1 | 20021127 | | |
| | R: BE, CH, DE, ES, FR, GB, IT, LI, NL | | | | |
| | CN 1189153 | A | 19980729 | CN 1996-195072 | 19960429 |
| | CN 1131209 | B | 20031217 | | |
| | BR 9608229 | A | 19981229 | BR 1996-8229 | 19960429 |
| | JP 11505220 | T | 19990518 | JP 1996-533707 | 19960429 |
| | ES 2184858 | T3 | 20030416 | ES 1996-914146 | 19960429 |
| | CN 1473814 | A | 20040211 | CN 2003-2003136022 | 19960429 |
| | ZA 9603633 | A | 19961125 | ZA 1996-3633 | 19960508 |
| | US 6316486 | B1 | 20011113 | US 1997-945664 | 19971031 |
| | US 6380246 | B1 | 20020430 | US 1999-404424 | 19990923 |
| | US 2003199572 | A1 | 20031023 | US 2001-17695 | 20011214 |
| | US 6858741 | B2 | 20050222 | | |
| | US 2005164885 | A1 | 20050728 | US 2004-903550 | 20040730 |
| PRAI | DE 1995-19516258 | A | 19950509 | | |
| | DE 1995-19545467 | A | 19951206 | | |
| | WO 1996-EP1781 | W | 19960429 | | |
| | WO 1996-EP17871 | W | 19960429 | | |
| | US 1997-945664 | B3 | 19971031 | | |
| | US 1997-945665 | A3 | 19971031 | | |
| | US 1999-404424 | A3 | 19990923 | | |
| | US 2001-17695 | A3 | 20011214 | | |

OS MARPAT 126:74741

IT 185152-87-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of alkyl dihalophenyl-substituted keto enols as pesticides and herbicides)

RN 185152-87-8 CAPLUS

CN Proline, 1-[(2,6-dichloro-4-methylphenyl)acetyl]-4,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

10/712,456-ALW



L4 ANSWER 118 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1997:9927 CAPLUS

DN 126:144109

TI Preparation of substituted bicyclic 3-arylpyrrolidine-2,4-dione derivatives as insecticides, acaricides, and herbicides

IN Santel, Hans J.; Schmidt, Robert R.; Wachendorff-neumann, Ulrike; Erdelen, Christoph; Bretschneider, Thomas; Fischer, Reiner; Hagemann, Hermann; Kruger, Bernd-wieland; Lurssen, Klaus

PA Bayer A.-G., Germany

SO U.S., 34 pp., Cont.-in-part of U.S. Ser. No. 134,430, abandoned.


CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | US 5585384 | A | 19961217 | US 1994-292111 | 19940817 |
| | DE 4102778 | A1 | 19920806 | DE 1991-4102778 | 19910131 |
| | US 5288874 | A | 19940222 | US 1992-826303 | 19920124 |
| | US 5693663 | A | 19971202 | US 1996-700264 | 19960820 |
| PRAI | DE 1991-4102778 | A | 19910131 | | |
| | US 1992-826303 | A3 | 19920124 | | |
| | US 1993-134430 | B2 | 19931008 | | |
| | US 1994-292111 | A3 | 19940817 | | |
| OS | CASREACT 126:144109; MARPAT 126:144109 | | | | |
| IT | 144946-35-0 | | | | |
| | RL: RCT (Reactant); RACT (Reactant or reagent) | | | | |
| | (preparation of substituted bicyclic arylpyrrolidinedione derivs. as insecticides, acaricides, and herbicides) | | | | |
| RN | 144946-35-0 CAPLUS | | | | |
| CN | Proline, 4,5-dimethyl-1-[(2,4,6-trimethylphenyl)acetyl]-, ethyl ester (9CI) (CA INDEX NAME) | | | | |



IT 144946-36-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of substituted bicyclic arylpyrrolidinedione derivs. as insecticides, acaricides, and herbicides)

RN 144946-36-1 CAPLUS

CN L-Proline, 4-hydroxy-1-[(2,4,6-trimethylphenyl)acetyl]-, methyl ester, trans- (9CI) (CA INDEX NAME)

10/712,456-ALW

Absolute stereochemistry.



L4 ANSWER 119 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1996:593835 CAPLUS

DN 125:248489

TI Preparation of dipeptide derivatives as cell adhesion inhibitors

IN Adams, Steven P.; Lin, Ko-Chung; Lee, Wen-Cherng; Castro, Alfredo C.;
Zimmerman, Craig N.; Hammond, Charles E.; Liao, Yu-Sheng; Cuervo, Julio
Hernan; Singh, Juswinder

PA Biogen, Inc., USA

SO PCT Int. Appl., 169 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|------------------|----------|
| PI | WO 9622966 | A1 | 19960801 | WO 1996-US1349 | 19960118 |
| | W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE | | | | |
| | US 6306840 | B1 | 20011023 | US 1995-376372 | 19950123 |
| | CA 2211181 | A1 | 19960801 | CA 1996-2211181 | 19960118 |
| | AU 9649115 | A | 19960814 | AU 1996-49115 | 19960118 |
| | AU 718926 | B2 | 20000504 | | |
| | EP 805796 | A1 | 19971112 | EP 1996-905316 | 19960118 |
| | EP 805796 | B1 | 20021211 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI | | | | |
| | BR 9606778 | A | 19980106 | BR 1996-6778 | 19960118 |
| | CN 1177343 | A | 19980325 | CN 1996-192270 | 19960118 |
| | HU 9702461 | A2 | 19980428 | HU 1997-2461 | 19960118 |
| | HU 223350 | B1 | 20040628 | | |
| | JP 10513160 | T | 19981215 | JP 1996-523071 | 19960118 |
| | EP 1142867 | A2 | 20011010 | EP 2001-107877 | 19960118 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI | | | | |
| | AT 229498 | T | 20021215 | AT 1996-905316 | 19960118 |
| | ES 2183937 | T3 | 20030401 | ES 1996-905316 | 19960118 |
| | CZ 291556 | B6 | 20030416 | CZ 1997-2340 | 19960118 |
| | PT 805796 | T | 20030430 | PT 1996-905316 | 19960118 |
| | EE 4111 | B1 | 20030815 | EE 1997-172 | 19960118 |
| | SK 283724 | B6 | 20031202 | SK 1997-987 | 19960118 |
| | PL 187313 | B1 | 20040630 | PL 1996-321848 | 19960118 |
| | RO 119885 | B1 | 20050530 | RO 1997-1369 | 19960118 |
| | TW 500714 | B | 20020901 | TW 1996-85100690 | 19960122 |
| | IL 116846 | A | 20021110 | IL 1996-116846 | 19960122 |
| | NO 9703384 | A | 19970919 | NO 1997-3384 | 19970722 |
| | NO 320914 | B1 | 20060213 | | |
| | FI 9703087 | A | 19970922 | FI 1997-3087 | 19970722 |
| | BG 63383 | B1 | 20011231 | BG 1997-101841 | 19970821 |
| | US 6376538 | B1 | 20020423 | US 1997-875321 | 19970919 |
| | HK 1005241 | A1 | 20030822 | HK 1998-104006 | 19980508 |
| | AU 766538 | B2 | 20031016 | AU 2000-62432 | 20001002 |
| | US 2003083267 | A1 | 20030501 | US 2001-935461 | 20010822 |
| | US 6624152 | B2 | 20030923 | | |
| | US 2003018016 | A1 | 20030123 | US 2001-2341 | 20011023 |
| | US 6630512 | B2 | 20031007 | | |
| | US 7001921 | B1 | 20060221 | US 2003-625626 | 20030724 |
| | US 2006166866 | A1 | 20060727 | US 2003-679478 | 20031007 |

10/712,456-ALW

PRAI US 1995-376372 A2 19950123
AU 1996-49115 A3 19960118
EP 1996-905316 A3 19960118
WO 1996-US1349 W 19960118
US 1997-875321 A3 19970919
US 2001-935461 A1 20010822
US 2001-2341 A1 20011023
OS MARPAT 125:248489
IT 181519-89-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of β -amino acid dipeptide derivs. as cell adhesion
inhibitors)
RN 181519-89-1 CAPLUS
CN 1,3-Benzodioxole-5-propanoic acid, β -[[[(2S)-1-[[4-[[[(2-
methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-2-
pyrrolidinyl]carbonyl]amino]-, methyl ester, (β S)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.



L4 ANSWER 120 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1996:504110 CAPLUS

DN 125:143332

TI Preparation of carbamoylprolylnaphthylalanineamides and related compounds as tachykinin antagonists.

IN Ko, Soo Young; Walpole, Christopher

PA Sandoz Ltd., Switz.; Sandoz-Patent-GmbH; Sandoz Erfindungen Verwaltungsgesellschaft M.B.H.; Sandoz Pharmaceuticals (Uk) Ltd.

SO PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9618643 | A1 | 19960620 | WO 1995-EP4910 | 19951212 |
| | W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT | | | | |
| | RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | IN 1995MA01494 | A | 20050225 | IN 1995-MA1494 | 19951120 |
| | CA 2204130 | A1 | 19960620 | CA 1995-2204130 | 19951212 |
| | AU 9643437 | A | 19960703 | AU 1996-43437 | 19951212 |
| | EP 797583 | A1 | 19971001 | EP 1995-942131 | 19951212 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI | | | | |
| | BR 9509997 | A | 19971230 | BR 1995-9997 | 19951212 |
| | CN 1169731 | A | 19980107 | CN 1995-196794 | 19951212 |
| | HU 77002 | A2 | 19980302 | HU 1997-1897 | 19951212 |
| | ZA 9510618 | A | 19970613 | ZA 1995-10618 | 19951213 |
| | FI 9701685 | A | 19970813 | FI 1997-1685 | 19970418 |
| | NO 9702526 | A | 19970603 | NO 1997-2526 | 19970603 |
| PRAI | GB 1994-25085 | A | 19941213 | | |
| | GB 1994-26016 | A | 19941222 | | |
| | WO 1995-EP4910 | W | 19951212 | | |

OS MARPAT 125:143332

IT 180047-07-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of carbamoylprolylnaphthylalanineamides and related compds. as tachykinin antagonists)

RN 180047-07-8 CAPLUS

CN L-Alaninamide, 1-[[[(4-nitrophenyl)amino]carbonyl]-L-prolyl-N-methyl-3-(2-naphthalenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 121 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1996:440544 CAPLUS
DN 125:114472
TI Preparation of pyrrolidinecarboxylic acid derivatives as angiotensin II antagonists.
IN Yanagisawa, Hiroaki; Kanezaki, Takuo; Amamiya, Yosha; Furusawa, Juji; Mizuno, Makoto
PA Sankyo Co, Japan
SO Jpn. Kokai Tokkyo Koho, 259 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------|------|----------|-----------------|----------|
| PI | JP 08092207 | A | 19960409 | JP 1995-189453 | 19950725 |
| PRAI | JP 1995-189453 | A | 19950725 | | |
| | JP 1994-174452 | | 19940726 | | |
| OS | MARPAT 125:114472 | | | | |
| IT | 178866-87-0P | | | | |

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolidinecarboxylic acid derivs. as angiotensin II antagonists.)

RN 178866-87-0 CAPLUS

CN L-Proline, 1-[(4-hydroxyphenyl)acetyl]-4-[(1-oxobutyl)[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]-, cis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 178867-28-2P 178868-48-9P 178868-49-0P
178868-50-3P 178868-51-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolidinecarboxylic acid derivs. as angiotensin II antagonists.)

RN 178867-28-2 CAPLUS

CN L-Proline, 4-azido-1-[[4-(methoxymethoxy)phenyl]acetyl]-, methyl ester, cis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 178868-48-9 CAPLUS

CN L-Proline, 1-[[4-(methoxymethoxy)phenyl]acetyl]-4-[[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]amino]-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178868-49-0 CAPLUS

CN L-Proline, 1-[[4-(methoxymethoxy)phenyl]acetyl]-4-[(1-oxobutyl)[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]amino]-, methyl ester, cis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 178868-50-3 CAPLUS

CN L-Proline, 1-[[4-(methoxymethoxy)phenyl]acetyl]-4-[(1-oxobutyl)[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]amino]-, methyl ester, cis- (9CI) (CA INDEX NAME)

10/712,456-ALW


Absolute stereochemistry.



RN 178868-51-4 CAPLUS

CN L-Proline, 1-[(4-hydroxyphenyl)acetyl]-4-[(1-oxobutyl)[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]-, methyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 122 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1996:334305 CAPLUS
DN 125:75231
TI Intestinal absorption studies on peptide mimetic α -methyldopa
prodrugs
AU Wang, Hui-Po; Lu, Hsiao-Hwa; Lee, Jia-Shuai; Cheng, Chih-Yuan; Mah,
Jin-Ran; Ku, Ching-Yi; Hsu, Wenlie; Yen, Chen-Fang; Lin, Chun-Jung; et al.
CS College Medicine, National Taiwan University, Taipei, Taiwan
SO Journal of Pharmacy and Pharmacology (1996), 48(3), 270-276
CODEN: JPPMAB; ISSN: 0022-3573
PB Royal Pharmaceutical Society of Great Britain
DT Journal
LA English
IT 178620-95-6
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(intestinal absorption studies on peptide mimetic methyldopa prodrugs)
RN 178620-95-6 CAPLUS
CN L-Tyrosine, 3-hydroxy-N-[1-[D-2-(4-hydroxyphenyl)glycyl]-L-prolyl]- α -
methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/712,456-ALW


L4 ANSWER 123 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1995:857584 CAPLUS
DN 124:30395
TI Synthesis and pharmacological activities of a novel tripeptide mimetic dopamine prodrug
AU Wang, Hui-Po; Lee, Jia-Shuai; Tsai, Ming-Cheng; Lu, Hsiao-Hwa; Hsu, Wenlie
CS School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan
SO Bioorganic & Medicinal Chemistry Letters (1995), 5(19), 2195-8
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier
DT Journal
LA English
IT 171860-38-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and pharmacol. activities of a novel dopamine prodrug tripeptide)
RN 171860-38-1 CAPLUS
CN L-Tyrosine, (2R)-2-(4-hydroxyphenyl)glycyl-L-prolyl-3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 146622-05-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and pharmacol. activities of a novel dopamine prodrug tripeptide)
RN 146622-05-1 CAPLUS
CN L-Proline, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 171860-39-2P

10/712,456-ALW


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and pharmacol. activities of a novel dopamine prodrug tripeptide)

RN 171860-39-2 CAPLUS

CN L-Tyrosine, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl-L-prolyl-3-hydroxy-, phenylmethyl ester (9CI) (CA INDEX NAME).

Absolute stereochemistry.



L4 ANSWER 124 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1995:835486 CAPLUS

DN 123:257395

TI Imidazolyl amino acid derivatives as angiotensin II antagonists

IN Boyd, Donald B.; Hauser, Kenneth L.; Lifer, Sherryl L.; Marshall, Winston S.; Palkowitz, Alan D.; Pfeifer, William; Reel, Jon K.; Simon, Richard L.; Steinberg, Mitchell I.; et al.

PA Eli Lilly and Co., USA

SO U.S., 29 pp. Cont.-in-part of U.S. Ser. No. 892,867, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | US 5401851 | A | 19950328 | US 1993-49917 | 19930420 |
| | CA 2097462 | A1 | 19931204 | CA 1993-2097462 | 19930601 |
| | HU 64328 | A2 | 19931228 | HU 1993-1603 | 19930601 |
| | IL 105877 | A | 19980715 | IL 1993-105877 | 19930601 |
| | NO 9302005 | A | 19931206 | NO 1993-2005 | 19930602 |
| | EP 573271 | A1 | 19931208 | EP 1993-304264 | 19930602 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| | AU 9339985 | A | 19940120 | AU 1993-39985 | 19930602 |
| | AU 667903 | B2 | 19960418 | | |
| | RU 2110515 | C1 | 19980510 | RU 1993-46497 | 19930602 |
| | CN 1085897 | A | 19940427 | CN 1993-107578 | 19930603 |
| | CN 1045768 | B | 19991020 | | |
| | JP 07304752 | A | 19951121 | JP 1993-133212 | 19930603 |
| | PL 173340 | B1 | 19980227 | PL 1993-299176 | 19930603 |
| | US 5484780 | A | 19960116 | US 1994-355778 | 19941214 |
| PRAI | US 1992-892867 | B2 | 19920603 | | |
| | US 1993-49917 | A | 19930420 | | |

OS CASREACT 123:257395; MARPAT 123:257395


IT 157177-14-5P

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (imidazolyl amino acid derivs. as angiotensin II antagonists)

RN 157177-14-5 CAPLUS

CN L-Proline, 4-[4-[2-(2-carboxy-1-pyrrolidinyl)-2-oxoethyl]phenoxy]-1-[1-oxo-2-[4-[(2-sulfobenzoyl)amino]-1H-imidazol-1-yl]octyl]-, [1(S*),2 α ,4 α (R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 774227-02-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(imidazolyl amino acid derivs. as angiotensin II antagonists)


RN 774227-02-0 CAPLUS

CN L-Proline, 4-[4-[2-[(2S)-2-carboxy-1-pyrrolidinyl]-2-oxoethyl]phenoxy]-,

10/712,456-ALW

2-methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW


L4 ANSWER 125 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1995:733495 CAPLUS
DN 124:9454
TI Tripeptide antithrombotic agents
IN Gesellchen, Paul D.; Shuman, Robert T.
PA Eli Lilly and Co., USA
SO U.S., 20 pp. Cont.-in-part of U.S. Ser. No. 756,091.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|----------|
| PI | US 5430023 | A | 19950704 | US 1993-121134 | 19930914 |
| | IL 99527 | A | 19970814 | IL 1991-99527 | 19910919 |
| | CA 2052013 | A1 | 19920329 | CA 1991-2052013 | 19910923 |
| | CA 2052013 | C | 20010130 | | |
| | HU 59162 | A2 | 19920428 | HU 1991-3037 | 19910923 |
| | HU 217441 | B | 20000128 | | |
| | ZA 9107572 | A | 19930323 | ZA 1991-7572 | 19910923 |
| | CZ 285980 | B6 | 19991215 | CZ 1991-2913 | 19910923 |
| | SK 281731 | B6 | 20010710 | SK 1991-2913 | 19910923 |
| | NO 9103773 | A | 19920330 | NO 1991-3773 | 19910926 |
| | NO 309984 | B1 | 20010430 | | |
| | AU 9184780 | A | 19920402 | AU 1991-84780 | 19910926 |
| | AU 645347 | B2 | 19940113 | | |
| | RU 2077538 | C1 | 19970420 | RU 1991-5001658 | 19910926 |
| | KR 219993 | B1 | 19991001 | KR 1991-16772 | 19910926 |
| | AT 211147 | T | 20020115 | AT 1995-201960 | 19910926 |
| | ES 2169105 | T3 | 20020701 | ES 1995-201960 | 19910926 |
| | AT 234857 | T | 20030415 | AT 1991-308785 | 19910926 |
| | ES 2194835 | T3 | 20031201 | ES 1991-308785 | 19910926 |
| | FI 9104566 | A | 19920329 | FI 1991-4566 | 19910927 |
| | FI 107733 | B1 | 20010928 | | |
| | CN 1060472 | A | 19920422 | CN 1991-109042 | 19910927 |
| | CN 1036399 | B | 19971112 | | |
| | BR 9104181 | A | 19920602 | BR 1991-4181 | 19910927 |
| | JP 04257600 | A | 19920911 | JP 1991-249093 | 19910927 |
| | JP 3023019 | B2 | 20000321 | | |
| | EP 643073 | A1 | 19950315 | EP 1994-306667 | 19940912 |
| | EP 643073 | B1 | 19971126 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| | ZA 9407015 | A | 19960312 | ZA 1994-7015 | 19940912 |
| | AT 160574 | T | 19971215 | AT 1994-306667 | 19940912 |
| | ES 2110186 | T3 | 19980201 | ES 1994-306667 | 19940912 |
| | IL 110933 | A | 19981227 | IL 1994-110933 | 19940912 |
| | PL 176448 | B1 | 19990531 | PL 1994-305009 | 19940912 |
| | CZ 286139 | B6 | 20000112 | CZ 1994-2220 | 19940912 |
| | CA 2131982 | A1 | 19950315 | CA 1994-2131982 | 19940913 |
| | CA 2131982 | C | 20030729 | | |
| | FI 9404231 | A | 19950315 | FI 1994-4231 | 19940913 |
| | NO 9403402 | A | 19950315 | NO 1994-3402 | 19940913 |
| | NO 310240 | B1 | 20010611 | | |
| | AU 9472948 | A | 19950330 | AU 1994-72948 | 19940913 |
| | AU 674773 | B2 | 19970109 | | |
| | HU 67849 | A2 | 19950529 | HU 1994-2626 | 19940913 |
| | HU 220620 | B1 | 20020328 | | |
| | BR 9403542 | A | 19950620 | BR 1994-3542 | 19940913 |
| | JP 07149791 | A | 19950613 | JP 1994-219854 | 19940914 |
| | CN 1106819 | A | 19950816 | CN 1994-115165 | 19940914 |
| | CN 1055698 | B | 20000823 | | |

10/712,456-ALW

| | | | | |
|---|---|----------|---------------|----------|
| RU 2105010 | C1 | 19980220 | RU 1994-34734 | 19940914 |
| HU 9500399 | A3 | 19951030 | HU 1995-399 | 19950622 |
| PRAI US 1990-589553 | B2 | 19900928 | | |
| US 1991-756091 | A2 | 19910906 | | |
| US 1993-121134 | A | 19930914 | | |
| OS CASREACT 124:9454; MARPAT 124:9454 | | | | |
| IT 141972-92-1P 141972-93-2P 141973-10-6P | | | | |
| 171228-00-5P 171228-01-6P | | | | |
| RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| (tripeptide antithrombotic agents) | | | | |
| RN 141972-92-1 | CAPLUS | | | |
| CN | L-Prolinamide, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-formylbutyl]-(9CI) (CA INDEX NAME) | | | |

Absolute stereochemistry.




RN 141972-93-2 CAPLUS
CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-D-2-(4-hydroxyphenyl)glycyl-N-[4-[(aminoiminomethyl)amino]-1-formylbutyl]-, (S)-, diacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 141972-92-1
CMF C24 H36 N6 O6


Absolute stereochemistry.




CM 2

10/712,456-ALW

CRN 64-19-7
CMF C2 H4 O2




RN 141973-10-6 CAPLUS
CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-D-2-(4-methoxyphenyl)glycyl-N-[4-[(aminoiminomethyl)amino]-1-formylbutyl]-, (S)-
(9CI) (CA INDEX NAME)



RN 171228-00-5 CAPLUS
CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-D-2-(4-methoxyphenyl)glycyl-N-[4-[(aminoiminomethyl)amino]-1-formylbutyl]-, (S)-, acetate (9CI) (CA INDEX NAME)

CM 1


CRN 141973-10-6
CMF C25 H38 N6 O6



CM 2

10/712,456-ALW


CRN 64-19-7
CMF C2 H4 O2



RN 171228-01-6 CAPLUS
CN L-Prolinamide, N-acetyl-D-2-(4-methoxyphenyl)glycyl-N-[4-
[(aminoiminomethyl)amino]-1-formylbutyl]-, (S)-, acetate (9CI) (CA INDEX
NAME)


CM 1

CRN 141973-12-8
CMF C22 H32 N6 O5



CM 2

CRN 64-19-7
CMF C2 H4 O2



10/712,456-ALW

L4 ANSWER 126 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1995:620916 CAPLUS

DN 123:40809

TI Synthesis of α -methyldopa prodrugs containing dipeptide moieties as tools for intestinal delivery

AU Wang, Hui-Po; Cheng, Chih-Yuan; Ma, Jin-Ran; Lee, Jia-Shuai

CS Coll. Med., Natl. Taiwan Univ., Taipei, Taiwan

SO Journal of the Chinese Chemical Society (Taipei) (1995), 42(3), 561-7

CODEN: JCCTAC; ISSN: 0009-4536

PB Chinese Chemical Society

DT Journal

LA English

IT 164353-64-4


RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(synthesis of α -methyldopa prodrugs containing dipeptide moieties for intestinal delivery)

RN 164353-64-4 CAPLUS

CN L-Alanine, 2-(3,4-dihydroxyphenyl)-N-[1-[D-2-(4-hydroxyphenyl)glycyl]-L-prolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 164353-71-3


RL: RCT (Reactant); RACT (Reactant or reagent)

(synthesis of α -methyldopa prodrugs containing dipeptide moieties for intestinal delivery)

RN 164353-71-3 CAPLUS

CN L-Proline, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

IT 146622-05-1P 164353-69-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of α -methyldopa prodrugs containing dipeptide moieties for intestinal delivery)

RN 146622-05-1 CAPLUS

CN L-Proline, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 164353-69-9 CAPLUS

CN L-Alanine, 2-(3,4-dihydroxyphenyl)-N-[1-[N-[(1,1-dimethylethoxy)carbonyl]-D-2-(4-hydroxyphenyl)glycyl]-L-prolyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 127 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1995:304927 CAPLUS

DN 122:82085

TI Preparation of acyclic peptides as cardiovascular agents (natriuretics).

IN Voges, Klaus Peter; Henning, Rolf; Huebsch, Walter; Lenfers, Jan Bernd;
Beuck, Martin; Theiss, Gudrun; Stasch, Johannes Peter; Hirth-Dietrich,
Claudia

PA Bayer A.-G., Germany

SO Ger. Offen., 73 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | DE 4242946 | A1 | 19940623 | DE 1992-4242946 | 19921218 |
| | CA 2151961 | A1 | 19940707 | CA 1993-2151961 | 19931206 |
| | WO 9414840 | A1 | 19940707 | WO 1993-EP3431 | 19931206 |
| | W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, VN | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | AU 9456970 | A | 19940719 | AU 1994-56970 | 19931206 |
| | EP 674655 | A1 | 19951004 | EP 1994-902694 | 19931206 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| PRAI | DE 1992-4242946 | A | 19921218 | | |
| | WO 1993-EP3431 | W | 19931206 | | |
| OS | MARPAT 122:82085 | | | | |
| IT | 160344-79-6P 160344-80-9P 160344-81-0P | | | | |
| | 160344-82-1P 160344-84-3P 160344-85-4P | | | | |
| | 160344-86-5P 160344-87-6P 160344-88-7P | | | | |
| | 160344-89-8P 160344-90-1P 160344-91-2P | | | | |
| | 160344-92-3P 160344-93-4P 160344-94-5P | | | | |
| | 160344-96-7P 160344-98-9P 160344-99-0P | | | | |
| | 160345-00-6P 160345-02-8P 160345-03-9P | | | | |
| | 160345-04-0P 160345-05-1P 160345-06-2P | | | | |
| | 160345-20-0P 160345-21-1P 160345-23-3P | | | | |
| | 160345-24-4P 160345-25-5P 160345-27-7P | | | | |
| | 160345-28-8P 160345-29-9P 160345-30-2P | | | | |
| | 160345-31-3P 160345-32-4P 160345-33-5P | | | | |
| | 160345-34-6P 160345-35-7P 160345-36-8P | | | | |
| | 160345-37-9P 160345-38-0P 160345-46-0P | | | | |
| | 160345-47-1P 160345-48-2P 160345-49-3P | | | | |
| | 160345-50-6P 160345-51-7P 160345-52-8P | | | | |
| | 160345-56-2P 160345-58-4P 160345-62-0P | | | | |
| | 160345-64-2P 160345-65-3P 160345-66-4P | | | | |
| | 160345-67-5P 160345-68-6P 160345-69-7P | | | | |
| | 160345-74-4P 160345-76-6P 160345-77-7P | | | | |
| | 160345-78-8P 160345-79-9P 160345-82-4P | | | | |
| | 160345-83-5P 160345-84-6P 160345-85-7P | | | | |
| | 160345-86-8P 160345-87-9P 160345-88-0P | | | | |
| | 160345-89-1P 160345-90-4P 160345-91-5P | | | | |
| | 160345-92-6P 160345-93-7P 160345-94-8P | | | | |
| | 160345-95-9P 160345-96-0P 160345-97-1P | | | | |
| | 160345-98-2P 160345-99-3P 160346-00-9P | | | | |
| | 160346-01-0P 160346-02-1P 160346-04-3P | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) | | | | |
| | (preparation of, as cardiovascular agent) | | | | |
| RN | 160344-79-6 CAPLUS | | | | |

10/712,456-ALW


CN L-Ornithinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylbutyl)-N5-[(phenylmethoxy)carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B






RN 160344-80-9 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 160344-81-0 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-trans-4-(phenylmethoxy)-L-prolyl-L-isoleucyl-L- α -aspartyl-N5-formyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 160344-82-1 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-trans-4-(phenylmethoxy)-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160344-84-3 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-α-aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 160344-85-4 CAPLUS


CN L-Ornithinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 160344-86-5 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)


10/712,456-ALW

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 160344-87-6 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 160344-88-7 CAPLUS

CN L-Ornithinamide, 1-[[4-[(phenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160344-89-8 CAPLUS

CN L-Ornithinamide, 1-[[4-[(phenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 160344-90-1 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(phenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-

10/712,456-ALW

isoleucyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 160344-91-2 CAPLUS

CN L-Isoleucinamide, 1-[[4-[[[(4-fluorophenyl)acetyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 160344-92-3 CAPLUS

CN L-Isoleucinamide, 1-[[4-[[[(3-fluorophenyl)acetyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 160344-93-4 CAPLUS


CN L-Isoleucinamide, 1-[[4-[[[(4-chlorophenyl)acetyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 160344-94-5 CAPLUS

CN L-Ornithinamide, 1-[[4-[(phenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 160344-96-7 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N5-acetyl-L-ornithyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160344-98-9 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)oxy]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 160344-99-0 CAPLUS

CN L-Isoleucinamide, 1-[[4-[bis[(3-fluorophenyl)methyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-α-aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 160345-00-6 CAPLUS

CN L-Isoleucinamide, 1-[[4-(benzoylamino)phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 160345-02-8 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N5-[(phenylmethoxy)carbonyl]-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 160345-03-9 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(3-fluorobenzoyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 160345-04-0 CAPLUS

CN L-Isoleucinamide, 1-[(4-aminophenyl)acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160345-05-1 CAPLUS

CN L-Isoleucinamide, 1-[[4-(acetamino)phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160345-06-2 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160345-20-0 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-1-aminocyclopentanecarbonyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 160345-21-1 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-phenylalanyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 160345-23-3 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-1-aminocyclopentanecarbonyl-L- α -aspartyl-N-(2-methylbutyl)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160345-24-4 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-1-aminocyclopentanecarbonyl-L- α -aspartyl-N5-[(1,1-dimethylethoxy)carbonyl]-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



— OBU-t

RN 160345-25-5 CAPLUS
 CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-2-cyclohexylglycyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 160345-27-7 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-1-aminocyclopentanecarbonyl-L- α -aspartyl-L-ornithyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—NH₂

RN 160345-28-8 CAPLUS



CN L-Ornithinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-2-methylalanyl-L- α -aspartyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 160345-29-9 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolylglycyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 160345-30-2 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-propyl-L-2-cyclohexylglycyl-L- α -aspartyl-N-(2-methylbutyl)- (9CI)
(CA INDEX NAME)



Absolute stereochemistry.



RN 160345-31-3 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-propyl-2-methylalanyl-L- α -aspartyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 160345-33-5 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-1-aminocyclopentanecarbonyl-L- α -aspartyl-N-(2-methylbutyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 160345-34-6 CAPLUS


CN L-Norvalinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylbutyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




Pr-n

RN 160345-35-7 CAPLUS


CN L-Norvalinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -glutamyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




Pr-n

10/712,456-ALW

RN 160345-36-8 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-asparaginyl-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B

NH₂



=O

(CH₂)₃NH₂

RN 160345-37-9 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-2-cyclohexylglycyl-L-asparaginyl-L-ornithyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 160345-38-0 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-asparaginyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 160345-46-0 CAPLUS


CN L-Argininamide, 1-[[4-[(phenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-α-aspartyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 160345-47-1 CAPLUS

CN L-Argininamide, 1-[[4-[(phenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 160345-48-2 CAPLUS

CN L-Argininamide, 1-[[4-[(phenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 160345-49-3 CAPLUS


CN L-Argininamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 160345-50-6 CAPLUS


CN L-Argininamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-α-aspartyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




10/712,456-ALW

RN 160345-51-7 CAPLUS


CN L-Argininamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 160345-52-8 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 160345-56-2 CAPLUS

CN L-Isoleucinamide, 1-[[4-[[[(4-fluorophenyl)methyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 160345-58-4 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N5-[(1,1-dimethylethoxy)carbonyl]-L-ornithyl-, monolithium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.





● Li



RN 160345-62-0 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolylglycyl-L- α -aspartyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

—CO₂H

RN 160345-64-2 CAPLUS


CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-

10/712,456-ALW


prolylglycyl-L- α -aspartyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 160345-65-3 CAPLUS



CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-2-methylalanyl-L- α -aspartyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 160345-66-4 CAPLUS


CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-1-aminocyclopentanecarbonyl-L- α -aspartyl-L-arginyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 160345-67-5 CAPLUS
 CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-2-cyclohexylglycyl-L- α -aspartyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 160345-68-6 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-propyl-3-methyl-L-valyl-L-α-aspartyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A








RN 160345-69-7 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-N-methylglycyl-L- α -aspartyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 160345-74-4 CAPLUS


CN L-Lysinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 160345-76-6 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-α-aspartyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 160345-77-7 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(phenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-norvalyl-L-arginyl- (9CI) (CA INDEX NAME)


10/712,456-ALW

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 160345-78-8 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(phenylacetyl)amino]phenyl]acetyl]-L-prolyl-N-methylglycyl-L- α -aspartyl-L-arginyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160345-79-9 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylacetyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-norvalyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 160345-82-4 CAPLUS

CN D-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-glutamyl-D-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A





RN 160345-83-5 CAPLUS
 CN D-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-2-cyclohexylglycyl-L-glutaminy-D-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

RN 160345-84-6 CAPLUS


CN D-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-2-cyclohexylglycyl-L- α -glutamyl-D-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 160345-85-7 CAPLUS

CN D-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-1-aminocyclopentanecarbonyl-L- α -glutamyl-D-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 160345-86-8 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolylglycyl-L- α -aspartyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 160345-87-9 CAPLUS


CN L-Lysinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolylglycyl-L- α -aspartyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 160345-88-0 CAPLUS

10/712,456-ALW


CN L-Lysinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolylglycyl-L- α -aspartyl-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 160345-89-1 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-arginyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 160345-90-4 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-D-prolyl-N-methylglycyl-L- α -aspartyl-L-arginyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 160345-91-5 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-D-prolyl-L-isoleucyl-L- α -aspartyl-L-arginyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 160345-92-6 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-asparaginyl-N5-[(1,1-dimethylethoxy)carbonyl]-L-ornithyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 160345-93-7 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-α-aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 160345-94-8 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -glutamyl-N5-acetyl-L-ornithyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 160345-95-9 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-2-cyclohexylglycyl-L- α -aspartyl-L-arginyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160345-96-0 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(cyclohexylmethyl)-N5-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 160345-97-1 CAPLUS
 CN L-Ornithinamide, 1-[[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-α-aspartyl-N-(2-methylbutyl)-N5-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B






RN 160346-00-9 CAPLUS

CN L-Isoleucinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L- α -aspartyl-L-ornithyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 160346-01-0 CAPLUS

CN Alaninamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-3-amino-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 160346-02-1 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-2-carboxyglycyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.








RN 160346-04-3 CAPLUS

CN L-Ornithinamide, 1-[[4-[(2-naphthalenylcarbonyl)amino]phenyl]acetyl]-L-prolyl-3-methyl-L-valyl-L- α -aspartyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 128 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1995:304926 CAPLUS

DN 122:82084

TI Preparation of sulfur-containing peptides as antihypertensives.

IN Voges, Klaus Peter; Henning, Rolf; Lenfers, Jan Bernd; Dressel, Juergen; Beuck, Martin; Theiss, Gudrun; Stasch, Johannes Peter; Hirth-Dietrich, Claudia; Bischoff, Erwin

PA Bayer A.-G., Germany

SO Ger. Offen., 37 pp.

CODEN: GWXXBX


DT Patent

LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|--|----------|
| PI | DE 4242945 | A1 | 19940623 | DE 1992-4242945 | 19921218 |
| | CA 2151959 | A1 | 19940707 | CA 1993-2151959 | 19931206 |
| | WO 9414839 | A1 | 19940707 | WO 1993-EP3430 | 19931206 |
| | W: | | | AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, VN | |
| | RW: | | | AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | |
| | AU 9456969 | A | 19940719 | AU 1994-56969 | 19931206 |
| | EP 674654 | A1 | 19951004 | EP 1994-902693 | 19931206 |
| | R: | | | AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | |
| | JP 08504779 | T | 19960521 | JP 1993-514731 | 19931206 |
| PRAI | DE 1992-4242945 | A | 19921218 | | |
| | WO 1993-EP3430 | W | 19931206 | | |
| OS | MARPAT 122:82084 | | | | |
| IT | 160344-71-8P 160344-72-9P 160344-73-0P | | | | |
| | RL: SPN (Synthetic preparation); PREP (Preparation) | | | | |
| | (preparation of, as intermediate for peptide derivative natriuretic) | | | | |
| RN | 160344-71-8 CAPLUS | | | | |
| CN | L-Isoleucine, N-[1-[[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]acetyl]-L-prolyl]-, phenylmethyl ester (9CI) (CA INDEX NAME) | | | | |


Absolute stereochemistry.



RN 160344-72-9 CAPLUS

CN L-Isoleucine, N-[1-[[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]acetyl]-L-prolyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

RN 160344-73-0 CAPLUS


CN L-Ornithinamide, 1-[[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N5-[(1,1-dimethylethoxy)carbonyl]-N-(2-methylbutyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT 160344-18-3P 160344-19-4P 160344-27-4P

160344-35-4P 160344-36-5P 160344-61-6P


160344-68-3P 160344-69-4P 160401-07-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as natriuretic)

RN 160344-18-3 CAPLUS

CN L-Ornithinamide, 1-[[4-[[[1-oxo-2-[[1-oxo-3-[(triphenylmethyl)thio]propyl]amino]-3-phenylpropyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

—CO₂H

RN 160344-19-4 CAPLUS

CN L-Ornithinamide, 1-[[4-[[2-[(3-mercapto-1-oxopropyl)amino]-1-oxo-3-phenylpropyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-N-(2-methylbutyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 160344-27-4 CAPLUS
CN L-Isoleucinamide, 1-[[4-[[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-ornithyl-, (S)- (9CI) (CA INDEX NAME)

Chemical structure of compound 10, showing a complex thioamide derivative. The structure includes a central amide linkage connecting a 4-phenylthioamide group to a 4-(4-ethylthio-2-methyl-1,3-dithiolan-2-yl)thioamide group. The latter is further substituted with a 3-aminopropyl chain and a 2-ethyl-4-methylthioamide group.

RN 160344-35-4 CAPLUS
CN L-Isoleucinamide, 1-[[4-[[2-[(mercaptoacetyl)amino]-1-oxo-3-phenylpropyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-ornithyl-, (S)- (9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 160344-61-6 CAPLUS


CN L-Isoleucinamide, 1-[[4-[[2-(mercaptomethyl)-1-oxo-3-phenylpropyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-α-aspartyl-L-ornithyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 160344-68-3 CAPLUS

CN L-Isoleucinamide, 1-[[4-[[2-(mercaptomethyl)-1-oxo-3-phenylpropyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L-α-aspartyl-L-arginyl-, (R)- (9CI) (CA INDEX NAME)





RN 160344-69-4 CAPLUS

CN L-Isoleucinamide, 1-[[4-[[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-arginyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 160401-07-0 CAPLUS

CN L-Isoleucinamide, 1-[[4-[[2-(mercaptomethyl)-1-oxo-3-phenylpropyl]amino]phenyl]acetyl]-L-prolyl-L-isoleucyl-L- α -aspartyl-L-arginyl-, (S)- (9CI). (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






10/712,456-ALW

L4 ANSWER 129 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1995:304885 CAPLUS
DN 122:106532
TI Preparation of amino acid- and peptideamides as tachykinin antagonists
IN Esser, Franz; Schnorrenberg, Gerd; Dollinger, Horst; Jung, Birgit;
Buerger, Erich
PA Boehringer Ingelheim KG, Germany; Boehringer Ingelheim International GmbH
SO PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 2


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 9405693 | A1 | 19940317 | WO 1993-EP2329 | 19930828 |
| | W: AU, BG, BY, CA, CZ, FI, HU, JP, KR, NO, NZ, PL, RU, SK, UA | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | DE 4243496 | A1 | 19940310 | DE 1992-4243496 | 19921222 |
| | DE 4315437 | A1 | 19941110 | DE 1993-4315437 | 19930508 |
| | EP 610487 | A1 | 19940817 | EP 1993-919208 | 19930828 |
| | EP 610487 | B1 | 19991110 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| | JP 07501085 | T | 19950202 | JP 1993-506852 | 19930828 |
| | AU 677792 | B2 | 19970508 | AU 1993-49547 | 19930828 |
| | AU 9349547 | A | 19940329 | | |
| | CN 1086222 | A | 19940504 | CN 1993-117349 | 19930903 |
| | FI 9401987 | A | 19940429 | FI 1994-1987 | 19940429 |
| | NO 9401611 | A | 19940502 | NO 1994-1611 | 19940502 |
| | GR 3032395 | T3 | 20000531 | GR 2000-400089 | 20000114 |
| PRAI | DE 1992-4229447 | A | 19920903 | | |
| | DE 1992-4243496 | A | 19921222 | | |
| | DE 1993-4315437 | A | 19930508 | | |
| | WO 1993-EP2329 | W | 19930828 | | |
| OS | MARPAT 122:106532 | | | | |
| IT | 159136-74-0P 160342-34-7P | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as neurokinin antagonist) | | | | |
| RN | 159136-74-0 CAPLUS | | | | |
| CN | Butanamide, 1-[(3,4-dimethoxyphenyl)acetyl]-trans-4-hydroxy-L-prolyl-N-methyl-4-phenyl-N-(phenylmethyl)-L-2-amino- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.



RN 160342-34-7 CAPLUS
CN 2-Pyrrolidinecarboxamide, 4-hydroxy-N-[2-[4-(2-methylphenyl)-1-piperazinyl]-1-(2-naphthalenylmethyl)-2-oxoethyl]-1-[(4-nitrophenyl)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/712,456-ALW



● HCl


10/712,456-ALW

L4 ANSWER 130 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1995:274880 CAPLUS
DN 122:55896
TI 1-(2-oxoacetyl)piperidine-2-carboxylic acid derivatives as
multi-drug-resistant cancer cell sensitizers
IN Armistead, David M.; Saunders, Jeffrey O.; Boger, Joshua S.
PA Vertex Pharmaceuticals Inc., USA
SO PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|--------------------|----------|
| PI | WO 9407858 | A1 | 19940414 | WO 1993-US9145 | 19930927 |
| | W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | NZ 314207 | A | 20001222 | NZ 1993-314207 | 19930727 |
| | IL 107109 | A | 19990312 | IL 1993-107109 | 19930926 |
| | AU 9351648 | A | 19940426 | AU 1993-51648 | 19930927 |
| | AU 690082 | B2 | 19980423 | | |
| | EP 662958 | A1 | 19950719 | EP 1993-922748 | 19930927 |
| | EP 662958 | B1 | 20021211 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| | JP 08502256 | T | 19960312 | JP 1994-509216 | 19930927 |
| | JP 3635493 | B2 | 20050406 | | |
| | HU 72046 | A2 | 19960328 | HU 1995-890 | 19930927 |
| | RU 2158258 | C2 | 20001027 | RU 1995-110938 | 19930927 |
| | CZ 287396 | B6 | 20001115 | CZ 1995-769 | 19930927 |
| | RO 117791 | B1 | 20020730 | RO 1995-599 | 19930927 |
| | AT 229506 | T | 20021215 | AT 1993-922748 | 19930927 |
| | PT 662958 | T | 20030430 | PT 1993-922748 | 19930927 |
| | CA 2144962 | C | 20030520 | CA 1993-2144962 | 19930927 |
| | ES 2188595 | T3 | 20030701 | ES 1993-922748 | 19930927 |
| | SK 284129 | B6 | 20040908 | SK 1995-389 | 19930927 |
| | CN 1088577 | A | 19940629 | CN 1993-118201 | 19930928 |
| | CN 1086386 | B | 20020619 | | |
| | CN 1494906 | A | 20040512 | CN 2002-2002108738 | 19930928 |
| | FI 9501454 | A | 19950327 | FI 1995-1454 | 19950327 |
| | NO 9501162 | A | 19950529 | NO 1995-1162 | 19950327 |
| | NO 305596 | B1 | 19990628 | | |
| | HK 1013992 | A1 | 20030815 | HK 1998-115242 | 19981223 |
| PRAI | US 1992-952299 | A | 19920928 | | |
| | WO 1993-US9145 | W | 19930927 | | |
| OS | MARPAT 122:55896 | | | | |
| IT | 159997-02-1P 159997-17-8P 159997-77-0P 159997-78-1P 159997-95-2P 160072-11-7P | | | | |
| | RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as sensitizer for multi-drug-resistant cancer cells) | | | | |
| RN | 159997-02-1 CAPLUS | | | | |
| CN | L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 1-(3-phenylpropyl)-4-(2-pyridinyl)butyl ester, (S)- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.


10/712,456-ALW



RN 159997-17-8 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 1-(3-phenylpropyl)-4-(2-pyridinyl)butyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159997-77-0 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, (1S)-1-[3,4,5-tris(4-pyridinylmethoxy)phenyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159997-78-1 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, (1R)-1-[3,4,5-tris(4-pyridinylmethoxy)phenyl]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159997-95-2 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 4-(3-pyridinyl)-1-[3-(3-pyridinyl)propyl]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 160072-11-7 CAPLUS

CN L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 2-(phenylmethoxy)-1-[(phenylmethoxy)phenyl]ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



D1-O-CH₂-Ph



L4 ANSWER 131 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1995:239986 CAPLUS

DN 122:32011

TI Imidazolyl-substituted prolinamides

IN Mueller-Gliemann, Matthias; Dressel, Juergen; Fey, Peter; Hanko, Rudolf; Huebsch, Walter; Kraemer, Thomas; Mueller, Ulrich; Beuck, Martin; Kazda, Stanislav; et al.

PA Bayer A.-G., Germany

SO Ger. Offen., 20 pp.

CODEN: GWXXBX


DT Patent

LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | DE 4302957 | A1 | 19940804 | DE 1993-4302957 | 19930203 |
| | EP 610697 | A1 | 19940817 | EP 1994-100845 | 19940121 |
| | EP 610697 | B1 | 19970312 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| | AT 150018 | T | 19970315 | AT 1994-100845 | 19940121 |
| | ES 2099494 | T3 | 19970516 | ES 1994-100845 | 19940121 |
| | US 5459156 | A | 19951017 | US 1994-188615 | 19940127 |
| | JP 06271573 | A | 19940927 | JP 1994-27586 | 19940201 |
| PRAI | DE 1993-4302957 | A | 19930203 | | |
| OS | CASREACT 122:32011; MARPAT 122:32011 | | | | |
| IT | 159582-52-2P 159582-53-3P 159582-54-4P 159582-55-5P 159582-56-6P 159582-57-7P 159582-58-8P 159582-59-9P 159582-60-2P 159582-61-3P 159582-62-4P 159582-63-5P 159582-64-6P 159582-65-7P 159582-66-8P 159582-67-9P 159582-68-0P 159582-69-1P 159582-70-4P 159582-71-5P 159652-40-1P 159652-41-2P | | | | |
| | RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as angiotensin antagonist) | | | | |
| RN | 159582-52-2 CAPLUS | | | | |
| CN | L-Proline, 1-[[4-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]phenyl]cyclopentylacetyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.




10/712,456-ALW

RN 159582-53-3 CAPLUS

CN L-Proline, 1-[[4-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]phenyl]cyclopentylacetyl]-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159582-54-4 CAPLUS

CN L-Proline, 1-[[4-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]phenyl]cyclopentylacetyl]-, 1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159582-55-5 CAPLUS

CN L-Proline, 1-[[4-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]phenyl]cyclopentylacetyl]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 159582-56-6 CAPLUS

CN L-Proline, 1-[[4-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]phenyl]cyclopentylacetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159582-57-7 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[[4-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]phenyl]cyclopentylacetyl]- (9CI) (CA INDEX NAME)

10/712,456-ALW



RN 159582-58-8 CAPLUS


CN 1H-Imidazole-5-carboxylic acid, 2-butyl-1-[[4-[2-(2-carboxy-1-pyrrolidinyl)-1-cyclopentyl-2-oxoethyl]phenyl]methyl]-4-chloro- (9CI) (CA INDEX NAME)



RN 159582-59-9 CAPLUS


CN 1H-Imidazole-5-carboxylic acid, 1-[[4-[2-[2-(aminocarbonyl)-1-pyrrolidinyl]-1-cyclopentyl-2-oxoethyl]phenyl]methyl]-2-butyl-4-chloro- (9CI) (CA INDEX NAME)

10/712,456-ALW



RN 159582-60-2 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[[4-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]phenyl]cyclopentylacetyl]-N-(2-hydroxy-1-phenylethyl)- (9CI)
(CA INDEX NAME)



RN 159582-61-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]cyclopentylacetyl]-N-(2-hydroxy-1-phenylethyl)- (9CI) (CA INDEX NAME)


10/712,456-ALW



RN 159582-62-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]cyclopentylacetyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159582-63-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]cyclopentylacetyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 159582-64-6 CAPLUS

CN L-Proline, 1-[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]cyclopentylacetyl]-, phenylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159582-65-7 CAPLUS

CN L-Proline, 1-[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]cyclopentylacetyl]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 159582-66-8 CAPLUS

CN 1H-Imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-[[4-[1-cyclopentyl-2-oxo-2-[2-[(phenylmethoxy)carbonyl]-1-pyrrolidinyl]ethyl]phenyl]methyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159582-67-9 CAPLUS

CN 1H-Imidazole-5-carboxylic acid, 2-butyl-4-chloro-1-[[4-[1-cyclopentyl-2-oxo-2-[2-[(phenylmethoxy)carbonyl]-1-pyrrolidinyl]ethyl]phenyl]methyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


CCCC1=CN=C(Cl)C=C1CNC(C1=CC=CC=C1)SC(=O)N2CCCC2C(=O)OCC3=CC=CC=C3

CN L-Proline, 1-[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]cyclopentylacetyl]-, 1,1-dimethylethyl ester, (R)- (9CI)
(CA INDEX NAME)

CN L-Proline, 1-[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]cyclopentylacetyl]-, 1,1-dimethylethyl ester, (S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 159582-70-4 CAPLUS

CN Glycinamide, 1-[[4-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]phenyl]cyclopentylacetyl]-L-prolyl-L-2-phenyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159582-71-5 CAPLUS


CN Glycinamide, 1-[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]cyclopentylacetyl]-L-prolyl-L-2-phenyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW




RN 159652-40-1 CAPLUS
CN Glycinamide, 1-[[4-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]phenyl]cyclopentylacetyl]-L-prolyl-L-2-phenyl-, (S)- (9CI) (CA INDEX NAME)



RN 159652-41-2 CAPLUS
CN Glycinamide, 1-[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]cyclopentylacetyl]-L-prolyl-L-2-phenyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



L4 ANSWER 132 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1995:228863 CAPLUS

DN 122:80946

TI Synthesis and antibacterial activity of novel carbapenems with a catechol or hydroxypyridone moiety

AU Sunagawa, Makoto; Sasaki, Akira; Yamaga, Hiroshi; Shinagawa, Hisatoshi; Fukasawa, Masatomo; Sumita, Yoshihiro

CS Development Res. Laboratories I, Sumitomo Pharmaceuticals Res. Cent., Osaka, 554, Japan

SO Journal of Antibiotics (1994), 47(11), 1354-8

CODEN: JANTAJ; ISSN: 0021-8820

PB Japan Antibiotics Research Association

DT Journal

LA English

IT 141817-33-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and bactericidal activity of carbapenems with a catechol or hydroxypyridine moiety)

RN 141817-33-6 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[1-[(3,4-dihydroxyphenyl)acetyl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, [4R-[3(3S*,5S*),4 α ,5 β ,6.alpha.(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 133 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1994:701326 CAPLUS

DN 121:301326

TI Preparation of new dipeptide derivatives as neurokinin antagonists

IN Schnorrenberg, Gerd; Esser, Franz; Dollinger, Horst; Jung, Birgit;
Buerger, Erich

PA Boehringer Ingelheim KG, Germany

SO Ger. Offen., 49 pp.

CODEN: GWXXBX

DT Patent


LA German

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | DE 4243496 | A1 | 19940310 | DE 1992-4243496 | 19921222 |
| | WO 9405693 | A1 | 19940317 | WO 1993-EP2329 | 19930828 |
| | W: AU, BG, BY, CA, CZ, FI, HU, JP, KR, NO, NZ, PL, RU, SK, UA | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | EP 610487 | A1 | 19940817 | EP 1993-919208 | 19930828 |
| | EP 610487 | B1 | 19991110 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| | JP 07501085 | T | 19950202 | JP 1993-506852 | 19930828 |
| | HU 70475 | A2 | 19951030 | HU 1994-1323 | 19930828 |
| | AU 677792 | B2 | 19970508 | AU 1993-49547 | 19930828 |
| | AU 9349547 | A | 19940329 | | |
| | AT 186548 | T | 19991115 | AT 1993-919208 | 19930828 |
| | ES 2137998 | T3 | 20000101 | ES 1993-919208 | 19930828 |
| | EP 979827 | A1 | 20000216 | EP 1999-100929 | 19930828 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE | | | | |
| | ZA 9306472 | A | 19940627 | ZA 1993-6472 | 19930902 |
| | US 5596000 | A | 19970121 | US 1993-116090 | 19930902 |
| | FI 9401987 | A | 19940429 | FI 1994-1987 | 19940429 |
| | NO 9401611 | A | 19940502 | NO 1994-1611 | 19940502 |
| | US 5849918 | A | 19981215 | US 1995-460964 | 19950605 |
| | US 6147212 | A | 20001114 | US 1998-111498 | 19980708 |
| | GR 3032395 | T3 | 20000531 | GR 2000-400089 | 20000114 |
| PRAI | DE 1992-4229447 | A1 | 19920903 | | |
| | DE 1992-4243496 | A | 19921222 | | |
| | DE 1993-4315437 | A | 19930508 | | |
| | EP 1993-919208 | A3 | 19930828 | | |
| | WO 1993-EP2329 | W | 19930828 | | |
| | US 1993-116090 | A3 | 19930902 | | |
| | US 1995-460964 | A3 | 19950605 | | |
| OS | CASREACT 121:301326; MARPAT 121:301326 | | | | |
| IT | 159136-74-0P | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as neurokinin antagonist) | | | | |
| RN | 159136-74-0 CAPLUS | | | | |
| CN | Butanamide, 1-[(3,4-dimethoxyphenyl)acetyl]-trans-4-hydroxy-L-prolyl-N-methyl-4-phenyl-N-(phenylmethyl)-L-2-amino- (9CI) (CA INDEX NAME) | | | | |


Absolute stereochemistry.

10/712,456-ALW



L4 ANSWER 134 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1994:680551 CAPLUS
 DN 121:280551
 TI Preparation of piperidylcarbonylamino derivatives as platelet aggregation inhibitors
 IN Tjoeng, Foe S.; Toth, Mihaly V.
 PA G.D. Searle and Co., USA; Monsanto Co.
 SO PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9419341 | A1 | 19940901 | WO 1994-US513 | 19940125 |
| | W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | US 6268380 | B1 | 20010731 | US 1993-19923 | 19930219 |
| | AU 9461236 | A | 19940914 | AU 1994-61236 | 19940125 |
| PRAI | US 1993-19923 | A | 19930219 | | |
| | WO 1994-US513 | W | 19940125 | | |
| OS | MARPAT 121:280551 | | | | |
| IT | 158983-01-8P 158983-02-9P 158983-03-0P 158983-04-1P | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (preparation of piperidylcarbonylamino derivs. as platelet aggregation inhibitors) | | | | |
| RN | 158983-01-8 CAPLUS | | | | |
| CN | β -Alanine, N-[1-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]-L-prolyl]-3-(3-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME) | | | | |



RN 158983-02-9 CAPLUS
 CN β -Alanine, N-[1-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]-L-prolyl]-3-(3-pyridinyl)-, ethyl ester, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


10/712,456-ALW

CRN 158983-01-8
CMF C23 H28 N6 O4




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 158983-03-0 CAPLUS
CN β -Alanine, N-[1-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]-L-prolyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 158983-04-1 CAPLUS

10/712,456-ALW

CN β -Alanine, N-[1-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]-L-prolyl]-3-(3-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 158983-03-0
CMF C21 H24 N6 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 158983-09-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of piperidylcarbonylamino derivs. as platelet aggregation inhibitors)

RN 158983-09-6 CAPLUS

CN L-Proline, 1-[[[4-(4-cyanophenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 135 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1994:558192 CAPLUS
DN 121:158192

IN Boyd, Donald Bradford; Hauser, Kenneth Lee; Lifer, Sherryl Lynn; Marshall, Winston Stanley; Palkowitz, Alan David; Pfeifer, William; Reel, Jon Kevin; Simon, Richard Lee; Steinberg, Mitchell Irvin; et al.

PA Eli Lilly and Co., USA
SO Eur. Pat. Appl., 56 pp.
CODEN: EPXXDW

LA English

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | EP 573271 | A1 | 19931208 | EP 1993-304264 | 19930602 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| | US 5401851 | A | 19950328 | US 1993-49917 | 19930420 |
| PRAI | US 1992-892867 | A | 19920603 | | |
| | US 1993-49917 | A | 19930420 | | |

OS MARPAT 121:158192

IT 157177-14-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as angiotensin II antagonist)

RN 157177-14-5 CAPLUS

CN L-Proline, 4-[4-[2-(2-carboxy-1-pyrrolidinyl)-2-oxoethyl]phenoxy]-1-[1-oxo-2-[4-[(2-sulfobenzoyl)amino]-1H-imidazol-1-yl]octyl]-, [1(S*),2 α ,4 α (R*)]-(9CI) (CA INDEX NAME)

OC(=O)c1ccccc1C(=O)Nc2ncn(C[C@H](C(=O)N3C[C@@H](C(=O)O)C[C@H](C3)COC4=CC=CC=C4CC(=O)N5C[C@H](C(=O)O)CC5)C[C@H](C)CC2)c2

10/712,456-ALW

L4 ANSWER 136 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1994:557541 CAPLUS

DN 121:157541

TI (2-oxoquinolin-1-yl)methylphenylacetic acid antihypertensives and antiatherosclerotics

IN Mueller-Gliemann, Matthias; Dressel, Juergen; Fey, Peter; Hanco, Rudolf; Huebsch, Walter; Kraemer, Thomas; Mueller, Ulrich; Raddatz, Siegfried; Beuck, Martin; et al.

PA Bayer A.-G., Germany

SO Ger. Offen., 17 pp.

CODEN: GWXXBX


DT Patent

LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | DE 4301900 | A1 | 19940728 | DE 1993-4301900 | 19930125 |
| | EP 608709 | A1 | 19940803 | EP 1994-100366 | 19940112 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| | JP 08003139 | A | 19960109 | JP 1994-18804 | 19940120 |
| PRAI | DE 1993-4301900 | A | 19930125 | | |
| OS | MARPAT 121:157541 | | | | |
| IT | 157312-10-2P 157312-11-3P 157312-12-4P 157312-14-6P | | | | |
| | RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as antihypertensive and antiatherosclerotic) | | | | |
| RN | 157312-10-2 CAPLUS | | | | |
| CN | L-Proline, 1-[cyclopentyl[4-[(2-oxo-1(2H)-quinolinyl)methyl]phenyl]acetyl]- , 1,1-dimethylethyl ester (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.




RN 157312-11-3 CAPLUS

CN L-Proline, 1-[cyclopentyl[4-[(2-oxo-1(2H)-quinolinyl)methyl]phenyl]acetyl]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/712,456-ALW



RN 157312-12-4 CAPLUS


CN 2-Pyrrolidinecarboxamide, 1-[cyclopentyl[4-[(2-oxo-1(2H)-quinolinyl)methyl]phenyl]acetyl]-N-(2-hydroxy-1-phenylethyl)- (9CI) (CA INDEX NAME)



RN 157312-14-6 CAPLUS


CN Glycinamide, 1-[cyclopentyl[4-[(2-oxo-1(2H)-quinolinyl)methyl]phenyl]acetyl]-L-prolyl-2-phenyl- (9CI) (CA INDEX NAME)

10/712,456-ALW




L4 ANSWER 137 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1993:626402 CAPLUS
 DN 119:226402
 TI Intramolecular photochemistry in β -turned dipeptide bridged molecules
 AU Tamiaki, Hitoshi; Kiyomori, Ayumu; Maruyama, Kazuhiro
 CS Fac. Sci., Kyoto Univ., Kyoto, 606, Japan
 SO Bulletin of the Chemical Society of Japan (1993), 66(6), 1768-72
 CODEN: BCSJA8; ISSN: 0009-2673
 DT Journal
 LA English
 IT 150881-15-5P 150881-16-6P 150881-17-7P
 150881-18-8P 150881-19-9P 150881-20-2P
 150903-47-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and photolysis of, effect of alkyl chain and conformation on
 quantum yield of)
 RN 150881-15-5 CAPLUS
 CN Glycinamide, 1-[(4-benzoylphenyl)acetyl]-L-prolyl-N-propyl- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 150881-16-6 CAPLUS
 CN Glycinamide, 1-[(4-benzoylphenyl)acetyl]-L-prolyl-N-butyl- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



RN 150881-17-7 CAPLUS
 CN Glycinamide, 1-[(4-benzoylphenyl)acetyl]-L-prolyl-N-pentyl- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

RN 150881-18-8 CAPLUS

CN Glycinamide, 1-[(4-benzoylphenyl)acetyl]-L-prolyl-N-hexyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 150881-19-9 CAPLUS

CN Glycinamide, 1-[(4-benzoylphenyl)acetyl]-L-prolyl-N-heptyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 150881-20-2 CAPLUS

CN L-Serinamide, 1-[(4-benzoylphenyl)acetyl]-D-prolyl-N-methyl-O-pentyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 150903-47-2 CAPLUS

CN L-Serinamide, 1-[(4-benzoylphenyl)acetyl]-D-prolyl-O-methyl-N-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 138 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1993:495338 CAPLUS

DN 119:95338

TI Preparation of 1-[(3,4,5-trimethoxyphenyl)glyoxyl]pipecolic esters as immunosuppressive compounds

IN Armistead, David M.

PA Vertex Pharmaceuticals Inc., USA

SO PCT Int. Appl., 67 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 4

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 9219593 | A1 | 19921112 | WO 1992-US3913 | 19920511 |
| | W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE | | | | |
| | RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG | | | | |
| | CA 2102180 | A1 | 19921110 | CA 1992-2102180 | 19920511 |
| | CA 2102180 | C | 20020723 | | |
| | AU 9219957 | A | 19921221 | AU 1992-19957 | 19920511 |
| | EP 584223 | A1 | 19940302 | EP 1992-912076 | 19920511 |
| | EP 584223 | B1 | 19990811 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| | JP 06508125 | T | 19940914 | JP 1992-512042 | 19920511 |
| | JP 3145709 | B2 | 20010312 | | |
| | HU 68332 | A2 | 19950628 | HU 1993-3184 | 19920511 |
| | HU 217621 | B | 20000328 | | |
| | AT 183178 | T | 19990815 | AT 1992-912076 | 19920511 |
| | ES 2137186 | T3 | 19991216 | ES 1992-912076 | 19920511 |
| | FI 104967 | B1 | 20000515 | FI 1993-4925 | 19931108 |
| | HK 1013994 | A1 | 20000915 | HK 1998-115248 | 19981223 |
| | GR 3031825 | T3 | 20000229 | GR 1999-402915 | 19991111 |
| PRAI | US 1991-697785 | A | 19910509 | | |
| | WO 1992-US3913 | A | 19920511 | | |
| OS | MARPAT 119:95338 | | | | |
| IT | 145913-35-5 | | | | |
| | RL: RCT (Reactant); RACT (Reactant or reagent) | | | | |
| | (immunosuppressant) | | | | |
| RN | 145913-35-5 CAPLUS | | | | |
| CN | L-Proline, 1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, 1-(3-phenylpropyl)-4-(2-pyridinyl)butyl ester (9CI) (CA INDEX NAME) | | | | |


Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 139 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1993:169566 CAPLUS
DN 118:169566
TI Highly selective tripeptide thrombin inhibitors
AU Shuman, Robert T.; Rothenberger, Robert B.; Campbell, Charles S.; Smith, Gerald F.; Gifford-Moore, Donetta S.; Gesellchen, Paul D.
CS Lilly Res. Lab., Eli Lilly and Co., Indianapolis, IN, 46285, USA
SO Journal of Medicinal Chemistry (1993), 36(3), 314-19
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 118:169566
IT 146622-05-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and peptide coupling of, with arginine lactam)
RN 146622-05-1 CAPLUS
CN L-Proline, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 141972-93-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and thrombin-inhibiting activity of)
RN 141972-93-2 CAPLUS
CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-D-2-(4-hydroxyphenyl)glycyl-N-[4-[(aminoiminomethyl)amino]-1-formylbutyl]-, (S)-, diacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 141972-92-1
CMF C24 H36 N6 O6

Absolute stereochemistry.


10/712,456-ALW



CM 2

CRN 64-19-7


CMF C2 H4 O2



10/712,456-ALW

L4 ANSWER 140 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1993:6860 CAPLUS
DN 118:6860
TI Preparation of substituted bicyclic 3-arylpyrrolidine-2,4-dione
derivatives as pesticides and herbicides
IN Santel, Hans Joachim; Schmidt, Robert R.; Wachendorff-Neumann, Ulrike;
Erdelen, Christoph; Bretschneider, Thomas; Fischer, Reiner; Hagemann,
Hermann; Krueger, Bernd Wieland; Luerssen, Klaus
PA Bayer A.-G., Germany
SO Ger. Offen., 44 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | DE 4102778 | A1 | 19920806 | DE 1991-4102778 | 19910131 |
| | EP 501129 | A1 | 19920902 | EP 1992-100826 | 19920120 |
| | EP 501129 | B1 | 19990714 | | |
| | R: BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL | | | | |
| | ES 2135392 | T3 | 19991101 | ES 1992-100826 | 19920120 |
| | US 5288874 | A | 19940222 | US 1992-826303 | 19920124 |
| | JP 04338390 | A | 19921125 | JP 1992-34016 | 19920127 |
| | JP 3216901 | B2 | 20011009 | | |
| | ZA 9200643 | A | 19921028 | ZA 1992-643 | 19920130 |
| | BR 9200318 | A | 19921006 | BR 1992-318 | 19920131 |
| | US 5585384 | A | 19961217 | US 1994-292111 | 19940817 |
| | US 5693663 | A | 19971202 | US 1996-700264 | 19960820 |
| PRAI | DE 1991-4102778 | A | 19910131 | | |
| | US 1992-826303 | A3 | 19920124 | | |
| | US 1993-134430 | B2 | 19931008 | | |
| | US 1994-292111 | A3 | 19940817 | | |
| OS | MARPAT 118:6860 | | | | |
| IT | 144946-35-0P 144946-36-1P | | | | |
| | RL: SPN (Synthetic preparation); PREP (Preparation) | | | | |
| | (preparation of, as intermediate for pesticides and herbicides) | | | | |
| RN | 144946-35-0 CAPLUS | | | | |
| CN | Proline, 4,5-dimethyl-1-[(2,4,6-trimethylphenyl)acetyl]-, ethyl ester | | | | |
| | (9CI) (CA INDEX NAME) | | | | |




RN 144946-36-1 CAPLUS
CN L-Proline, 4-hydroxy-1-[(2,4,6-trimethylphenyl)acetyl]-, methyl ester,

10/712,456-ALW

trans- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 141 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1993:235 CAPLUS
DN 118:235
TI A series of highly selective thrombin inhibitors
AU Shuman, Robert T.; Rothenberger, Robert B.; Campbell, Charles S.; Smith, Gerald F.; Gifford-Moore, Donetta S.; Gesellchen, Paul D.
CS Lilly Res. Lab., Indianapolis, IN, 46285, USA
SO Pept.: Chem. Biol., Proc. Am. Pept. Symp., 12th (1992), Meeting Date 1991, 801-2. Editor(s): Smith, John A.; Rivier, Jean E. Publisher: ESCOM, Leiden, Neth.
CODEN: 57XGA9
DT Conference
LA English
IT 141972-92-1
RL: BIOL (Biological study)
(as thrombin inhibitor, structure in relation to)
RN 141972-92-1 CAPLUS
CN L-Prolinamide, (2R)-N-[(1,1-dimethylethoxy)carbonyl]-2-(4-hydroxyphenyl)glycyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-formylbutyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 142 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1992:449275 CAPLUS
 DN 117:49275
 TI Preparation of tripeptides as antithrombotic agents
 IN Gesellchen, Paul David; Shuman, Robert Theodore
 PA Eli Lilly and Co., USA
 SO Eur. Pat. Appl., 24 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | EP 479489 | A2 | 19920408 | EP 1991-308785 | 19910926 |
| | EP 479489 | A3 | 19931013 | | |
| | EP 479489 | B1 | 20030319 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| | IL 99527 | A | 19970814 | IL 1991-99527 | 19910919 |
| | CA 2052013 | A1 | 19920329 | CA 1991-2052013 | 19910923 |
| | CA 2052013 | C | 20010130 | | |
| | HU 59162 | A2 | 19920428 | HU 1991-3037 | 19910923 |
| | HU 217441 | B | 20000128 | | |
| | ZA 9107572 | A | 19930323 | ZA 1991-7572 | 19910923 |
| | CZ 285980 | B6 | 19991215 | CZ 1991-2913 | 19910923 |
| | SK 281731 | B6 | 20010710 | SK 1991-2913 | 19910923 |
| | NO 9103773 | A | 19920330 | NO 1991-3773 | 19910926 |
| | NO 309984 | B1 | 20010430 | | |
| | AU 9184780 | A | 19920402 | AU 1991-84780 | 19910926 |
| | AU 645347 | B2 | 19940113 | | |
| | EP 684258 | A2 | 19951129 | EP 1995-201959 | 19910926 |
| | EP 684258 | A3 | 19960110 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| | EP 685489 | A2 | 19951206 | EP 1995-201960 | 19910926 |
| | EP 685489 | A3 | 19960110 | | |
| | EP 685489 | B1 | 20011219 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| | RU 2077538 | C1 | 19970420 | RU 1991-5001658 | 19910926 |
| | EP 837071 | A1 | 19980422 | EP 1997-203616 | 19910926 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| | KR 219993 | B1 | 19991001 | KR 1991-16772 | 19910926 |
| | AT 211147 | T | 20020115 | AT 1995-201960 | 19910926 |
| | ES 2169105 | T3 | 20020701 | ES 1995-201960 | 19910926 |
| | AT 234857 | T | 20030415 | AT 1991-308785 | 19910926 |
| | ES 2194835 | T3 | 20031201 | ES 1991-308785 | 19910926 |
| | FI 9104566 | A | 19920329 | FI 1991-4566 | 19910927 |
| | FI 107733 | B1 | 20010928 | | |
| | CN 1060472 | A | 19920422 | CN 1991-109042 | 19910927 |
| | CN 1036399 | B | 19971112 | | |
| | BR 9104181 | A | 19920602 | BR 1991-4181 | 19910927 |
| | JP 04257600 | A | 19920911 | JP 1991-249093 | 19910927 |
| | JP 3023019 | B2 | 20000321 | | |
| | HU 9500399 | A3 | 19951030 | HU 1995-399 | 19950622 |
| PRAI | US 1990-589553 | A | 19900928 | | |
| | US 1991-756091 | A | 19910906 | | |
| | EP 1991-308785 | A3 | 19910926 | | |
| OS | MARPAT 117:49275 | | | | |
| IT | 141972-93-2P 141973-11-7P 141973-13-9P | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) | | | | |
| | (preparation of, as antithrombotic) | | | | |

10/712,456-ALW

RN 141972-93-2 CAPLUS


CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-D-2-(4-hydroxyphenyl)glycyl-N-[4-[(aminoiminomethyl)amino]-1-formylbutyl]-, (S)-, diacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 141972-92-1

CMF C24 H36 N6 O6


Absolute stereochemistry.



CM 2

CRN 64-19-7

CMF C2 H4 O2



RN 141973-11-7 CAPLUS


CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-D-2-(4-methoxyphenyl)glycyl-N-[4-[(aminoiminomethyl)amino]-1-formylbutyl]-, (S)-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 141973-10-6


CMF C25 H38 N6 O6

10/712,456-ALW



CM 2


CRN 64-19-7
CMF C2 H4 O2



RN 141973-13-9 CAPLUS
CN L-Prolinamide, N-acetyl-D-2-(4-methoxyphenyl)glycyl-N-[4-
[(aminoiminomethyl)amino]-1-formylbutyl]-, (S)-, monoacetate (9CI) (CA
INDEX NAME)

CM 1


CRN 141973-12-8
CMF C22 H32 N6 O5



CM 2

CRN 64-19-7
CMF C2 H4 O2

10/712,456-ALW





L4 ANSWER 143 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1992:407729 CAPLUS
 DN 117:7729
 TI Beta-lactam compounds, and their production and use
 IN Sunagawa, Makoto; Sasaki, Akira; Yamaga, Hiroshi; Shinagawa, Hisatoshi;
 Fukasawa, Masatomo; Sumita, Yoshihiro
 PA Sumitomo Pharmaceuticals Co., Ltd., Japan
 SO Eur. Pat. Appl., 129 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | EP 472062 | A1 | 19920226 | EP 1991-113384 | 19910809 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| | AU 9181724 | A | 19920213 | AU 1991-81724 | 19910808 |
| | AU 644008 | B2 | 19931202 | | |
| | CA 2048887 | A1 | 19920211 | CA 1991-2048887 | 19910809 |
| | JP 05230061 | A | 19930907 | JP 1991-225177 | 19910809 |
| | JP 3242677 | B2 | 20011225 | | |
| PRAI | JP 1990-212102 | A | 19900810 | | |
| | JP 1990-415862 | A | 19901227 | | |
| | JP 1990-416070 | A | 19901228 | | |
| OS | MARPAT 117:7729 | | | | |
| IT | 141817-31-4P 141817-32-5P 141817-33-6P | | | | |
| | 141817-37-0P 141817-38-1P 141817-39-2P | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) | | | | |
| | (preparation of, as antimicrobial) | | | | |
| RN | 141817-31-4 CAPLUS | | | | |
| CN | 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[1-[[3,4-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]acetyl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4-nitrophenyl)methyl ester, [4R-[3(3S*,5S*),4 α ,5 β ,6 α (R*)]]- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.

PAGE 1-A







RN 141817-32-5 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[1-[(3,4-dihydroxyphenyl)acetyl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4-nitrophenyl)methyl ester, [4R-[3(3S*,5S*),4 α ,5 β ,6 α (R*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141817-33-6 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[1-[(3,4-dihydroxyphenyl)acetyl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, [4R-[3(3S*,5S*),4 α ,5 β ,6.alpha.(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

RN 141817-37-0 CAPLUS


CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[1-[[[3,4-bis[[1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]amino]carbonyl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4-nitrophenyl)methyl ester, [4R-[3(3S*,5S*),4 α ,5 β ,6 β],6 α -(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A



RN 141817-38-1 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[1-[[[3,4-dihydroxyphenyl]amino]carbonyl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4-nitrophenyl)methyl ester, [4R-[3(3S*,5S*),4 α ,5 β ,6 α -(R*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141817-39-2 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[1-[[[(3,4-dihydroxyphenyl)amino]carbonyl]-5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, [4R-[3(3S*,5S*);4 α ,5 β ,6 α (R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 144 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1992:6967 CAPLUS

DN 116:6967

TI Preparation of amino acid (4-azolylmethyl)anilides as angiotensin II antagonists

IN Hodges, John C.; Sircar, Ila

PA Warner-Lambert Co., USA

SO U.S., 14 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|------------------------------------|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | US 5041552 | A | 19910820 | US 1990-529071 | 19900525 |
| | US 5045540 | A | 19910903 | US 1991-684638 | 19910412 |
| PRAI | US 1990-529071 | A3 | 19900525 | | |
| OS | CASREACT 116:6967; MARPAT 116:6967 | | | | |
| IT | 137686-02-3P | | | | |

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as angiotensin II antagonist)

RN 137686-02-3 CAPLUS

CN L-Proline, 1-[[[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/712,456-ALW


L4 ANSWER 145 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1991:471509 CAPLUS
DN 115:71509
TI Asymmetric synthesis of heterocycles using charge transfer complex intermediates
AU Lemaire, Marc; Guy, Alain; Imbert, Dominique; Guette, Jean Paul
CS Lab. Catal. Synth. Org., CNRS, Villeurbanne, 69622, Fr.
SO New Journal of Chemistry (1991), 15(5), 379-84
CODEN: NJCHE5; ISSN: 1144-0546
DT Journal
LA English
OS CASREACT 115:71509
IT 135066-10-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and attempted oxidative cyclization of, with DDQ)
RN 135066-10-3 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[[4-(1-methylethoxy)phenyl]acetyl]-N-(phenylmethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 105988-50-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oxidative cyclization of, with DDQ)
RN 105988-50-9 CAPLUS
CN L-Proline, 1-[[4-(1-methylethoxy)phenyl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 107672-35-5P 135066-17-0P 135066-18-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oxidative cyclization of, with DDQ, morpholinedione from)
RN 107672-35-5 CAPLUS
CN L-Proline, 1-[(3,4-dimethoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 135066-17-0 CAPLUS

CN L-Proline, 1-[(4-propoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 135066-18-1 CAPLUS

CN L-Proline, 1-[[4-(1,1-dimethylethoxy)phenyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 135066-20-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and oxidative cyclization of, with DDQ, morpholinedione via)

RN 135066-20-5 CAPLUS

CN L-Proline, 1-[(4-methoxy-1-naphthalenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 146 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1991:429390 CAPLUS

DN 115:29390

TI Preparation of N-(pyrrolidinyl-or piperidinylalkyl)dibenzo[b,e][1,4]thiazepines as calcium antagonists for treatment of gastrointestinal motility disorders

IN Alker, David; Bass, Robert J.; Cross, Peter Edward

PA Pfizer Ltd., UK; Pfizer Inc.

SO Eur. Pat. Appl., 66 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | EP 404359 | A1 | 19901227 | EP 1990-305718 | 19900525 |
| | EP 404359 | B1 | 19940629 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| | US 5071844 | A | 19911210 | US 1990-527616 | 19900523 |
| | CA 2017535 | A1 | 19901127 | CA 1990-2017535 | 19900525 |
| | CA 2017535 | C | 20000229 | | |
| | NO 9002336 | A | 19901128 | NO 1990-2336 | 19900525 |
| | AU 9055954 | A | 19901129 | AU 1990-55954 | 19900525 |
| | DD 294718 | A5 | 19911010 | DD 1990-340993 | 19900525 |
| | HU 58329 | A2 | 19920228 | HU 1990-3197 | 19900525 |
| | ES 2055867 | T3 | 19940901 | ES 1990-305718 | 19900525 |
| | FI 96950 | B | 19960614 | FI 1990-2632 | 19900525 |
| | FI 96950 | C | 19960925 | | |
| | CN 1047673 | A | 19901212 | CN 1990-103954 | 19900526 |
| | JP 03017079 | A | 19910125 | JP 1990-138177 | 19900528 |
| | JP 05007389 | B | 19930128 | | |
| PRAI | GB 1989-12303 | A | 19890527 | | |

OS MARPAT 115:29390

IT 133714-93-9P 134621-58-2P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as intermediate for dibenzothiazepine calcium antagonists)

RN 133714-93-9 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[2-[[(2-bromophenyl)methyl]thio]phenyl]-1-[(4-methoxyphenyl)acetyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 134621-58-2 CAPLUS

CN L-Proline, 1-[(4-methoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



10/712,456-ALW

L4 ANSWER 147 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1991:110785 CAPLUS
DN 114:110785
TI Enantioselective α -monofluorination of benzylic derivatives
IN Chebli, Samir; Laurent, Eliane; Marquet, Bernard
PA Rhone-Poulenc Chimie SA, Fr.
SO Fr. Demande, 8 pp.
CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------|------|----------|-----------------|----------|
| | ----- | --- | ----- | ----- | ----- |
| PI | FR 2641002 | A1 | 19900629 | FR 1988-17072 | 19881223 |
| PRAI | FR 1988-17072 | | 19881223 | | |
| OS | MARPAT 114:110785 | | | | |
| IT | 130517-54-3 | | | | |

RL: RCT (Reactant); RACT (Reactant or reagent)
(enantioselective fluorination of, electrochem.)

RN 130517-54-3 CAPLUS

CN L-Proline, 1-[(4-methoxyphenyl)acetyl]-, 1-methylethyl ester (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



10/712,456-ALW


L4 ANSWER 148 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1990:611511 CAPLUS
DN 113:211511
TI Diastereoselective fluorination at benzylic position by anodic oxidation
AU Kabore, Leopold; Chebli, Samir; Faure, Rene; Laurent, Eliane; Marquet, Bernard
CS Lab. Chim. Org., UCB-Lyon I, Villeurbanne, 69622, Fr.
SO Tetrahedron Letters (1990), 31(22), 3137-40
CODEN: TELEAY; ISSN: 0040-4039
DT Journal
LA English
OS CASREACT 113:211511
IT 130517-60-1P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and absolute configuration of)
RN 130517-60-1 CAPLUS
CN L-Proline, 1-[fluoro(4-methoxyphenyl)acetyl]-, 1-methylethyl ester, (S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 130517-61-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 130517-61-2 CAPLUS
CN L-Proline, 1-[fluoro(4-methoxyphenyl)acetyl]-, 1-methylethyl ester, (R)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 130517-54-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(regio- and stereoselective electrochem. fluorination of)
RN 130517-54-3 CAPLUS
CN L-Proline, 1-[(4-methoxyphenyl)acetyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW




10/712,456-ALW

L4 ANSWER 149 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1990:591153 CAPLUS
DN 113:191153
TI Preparation of fused 3-arylpyrrolidine-2,4-diones as pesticides
IN Fischer, Reiner; Krebs, Andreas; Marhold, Albrecht; Santel, Hans Joachim;
Schmidt, Robert R.; Luerksen, Klaus; Hagemann, Hermann; Becker, Benedikt;
Schaller, Klaus; Stendel, Wilhelm
PA Bayer A.-G., Germany
SO Eur. Pat. Appl., 60 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | EP 355599 | A1 | 19900228 | EP 1989-114789 | 19890810 |
| | EP 355599 | B1 | 19930519 | | |
| | R: BE, CH, DE, ES, FR, GB, GR, IT, LI, NL | | | | |
| | DE 3831852 | A1 | 19900222 | DE 1988-3831852 | 19880920 |
| | DE 3913682 | A1 | 19901031 | DE 1989-3913682 | 19890426 |
| | US 5091537 | A | 19920225 | US 1990-564267 | 19900808 |
| | US 5142065 | A | 19920825 | US 1991-710411 | 19910605 |
| PRAI | DE 1988-3828404 | A | 19880820 | | |
| | DE 1988-3831852 | A | 19880920 | | |
| | DE 1989-3913682 | A | 19890426 | | |
| | US 1989-391227 | A3 | 19890808 | | |
| | US 1990-564267 | A3 | 19900808 | | |
| OS | CASREACT 113:191153; MARPAT 113:191153 | | | | |
| IT | 129009-78-5P 129009-79-6P | | | | |
| | RL: SPN (Synthetic preparation); PREP (Preparation) | | | | |
| | (preparation of, as intermediate for arylpyrrolidinedione pesticides) | | | | |
| RN | 129009-78-5 CAPLUS | | | | |
| CN | L-Proline, 1-[(2,4,6-trimethylphenyl)acetyl]- (9CI) (CA INDEX NAME) | | | | |


Absolute stereochemistry.



RN 129009-79-6 CAPLUS
CN L-Proline, 1-[(2,4,6-trimethylphenyl)acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



L4 ANSWER 150 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1989:633688 CAPLUS

DN 111:233688

TI Preparation and testing of peptidylhydroxamic acid derivatives as collagenase inhibitors

IN Kotake, Shinjiro; Okayama, Tooru; Ohata, Masami; Morikawa, Tadanori; Nagai, Yutaka

PA Fuji Chemicals Industrial Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 11 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | JP 01146896 | A | 19890608 | JP 1987-305836 | 19871204 |
| PRAI | JP 1987-305836 | | 19871204 | | |
| OS | MARPAT 111:233688 | | | | |
| IT | 123984-02-1P 123984-09-8P 123984-10-1P 123984-11-2P | | | | |

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as collagenase inhibitor)

RN 123984-02-1 CAPLUS

CN Glycinamide, 1-[2-(4-hydroxyphenyl)-1-oxopropyl]-L-prolyl-D-leucyl-N-hydroxy-N2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 123984-09-8 CAPLUS

CN L-Alaninamide, 1-[2-(4-hydroxyphenyl)-1-oxopropyl]-L-prolyl-L-leucyl-N-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 123984-10-1 CAPLUS

CN D-Alaninamide, 1-[2-(4-hydroxyphenyl)-1-oxopropyl]-L-prolyl-D-leucyl-N-hydroxy- (9CI) (CA INDEX NAME)

10/712,456-ALW


Absolute stereochemistry.



RN 123984-11-2 CAPLUS

CN L-Valinamide, 1-[2-(4-hydroxyphenyl)-1-oxopropyl]-L-prolyl-L-leucyl-N-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 123984-26-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of, as intermediate for peptidylhydroxamic acid collagenase inhibitor)

RN 123984-26-9 CAPLUS

CN Glycine, N-[N-[1-[2-(4-hydroxyphenyl)-1-oxopropyl]-L-prolyl]-D-leucyl]-N-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 151 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1989:66645 CAPLUS
DN 110:66645
TI Second harmonic generation by carbamic acid derivatives
IN Tiers, George V. D.
PA Minnesota Mining and Manufacturing Co., USA
SO Eur. Pat. Appl., 43 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------------------------|------|----------|-----------------|----------|
| PI | EP 271251 | A1 | 19880615 | EP 1987-310372 | 19871125 |
| | R: CH, DE, FR, GB, IT, LI, NL, SE | | | | |
| | AU 8780678 | A | 19880609 | AU 1987-80678 | 19871104 |
| | AU 620796 | B2 | 19920227 | | |
| | JP 63163828 | A | 19880707 | JP 1987-305533 | 19871202 |
| PRAI | US 1986-937234 | A | 19861203 | | |
| OS | MARPAT 110:66645 | | | | |
| IT | 117368-94-2P | | | | |


RL: PREP (Preparation)

(preparation of, as optical nonlinear material for second harmonic generation)

RN 117368-94-2 CAPLUS

CN L-Proline, 1-[[[(4-nitrophenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/712,456-ALW


L4 ANSWER 152 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1988:611411 CAPLUS
DN 109:211411
TI Studies on pyrrolidinones. Synthesis of N-acylpyroglutamic acids having
bactericide and fungicide properties
AU Rigo, Benoit; Lespagnol, Charles; Pauly, Marc
CS Lab. Synth. Org., Hautes Etud. Ind., Lille, 59046, Fr.
SO Journal of Heterocyclic Chemistry (1988), 25(1), 59-63
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
OS CASREACT 109:211411
IT 98062-44-3P 117286-67-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antibacterial and antifungal activities of)
RN 98062-44-3 CAPLUS
CN L-Proline, 1-[(4-nitrophenyl)acetyl]-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117286-67-6 CAPLUS
CN L-Proline, 1-[(4-methoxyphenyl)acetyl]-5-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 153 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1988:570824 CAPLUS
DN 109:170824
TI Studies on pyrrolidinones. Synthesis of N-acylpyrroglutamic esters with
bactericide and fungicide properties
AU Rigo, Benoit; Lespagnol, Charles; Pauly, Marc
CS Lab. Synth. Org., Ec. Hautes Etud. Ind., Lille, 59046, Fr.
SO Journal of Heterocyclic Chemistry (1988), 25(1), 49-57
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
OS CASREACT 109:170824
IT 98062-41-0P 98062-42-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological
study); PREP (Preparation)
(preparation and antibacterial activity of)
RN 98062-41-0 CAPLUS
CN L-Proline, 1-[(4-nitrophenyl)acetyl]-5-oxo-, methyl ester (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 98062-42-1 CAPLUS
CN L-Proline, 1-[(4-methoxyphenyl)acetyl]-5-oxo-, methyl ester (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



10/712,456-ALW

L4 ANSWER 154 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1988:510249 CAPLUS

DN 109:110249

TI Preparation of 4-hydroxy-2(5H)-thiophenones and -pyrrolinones as
circulatory system oxygen and radical scavengers

IN Terao, Shinji; Hirata, Minoru

PA Takeda Chemical Industries, Ltd., Japan

SO Eur. Pat. Appl., 35 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|-------|----------|-----------------|----------|
| | ----- | ----- | ----- | ----- | ----- |
| PI | EP 262399 | A2 | 19880406 | EP 1987-112444 | 19870827 |
| | EP 262399 | A3 | 19890426 | | |
| | EP 262399 | B1 | 19930203 | | |
| | R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| | JP 63159367 | A | 19880702 | JP 1987-198454 | 19870807 |
| | JP 08009593 | B | 19960131 | | |
| | US 4925868 | A | 19900515 | US 1987-84177 | 19870812 |
| | CA 1321390 | C | 19930817 | CA 1987-545176 | 19870824 |
| | AT 85325 | T | 19930215 | AT 1987-112444 | 19870827 |
| PRAI | JP 1986-204833 | A | 19860829 | | |
| | EP 1987-112444 | A | 19870827 | | |

OS MARPAT 109:110249

IT 115882-44-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation and reaction of, in preparation of circulatory system oxygen
and radical scavengers)

RN 115882-44-5 CAPLUS

CN L-Proline, 1-[[4-(dodecyloxy)phenyl]acetyl]-, ethyl ester (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



10/712,456-ALW


L4 ANSWER 155 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1987:176711 CAPLUS
DN 106:176711
TI A novel and stereoselective synthesis of (\pm)-cephalotaxine and its analog
AU Yasuda, Shingo; Yamada, Toru; Hanaoka, Miyoji
CS Fac. Pharm. Sci., Kanazawa Univ., Kanazawa, 920, Japan
SO Tetrahedron Letters (1986), 27(18), 2023-6
CODEN: TELEAY; ISSN: 0040-4039
DT Journal
LA English
OS CASREACT 106:176711
IT 107672-34-4P 107672-35-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, in stereoselective synthesis of cephalotaxine)
RN 107672-34-4 CAPLUS
CN L-Proline, 1-[(3,4-dimethoxyphenyl)acetyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 107672-35-5 CAPLUS
CN L-Proline, 1-[(3,4-dimethoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

L4 ANSWER 156 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1987:102676 CAPLUS
DN 106:102676
TI N-Acylpyrrolidine derivatives, their preparation, their pharmaceutical composition and use
IN Tanaka, Takaharu; Saitoh, Masayuki; Hashimoto, Masaki; Higuchi, Naoki
PA Suntory, Ltd., Japan
SO Eur. Pat. Appl., 33 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | EP 201742 | A2 | 19861120 | EP 1986-105232 | 19860416 |
| | EP 201742 | A3 | 19881214 | | |
| | EP 201742 | B1 | 19921230 | | |
| | R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE | | | | |
| | JP 61238776 | A | 19861024 | JP 1985-80870 | 19850416 |
| | JP 06023190 | B | 19940330 | | |
| | US 4701465 | A | 19871020 | US 1986-852711 | 19860416 |
| | CA 1267149 | A1 | 19900327 | CA 1986-506768 | 19860416 |
| | AT 84025 | T | 19930115 | AT 1986-105232 | 19860416 |
| PRAI | JP 1985-80870 | A | 19850416 | | |
| | EP 1986-105232 | A | 19860416 | | |
| OS | MARPAT 106:102676 | | | | |
| IT | 106789-32-6P | | | | |
| | RL: SPN (Synthetic preparation); PREP (Préparation) (preparation of, as anti-amnesic and prolyl endopeptidase inhibitor) | | | | |
| RN | 106789-32-6 CAPLUS | | | | |
| CN | L-Proline, 1-[(4-methoxyphenyl)acetyl]-, methyl ester (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.




L4 ANSWER 157 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1987:32128 CAPLUS
 DN 106:32128
 TI Asymmetric control of oxidation of aromatic substrates using a
 donor-acceptor interaction
 AU Lemaire, Marc; Guy, Alain; Imbert, Dominique; Guette, Jean Paul
 CS Lab. Chim. Org., Conserv. Natl. Arts Metiers, Paris, 75141, Fr.
 SO Journal of the Chemical Society, Chemical Communications (1986), (10),
 741-2
 CODEN: JCCCAT; ISSN: 0022-4936
 DT Journal
 LA English
 OS CASREACT 106:32128
 IT 105988-50-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (oxidative cyclization of, stereoselective)
 RN 105988-50-9 CAPLUS
 CN L-Proline, 1-[[4-(1-methylethoxy)phenyl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 105988-47-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (oxidation of, stereoselective)
 RN 105988-47-4 CAPLUS
 CN L-Proline, 1-[[4-(1-methylethoxy)phenyl]acetyl]-, 1-methylethyl ester
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 105988-48-5P 105988-49-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 105988-48-5 CAPLUS
 CN L-Proline, 1-[(acetyloxy)[4-(1-methylethoxy)phenyl]acetyl]-, 1-methylethyl
 ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 105988-49-6 CAPLUS

CN L-Proline, 1-[(acetyloxy)[4-(1-methylethoxy)phenyl]acetyl]-, 1-methylethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

L4 ANSWER 158 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1986:627298 CAPLUS
DN 105:227298
TI N-Adamantylpyroglutamides
IN Laruelle, Claude; Lepant, Marcel; Raynier, Bernard
PA Panmedica S. A., Fr.
SO Fr. Demande, 30 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| | ----- | --- | ----- | ----- | ----- |
| PI | FR 2572399 | A1 | 19860502 | FR 1984-16656 | 19841031 |
| | FR 2572399 | B1 | 19870116 | | |
| | EP 187052 | A1 | 19860709 | EP 1985-401976 | 19851010 |
| | EP 187052 | B1 | 19900131 | | |
| | R: AT, BE, CH, DE, IT, LI, LU, NL, SE | | | | |
| | AT 49957 | T | 19900215 | AT 1985-401976 | 19851010 |
| | US 4661512 | A | 19870428 | US 1985-787995 | 19851016 |
| | AU 8548846 | A | 19860508 | AU 1985-48846 | 19851018 |
| | AU 583543 | B2 | 19890504 | | |
| | ZA 8508169 | A | 19860625 | ZA 1985-8169 | 19851024 |
| | ES 548357 | A1 | 19870116 | ES 1985-548357 | 19851030 |
| | JP 61109766 | A | 19860528 | JP 1985-246119 | 19851031 |
| PRAI | FR 1984-16656 | A | 19841031 | | |
| | EP 1985-401976 | A | 19851010 | | |
| OS | CASREACT 105:227298; MARPAT 105:227298 | | | | |
| IT | 105425-10-3P | | | | |
| | RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and hydrogenolysis of) | | | | |
| RN | 105425-10-3 CAPLUS | | | | |
| CN | L-Proline, 1-[(3,4-dimethoxyphenyl)acetyl]-5-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.




IT 105425-12-5P 105425-22-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as pharmaceutical)
RN 105425-12-5 CAPLUS

10/712,456-ALW


CN 2-Pyrrolidinecarboxamide, 1-[(3,4-dimethoxyphenyl)acetyl]-5-oxo-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 105425-22-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[(3,4-dimethoxyphenyl)acetyl]-5-oxo-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl- (9CI) (CA INDEX NAME)



IT 105425-11-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, chlorination, and amination of)

RN 105425-11-4 CAPLUS

CN L-Proline, 1-[(3,4-dimethoxyphenyl)acetyl]-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/712,456-ALW



L4 ANSWER 159 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1986:29388 CAPLUS

DN 104:29388

TI Synthesis and effect of affinity-labeled analogs and partial sequences of the bradykinin potentiating nonapeptide BPP9 α (teprotide)

AU Reissmann, S.; Paegelow, I.; Filatova, M. P.; Krit, N. A.; Arold, H.

CS Wissenschaftsbereich Allg. Biochem., Friedrich-Schiller-Univ., Jena, DDR-6900, Ger. Dem. Rep.

SO Pharmazie (1985), 40(5), 314-17

CODEN: PHARAT; ISSN: 0031-7144

DT Journal

LA German

IT 99741-86-3P

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation and bradykinin activation response to)


RN 99741-86-3 CAPLUS

CN Bradykinin potentiator B, 1-[1-[[4-[bis(2-chloroethyl)amino]phenyl]acetyl]-L-proline]-2-L-tryptophan-3-de-L-leucine-4-de-L-proline-8-L-glutamine-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





10/712,456-ALW

L4 ANSWER 160 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1985:523914 CAPLUS

DN 103:123914

TI Pyroglutamic derivatives, their intermediates and their use as bactericides or fungicides

IN Pauly, Marc

PA Laboratoires Serobiologiques S. A., Fr.

SO Eur. Pat. Appl., 33 pp.

CODEN: EPXXDW

DT Patent

LA French

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | EP 135444 | A1 | 19850327 | EP 1984-401803 | 19840912 |
| | EP 135444 | B1 | 19890118 | | |
| | R: AT, BE, CH, DE, GB, IT, LI, LU, NL, SE | | | | |
| | FR 2551751 | A1 | 19850315 | FR 1983-14480 | 19830912 |
| | FR 2551751 | B1 | 19860425 | | |
| | JP 60149559 | A | 19850807 | JP 1984-191420 | 19840912 |
| | AT 40113 | T | 19890215 | AT 1984-401803 | 19840912 |
| PRAI | FR 1983-14480 | A | 19830912 | | |
| | EP 1984-401803 | A | 19840912 | | |

OS CASREACT 103:123914; MARPAT 103:123914


IT 98062-41-0 98062-42-1 98062-44-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(bactericidal and fungicidal activities of)

RN 98062-41-0 CAPLUS

CN L-Proline, 1-[(4-nitrophenyl)acetyl]-5-oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 98062-42-1 CAPLUS

CN L-Proline, 1-[(4-methoxyphenyl)acetyl]-5-oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/712,456-ALW



RN 98062-44-3 CAPLUS

CN L-Proline, 1-[(4-nitrophenyl)acetyl]-5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/712,456-ALW

L4 ANSWER 161 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1984:423391 CAPLUS

DN 101:23391

TI Derivatives of 2,3,5,6,7,7a-hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazole-5-carboxylic acids

AU Fontanella, L.; Corsico, N.; Diena, A.; Occelli, E.

CS Lab. Ric., Gruppo Lepetit S.p.A., Milan, Italy

SO Farmaco, Edizione Scientifica (1984), 39(2), 133-53

CODEN: FRPSAX; ISSN: 0430-0920

DT Journal

LA Italian

OS CASREACT 101:23391


IT 90513-55-6P 90513-58-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and cyclocondensation-saponification of)


RN 90513-55-6 CAPLUS

CN 2,5-Pyrrolidinedicarboxylic acid, 1-[[[4-methylphenyl]amino]carbonyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 90513-58-9 CAPLUS


CN 2,5-Pyrrolidinedicarboxylic acid, 1-[[[4-methoxyphenyl]amino]carbonyl]-, diethyl ester (9CI) (CA INDEX NAME)



10/712,456-ALW

L4 ANSWER 162 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1983:72508 CAPLUS
DN 98:72508
TI Phenanthroindolizidine and related alkaloids: synthesis of tylophorine,
septicine, and deoxytylophorinine
AU Cragg, John E.; Herbert, Richard B.; Jackson, Frederick B.; Moody,
Christopher J.; Nicolson, Ian T.
CS Dep. Org. Chem., Univ. Leeds, Leeds, LS2 9JT, UK
SO Journal of the Chemical Society, Perkin Transactions 1: Organic and
Bio-Organic Chemistry (1972-1999) (1982), (10), 2477-85
CODEN: JCPRB4; ISSN: 0300-922X
DT Journal
LA English
OS CASREACT 98:72508
IT 84382-49-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate in synthesis of tylophorine)
RN 84382-49-0 CAPLUS
CN L-Proline, 1-[2,3-bis(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]-, methyl
ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



10/712,456-ALW

L4 ANSWER 163 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1982:85815 CAPLUS
DN 96:85815
TI Chiral route to some alkaloids through asymmetric iodolactonization
AU Takano, Seiichi; Murakata, Chikara; Imamura, Yoko; Tamura, Nobuhiko;
Ogasawara, Kunio
CS Pharm. Inst., Tohoku Univ., Sendai, 980, Japan
SO Heterocycles (1981), 16(8), 1291-4
CODEN: HTCYAM; ISSN: 0385-5414
DT Journal
LA English
IT 80758-88-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(asym. iodolactonization of)
RN 80758-88-9 CAPLUS
CN L-Proline, 1-[2-(2-butenyl)-2-(3,4-dimethoxyphenyl)-1-oxo-4-hexenyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




L4 ANSWER 164 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1976:165199 CAPLUS
 DN 84:165199
 TI Chromogenic or fluorescent substrate for enzyme determination
 IN Svendsen, Lars G.
 PA Pentapharm A.-G., Switz.
 SO Ger. Offen., 67 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | DE 2527932 | A1 | 19760122 | DE 1975-2527932 | 19750623 |
| | DE 2527932 | C2 | 19830421 | | |
| | CH 609154 | A5 | 19790215 | CH 1974-9210 | 19740702 |
| | ZA 7504019 | A | 19760526 | ZA 1975-4019 | 19750624 |
| | NO 7502386 | A | 19760105 | NO 1975-2386 | 19750630 |
| | NO 147212 | B | 19821115 | | |
| | NO 147212 | C | 19830223 | | |
| | DD 120715 | A5 | 19760620 | DD 1975-186968 | 19750630 |
| | US 4016042 | A | 19770405 | US 1975-592023 | 19750630 |
| | CA 1049506 | A1 | 19790227 | CA 1975-230464 | 19750630 |
| | NL 7507802 | A | 19760106 | NL 1975-7802 | 19750701 |
| | NL 188354 | B | 19920102 | | |
| | NL 188354 | C | 19920601 | | |
| | AU 7582631 | A | 19770106 | AU 1975-82631 | 19750701 |
| | SE 424635 | B | 19820802 | SE 1975-7545 | 19750701 |
| | SE 424635 | C | 19821111 | | |
| | BE 830911 | A1 | 19751103 | BE 1975-157901 | 19750702 |
| | FR 2279106 | A1 | 19760213 | FR 1975-20756 | 19750702 |
| | FR 2279106 | B1 | 19810430 | | |
| | JP 51029998 | A | 19760313 | JP 1975-81754 | 19750702 |
| | JP 56022280 | B | 19810523 | | |
| PRAI | CH 1974-9210 | A | 19740702 | | |
| | CH 1975-6088 | A | 19750509 | | |
| IT | 59188-48-6P 59188-50-0P | | | | |
| | RL: SPN (Synthetic preparation); PREP (Preparation) | | | | |
| | (preparation of) | | | | |
| RN | 59188-48-6 CAPLUS | | | | |
| CN | L-Ornithinamide, 1-[[4-[[(phenylmethoxy) carbonyl] amino] phenyl] acetyl]-L-prolyl-L-phenylalanyl-N5-[imino(nitroamino)methyl]-N-(4-nitrophenyl)-(9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.

PAGE 1-A




—NO₂—NO₂

RN 59188-50-0 CAPLUS

CN L-Argininamide, 1-[(4-aminophenyl)acetyl]-L-prolyl-L-phenylalanyl-N-(4-nitrophenyl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

10/712,456-ALW


L4 ANSWER 165 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1974:507384 CAPLUS
DN 81:107384
TI Interaction of amino acids, peptides and leather powder with isocyanates
shoe adhesive components
AU Balabanaova, E.; Evtimova, R.; Mladenova, L.; Tsyetkov, P.
CS Bulg.
SO Kozharska i Obuvna Promishlenost (1973), 14(3), 8-12
CODEN: KZOPAS; ISSN: 0368-7295
DT Journal
LA Bulgarian
IT 52392-31-1P
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation of)
RN 52392-31-1 CAPLUS
CN L-Proline, 1,1',1''-[methylidynetris(4,1-phenyleneiminocarbonyl)]tris-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 166 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1974:121317 CAPLUS
 DN 80:121317
 TI Synthesis of long, hydrophilic, protein-crosslinking reagents
 AU Wetz, K.; Fasold, H.; Meyer, Ch.
 CS Inst. Biochem., Johann Wolfgang Goethe Univ., Frankfurt/Main, Fed. Rep. Ger.
 SO Analytical Biochemistry (1974), 58(2), 347-60
 CODEN: ANBCA2; ISSN: 0003-2697
 DT Journal
 LA English
 IT 52136-94-4P 52136-96-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, protein crosslinking reagent)
 RN 52136-94-4 CAPLUS
 CN Poly(1,2-pyrrolidinediylcarbonyl), α,α' -[azobis(4,1-phenyleneiminocarbonyl)]bis[ω -hydroxy-, (S)- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B



RN 52136-96-6 CAPLUS
 CN Poly(1,2-pyrrolidinediylcarbonyl), α,α' -[azobis(4,1-phenyleneiminocarbonyl)]bis[ω -[[2-[(iodoacetyl)amino]ethylamino]-, (S)- (9CI) (CA INDEX NAME)

PAGE 1-A





10/712,456-ALW

L4 ANSWER 167 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1973:453779 CAPLUS
DN 79:53779

TI Antiinflammatory L-hydroxyproline derivatives

IN Coirre, Paul; Coirre, Bertrand

SO Brit., 5 pp. Addn. to Brit. 1,246,141.

CODEN: BRXXAA

DT Patent

LA English

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---------------|------|----------|-----------------|----------|
| PI | GB 1315633 | A | 19730502 | GB 1971-33362 | 19710715 |
| PRAI | GB 1971-33362 | A | 19710715 | | |
| IT | 38357-44-7P | | | | |

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 38357-44-7 CAPLUS

CN L-Proline, 4-hydroxy-1-[[4-(2-methylpropyl)phenyl]acetyl]-, trans- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

L4 ANSWER 168 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1973:124436 CAPLUS
DN 78:124436
TI Analgesic and antiinflammatory L-4-hydroxyproline derivatives
IN Coirre, Paul; Coirre, Bertrand
SO Ger. Offen., 14 pp. Addn. to Ger. Offen. 1,795,327 (See Brit. 1,246,141 CA 75;140679b).
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | DE 2139476 | A1 | 19730215 | DE 1971-2139476 | 19710806 |
| PRAI | DE 1971-2139476 | A | 19710806 | | |
| IT | 38357-44-7P | | | | |

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 38357-44-7 CAPLUS
CN L-Proline, 4-hydroxy-1-[[4-(2-methylpropyl)phenyl]acetyl]-, trans- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




10/712,456-ALW

L4 ANSWER 169 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1972:527056 CAPLUS
DN 77:127056
TI L-Hydroxyproline derivatives active on the metabolism of conjunctival
tissue
IN Coirre, Paul; Coirre, Bertrand; Denis, J. C.; Rambaud, J.; Cahn, Jean
SO Fr. Demande, 9 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| | ----- | ---- | ----- | ----- | ----- |
| PI | FR 2081573 | A6 | 19711210 | FR 1970-8942 | 19700312 |
| | FR 2081573 | B2 | 19730406 | | |
| | SE 381653 | B | 19751215 | SE 1971-8659 | 19710312 |
| PRAI | FR 1970-8942 | A | 19700312 | | |
| IT | 38357-44-7P | | | | |
| | RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of) | | | | |
| RN | 38357-44-7 CAPLUS | | | | |
| CN | L-Proline, 4-hydroxy-1-[[4-(2-methylpropyl)phenyl]acetyl]-, trans- (9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.



L4 ANSWER 170 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1972:502249 CAPLUS
DN 77:102249

PA CIBA Ltd.

CODEN: FAXXA3

DT Patent

LA French

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------|------|----------|-----------------|------|
| PI | FR 94938 | | 19700123 | | |
| PRAI | DE 1967-667 | | 19670117 | | |
| IT | 38046-01-4P | | | | |

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 38046-01-4 CAPLUS

CN L-Prolinamide, L-valyl-N6-[(1,1-dimethylethoxy) carbonyl]-L-lysyl-L-valyl-L-tyrosyl- (9CI) (CA INDEX NAME)

CCOC(=O)NCCCCNC(=O)[C@H](S)NC(=O)[C@H](S)C(N)C(=O)N[C@@H](C)C(=O)NCC[C@H](C(=O)N1CC[C@H](S1)C(=O)N)C2=CC=C(O)C=C2

L4 ANSWER 171 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1969:502228 CAPLUS

DN 71:102228

TI Antitubercular cyclopeptides

IN Jolles, Georges

PA Rhone-Poulenc S. A.

SO Ger. Offen., 48 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|----------|
| PI | DE 1805280 | B2 | 19781130 | DE 1968-1805280 | 19681025 |
| | DE 1805280 | C3 | 19790802 | | |
| | FR 1578723 | A | 19690822 | FR 1967-125842 | 19671025 |
| | FR 94740 | E | 19691024 | FR 1968-144421 | 19680319 |
| | NL 6814446 | A | 19690429 | NL 1968-14446 | 19681009 |
| | BR 6803309 | D0 | 19730222 | BR 1968-203309 | 19681021 |
| | BR 6803310 | D0 | 19730222 | BR 1968-203310 | 19681021 |
| | BE 722846 | A | 19690424 | BE 1968-722846 | 19681024 |
| | GB 1190200 | A | 19700429 | GB 1968-1190200 | 19681024 |
| | CH 490339 | A | 19700515 | CH 1968-490339 | 19681024 |
| | CH 490340 | A | 19700515 | CH 1968-490340 | 19681024 |
| | NO 125142 | B | 19720724 | NO 1968-4227 | 19681024 |
| | SE 362641 | B | 19731217 | SE 1968-14415 | 19681024 |
| | JP 49005359 | B | 19740206 | JP 1968-77102 | 19681024 |
| | PL 79403 | B1 | 19750630 | PL 1968-129713 | 19681024 |
| | PL 79404 | B1 | 19750630 | PL 1968-129714 | 19681024 |
| | SE 388605 | B | 19761011 | SE 1971-8184 | 19681024 |
| | DK 140591 | B | 19791008 | DK 1968-5146 | 19681024 |
| | DK 140591 | C | 19800225 | | |
| | ES 359552 | A1 | 19700601 | ES 1968-359552 | 19681025 |
| | ES 359553 | A1 | 19700601 | ES 1968-359553 | 19681025 |
| | AT 286513 | B | 19701210 | AT 1968-10461 | 19681025 |
| | AT 298669 | B | 19720525 | AT 1968-10463 | 19681025 |
| | IL 30959 | A | 19730430 | IL 1968-30959 | 19681025 |
| | CS 151487 | B2 | 19731019 | CS 1968-7355 | 19681025 |
| | AT 311548 | B | 19731126 | AT 1970-5743 | 19681025 |
| | CS 152310 | B2 | 19731219 | CS 1968-7356 | 19681025 |
| | FI 49399 | B | 19750228 | FI 1968-3037 | 19681025 |
| | FI 49400 | B | 19750228 | FI 1968-3038 | 19681025 |
| | DE 1817960 | A1 | 19750710 | DE 1968-1817960 | 19681025 |
| | SU 535902 | A3 | 19761115 | SU 1968-1280361 | 19681025 |
| | US 3719656 | A | 19730306 | US 1969-888045 | 19691224 |
| | NO 135417 | B | 19761227 | NO 1971-2523 | 19710701 |
| | DK 7800006 | A | 19780102 | DK 1978-678 | 19780102 |
| PRAI | FR 1967-125842 | A | 19671025 | | |
| | FR 1968-144421 | A | 19680319 | | |
| | FR 1967-81425 | A | 19671112 | | |
| | FR 1968-44421 | A | 19680319 | | |
| | DK 1968-5146 | A | 19681024 | | |
| | NO 1968-4227 | A | 19681024 | | |
| | US 1968-770436 | A2 | 19681024 | | |

IT 23934-03-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 23934-03-4 CAPLUS

CN Glycine, N-[N-[1-[N-[N-[1-[N-[N-[1-(3-benzoylhydratropoyl)-trans-4-methyl-L-prolyl]-N-methyl-L-threonyl]-L-leucyl]-trans-4-methyl-L-prolyl]-L-leucyl]-N-methyl-L-valyl]-L-prolyl]-N-methyl-D-leucyl]-, ψ -lactone


10/712,456-ALW

(8CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



10/712,456-ALW


L4 ANSWER 172 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1960:110095 CAPLUS
DN 54:110095
OREF 54:20895d-g
TI Cancerolytic peptides with directed action
AU Knunyants, I. L.; Golubeva, N. E.; Kil'disheva, O. V.
SO Doklady Akademii Nauk SSSR (1960), 132, 836-8
CODEN: DANKAS; ISSN: 0002-3264
DT Journal
LA Unavailable
IT 103506-10-1P, Proline, 1-[[p-[bis(2-chloroethyl)amino]phenyl]acetyl]-, ethyl ester
RL: PREP (Preparation)
(preparation of)
RN 103506-10-1 CAPLUS
CN Proline, 1-[[p-[bis(2-chloroethyl)amino]phenyl]acetyl]-, ethyl ester (6CI)
(CA INDEX NAME)



10/712,456-ALW

L4 ANSWER 173 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1957:97969 CAPLUS
DN 51:97969
OREF 51:17615b-c
TI Infrared spectra of 3-phenyl-2-thiohydantoins of amino acids
AU Epp, Agnes
CS Natl. Research Council, Saskatoon, Can.
SO Anal. Chem. (1957), 29, 1283-7
CODEN: ANCHAM; ISSN: 0003-2700
DT Journal
LA Unavailable
IT 109068-49-7, Proline, 1-[(p-phenylazophenyl)thiocarbamoyl]-
(spectrum of)
RN 109068-49-7 CAPLUS
CN Proline, 1-[(p-phenylazophenyl)thiocarbamoyl]-, L- (6CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



10/712,456-ALW

L4 ANSWER 174 OF 174 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1956:73930 CAPLUS
DN 50:73930
OREF 50:13879g-i,13880a-b
TI The 3-o-nitrophenyl- and 3-(p-phenylazophenyl)-2-thio-hydantoins of amino acids
AU Ramachandran, L. K.; McConnell, W. B.
CS Natl. Research Council Can., Saskatoon, Saskatchewan
SO Journal of the American Chemical Society (1956), 78, 1255-7
CODEN: JACSAT; ISSN: 0002-7863
DT Journal
LA Unavailable
OS CASREACT 50:73930
IT 109068-49-7P, Proline, 1-[(p-phenylazophenyl)thiocarbamoyl]-
RL: PREP (Preparation)
(preparation of)
RN 109068-49-7 CAPLUS
CN Proline, 1-[(p-phenylazophenyl)thiocarbamoyl]-, L- (6CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



10/712,456-ALW

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

631.76

804.52

STN INTERNATIONAL LOGOFF AT 09:24:36 ON 29 MAY 2007